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Schistosoma mansoni 
Schistosomiasis is the major parasitic worm infection in the world, with some 200 
million people infected and another 600 million at risk of becoming infected (1;2). 
Today, schistosomiasis causes greater morbidity and mortality than all other worm 
infestations. The pathology of schistosomiasis is characterized by the formation of 
granulomas, causing intense inflammatory and immunologic responses, damaging 
the liver, intestine or bladder. Three species of schistosomes are responsible for the 
disease namely: Schistosoma mansoni, Schistosoma haematobium and Schistosoma 
japonicum. Schistosomiasis is as old as civilization as schistosome eggs have been 
identified in mummies of the 20th dynasty (1200-1090 BC). Schistosoma mansoni is 
found in tropical Africa, parts of southwest Asia, South America and the Caribbean 
Islands.  
 
Life cycle 
Schistosomes have complicated life cycles alternating between asexual generations in 
the invertebrate host (snail) and sexual generations in the vertebrate host. A 
schistosome egg hatches in fresh water, liberating a motile form, the miracidium 
(Figure 1). To survive, this miracidium must find a fresh water snail within 8-12 hrs 
and infect it. In the snail asexual reproduction of so-called sporocysts occur. In the 
snail, the sporocyst develops into the final larval stage, the cercariae. The cercariae 
escapes from the snail into the water and penetrates the skin of the human host, 
during which process it loses its forked tail and becomes an schistosomule, which is 
accompanied by profound changes in their metabolism and antigenic structure 
(Figure 1). The schistosomule migrates through tissues, penetrates blood vessels and 
is carried to the lung and subsequently to the liver. In the intestinal venules of the 
portal drainage schistosomules mature, forming pairs of male and female worms (4-5 
weeks after infection). The female worms of Schistosoma mansoni deposit immature 
eggs in the intestinal venules (Figure 1). Embryos develop during the passage of eggs 
through the tissues and the larvae are mature when eggs pass through the wall of the 
intestine or the urinary bladder and are discharged in the feces or urine. The eggs 
hatch in fresh water, liberating miracidia and completing the life cycle (Figure 1). 
During all life cycle stages the host is sequentially exposed to different sets of specific 
antigens, adult worm antigens and egg antigens, that are secreted/excreted. 
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Figure 1. The life-cycle of Schistosoma mansoni. 
Pathogenesis 
The female worm deposits hundreds to thousands of eggs daily for 5 to 30 years (3). 
Fortunately most infected persons harbor fewer than 10 adult females. About two-
thirds of the eggs fail to adhere to the endothelium and become lodged in the hepatic 
capillary bed. The exact mechanism by which eggs pass across the endothelium, 
intervening tissues and mucosal epithelium remains unknown, but clearly is 
dependent upon the host immune response, as egg excretion does not occur in 
animals that are immuno-compromised (4). Entrapped eggs die within 20 days and 
secrete numerous proteins, glycoproteins, glycolipids and polysaccharides that are 
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highly antigenic and can accelerate the inflammatory response (acute 
schistosomiasis), which may lead to severe pathology and ultimately death of the host 
(5;6). The immunologic and inflammatory reactions to the schistosomal eggs in 
tissues cause the manifestations of schistosomiasis. The basic lesion is a 
circumscribed granuloma or a cellular infiltrate of eosinophils and neutrophils 
around the egg. Granulomas that form around the eggs also obstruct the micro-
vascular blood supply and produce ischemic damage to adjacent tissue. The result is 
progressive scarring and dysfunction in the affected organs (7). When the worm 
burden is large, granulomatous response to the enormous number of eggs, poses 
significant problems to the distal colon and liver. Egg production also induces a 
switch in the immune response towards a TH2 response which is driven by a complex 
mixture of glycosylated components, called soluble egg antigens (SEA) (8;9). The 
pathology of schistosomiasis is largely chronic in nature, with less than 5% of infected 
individuals suffering severe disease (10). Chronic schistosomiasis may occur even 
without any recognizable symptoms and can last for decades. Morbidity arises slowly 
and is accompanied by pathological changes in affected organs. Mortality mainly 
occurs via liver fibrosis and portal hypertension. The disease weakens infected 
individuals and therefore has serious consequences on the socio-economic 
development of tropical and subtropical areas (11).  
  
 
Glycoconjugates in schistosomes 
Schistosomes can survive many years in the hostile environment of their definitive 
host. Thus, the parasite must have developed remarkable mechanisms to escape the 
immune response of its host. It is thought that the glycoconjugates that are 
abundantly expressed throughout all life stages of the parasite, play an important role 
in these escape mechanisms. Glycoconjugates in schistosomes display a broad array 
of oligosaccharides linked to proteins or lipids, creating glycoproteins and glycolipids. 
In the next paragraph the synthesis of glycoconjugates will be described shortly and 
examples in schistosomes will be discussed. 
 
Glycoproteins 
Glycoproteins are proteins that have attached to their polypeptide backbone one or 
more oligosaccharide chains covalently linked via N- or O-glycosidic linkage. Newly 
synthesized proteins are made in the endoplasmic reticulum (ER) and are co- or post-
Chapter 1                                                                                                                                                                       _ 
18
translationally modified with carbohydrate chains. The carbohydrate chain is 
synthesized by a series of stepwise-organized glycosyltransferases within the ER and 
Golgi apparatus. In addition, glycosidases can remove specific carbohydrates and 
thus modify the carbohydrate portion of the glycoconjugate. Other modifications of 
monosaccharides like for instance sulphation, methylation or phosphorylation, 
increase the diversity of glycans. 
 
N-glycans 
An oligosaccharide that is transferred to the side chain amino (NH2) group of an 
asparagin (Asn) in the protein is called N-linked. N-glycan synthesis starts with the 
formation of a common precursor structure Glc3Man9GlcNAc2 linked to the 
membrane bound lipid dolichol (Figure 2). The whole precursor structure is then 
transferred to the Asn residue of a newly synthesized peptide at the ribosome. This 
precursor oligosaccharide is extensively trimmed into an oligo-mannosidic type 
structure and this structure is then further processed. N-glycans contain a common 
core structure consisting of two N-acetylglucosamine (GlcNAc) residues and three 
mannose residues. According to their main structural features N-glycans can be 
divided into three major types: high mannose-type, hybrid-type and complex type 
(Figure 2) (12).  
 
Figure 2. The three major types of N-linked glycans. 
a. Oligomannose-type; b. Complex type; c. Hybrid-type. 
Explanation of glycan symbols:      GlcNAc;     Galactose ;     Glucose;     Mannose. 
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Schistosoma adult worm- and egg-derived glycoproteins contain typical N-linked 
oligomannose structures (Man5-9GlcNAc2-Asn) that occur in many eukaryotic and 
higher organisms including humans (13). However schistosomes can also synthesize 
complex-type N-glycans with di-, tri- and tetra-antennary structures, which 
sometimes have unusual core modifications. N-glycan structures of cercariae can be 
modified by β2-linked xylose (Figure 3 d) (14). Egg glycoproteins express truncated 
N-glycan core structures carrying α3-linked fucose in addition to β2-linked xylose, 
similar to typical allergenic plant N-glycans (Figure 3 e) (15). The N-linked bi-
antennary structures frequently contain instead of LacNac, terminal LacdiNAc (LDN, 
GalNAcβ1-4GlcNAcβ) with or without a fucose in an α1-3 linkage to the GlcNAc 
(LDNF) (16;17). These structures have now also been found in glycoproteins of both 
invertebrate and vertebrate origins (18). Recently Wuhrer et al., reported that N-
glycans of the worm stage of Schistosoma mansoni express besides poly Lewis x also 
poly LDN and poly LDNF structures (Figure 3 f). Poly LDN and poly LDNF had thus 
far not been reported to occur in natural systems (19).The highly branched tri- and 
tetra-antennary N-glycans of Schistosoma mansoni can carry Lewis x (Lex, Galβ1-
4(Fucα1-3)GlcNAc) and extended Lex antigens (17). Further highly antigenic 
structural elements are Fucα1-3GalNAcβ1-4GlcNAc (F-LDN) and Fucα1-3GalNAcβ1-
4[Fucα1-3]GlcNAc (F-LDN-F), which are both protein- and lipid-linked in cercariae 
and egg stages of the parasite (20). Terminal structures found on schistosome 
glycoconjugates are summarized in Table 1. 
 
Table 1. Common terminal glycan antigens found on Schistosome glycoconjugates. 
Explanation of Glycan symbols:      GalNAc;      GlcNAc;     Fucose;     Galactose.  
Chapter 1                                                                                                                                                                       _ 
20
Figure 3. Typical examples of N-glycans in Schistosoma mansoni. 
a. Trimannose structure; b. High mannose structure; c. N-glycan containing dicore-fucose bi-Lewis x; 
d. Truncated N-glycan found in cercariae with a β2-linked xylose; e. Truncated N-glycan found in eggs 
carrying α3-linked fucose in addition to β2-linked xylose; f. N-glycan containing poly LDN(F).  
Explanation of Glycan symbols:     GalNAc;       GlcNAc;     Fucose;     Mannose;      Xylose;     Galactose. 
O-glycans 
O-glycan synthesis is initiated by the transfer of a N-Acetylgalactosamine (GalNAc) to 
the hydroxyl (OH) group on the side chain of Serine (Ser) or Threonine (Thr) of the 
synthesized peptide. GalNAc can be further modified with GalNAc, GlcNAc or 
galactose, giving rise to different core structures. They can be elongated and 
terminally modified by galactose, GalNAc, GlcNAc, Fucose or N-acetylneuraminic 
acid (NeuAc), leading to a great variety of O-glycans. In normal mammalian cells, 
four common core structures of O-glycan can be synthesized. Core 1 is the precursor 
structure for the synthesis of core 2 and core 3 is the precursor for core 4 (Figure 4). 
All four common core structures may be elongated, sialylated, fucosylated and 
sulfated to form functional carbohydrate structures.   
 
Figure 4. Biosynthesis of O-
glycan core structures. 
The initial step of O-glycosylation is 
the addition of GalNAc to serine or 
threonine of a glycoprotein. 
Addition of β1,3-linked galactose 
and β1,3-linked N-
acetylglucosamine results in the 
formation of core 1 and core 3, 
respectively. Core 2 and core 4 are 
formed by addition of N-
acetylglucosamine, which is 
catalyzed by a unique enzyme for 
each reaction.  
 
Explanation of the glycan symbols:      GalNAc;        GlcNAc;     Galactose. 
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Schistosomes synthesize O-glycans ranging from single O-linked GlcNAc residues or 
short mucin-type disaccharides on glycoproteins from S. mansoni schistosomula and 
adult worms (13;21), to very large and complex multi-fucosylated O-glycans from the 
cercarial glycocalyx (Figure 5c) (22). Cercarial O-glycans have been described to carry 
both LN and LDN-based structures that are frequently (multi-) fucosylated (23). In 
addition, it has been shown that two major antigens, which are regularly being 
released from the gut of adult worms in relatively high amounts, namely circulating 
cathodic and anodic antigen (CCA and CAA respectively), contain large unusual O-
glycans. The major fraction of the O-linked glycans of CCA consists of a poly-Lex  
backbone of approximately 25 repeating units, having a GalNAc as the reducing 
terminal moiety (Figure 5e). CAA is negatively charged, its O-glycan are constructed 
of repeats of β1-6-linked GalNAc residues substituted with β1-3 –linked glucuronic 
acid (GlcA). Furthermore a small portion of poly-Lex carbohydrate chains were found 
to be present on CAA (Figure 5d)(24). 
 
Figure 5. Examples of O-glycans found in Schistosoma mansoni. 
a) O-glycan containing Lewis x with a ‘novel’ core structure (23); b) O-glycan containing extended 
Lewis x antigens; c) O-glycan of the cercarial glycocalyx; d) Circulating Anodic Antigen (CAA); e) 
Circulating Cathodic Antigen (CCA). 
Explanation of glycan symbols:     GlcNAc;      GalNAc;      Fucose;     Galactose;      Glucuronic acid. 
 
Glycolipids  
Glycolipids are a subgroup of lipids containing sugar moieties and are ubiquitous 
components of the plasma membrane of all vertebrate cells. The most common 
glycolipids in mammals are a class of sphingolipids, glycosphingolipids (GSLs). 
GSLs are considered to be receptors for microorganisms and their toxins, modulators 
of cell growth and differentiation, and organizers of cellular attachment to matrices 
(25;26) . More than 400 species of GSLs possessing different sugar structures have 
been reported in vertebrates. In the pathway of GSL synthesis, the first step is 
transfer of glucose or galactose to a ceramide to produce glucosylceramide (GlcCer) 
or galactosylceramide (GalCer), respectively. This transfer reaction is catalyzed by 
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UDP glucose:ceramide:glucosyltransferase (GlcT) and UDP-galactose:ceramide: 
galactosyltransferase (GalT), respectively. The sugar chains can be extended by the 
sequential transfer of monosaccharides to a GlcCer or GalCer by one of a serie of 
specific glycosyltransferases, all of which are localized on the lumen side of the Golgi 
membrane (27;28). Thus GlcCer produced on the cytosolic side of the Golgi 
membrane must be transferred (flip-flopped) to the lumen side by a putative enzyme, 
'flippase,' which has not yet been characterized (28). In plasma membrane, GSLs 
form clusters, called lipid rafts, with cholesterol and relatively less phospholipids 
than other areas of plasma membrane (29). There are receptors for intercellular 
signal transducers such as GPI-anchored proteins on the exoplasmic face of the rafts 
and Src family kinases on the cytosolic face, indicating that GSLs play a role in 
transmembrane signal transduction (29).  
Schistosome glycolipids 
Schistosomes synthesize glycolipids with a glucocerebroside precursor similar to 
vertebrates. The glucocerebroside is not galactosylated as in vertebrates (Galβ1-4Glc-
ceramide) (Figure 6a), but is instead modified by addition of a β1,4-GalNAc residue 
to generate the ‘schisto core’ structure GalNAcβ1-4Glcβ1-ceramide (Figure 6b) (30). 
Extensions of the schisto-core can be complex, with either common structural 
elements found in N- and O-glycans, or with specific modifications found so far only 
on glycolipids. The most predominant phospholipids in adults of Schistosoma 
mansoni are phosphatidylcholine (PC) and phosphatidylethanolamine (PE), but also 
in other stages of the life cycle glycolipids are present. Detailed analyses of the major 
egg glycolipids of S. mansoni have demonstrated that these contain extensions with 
the repeating unit -4(Fucα1-2Fucα1-3)GlcNAcβ1- terminating with (Fucα1-
2)0/1Fucα1-3GalNAc at the non-reducing end (15). Glycolipids have extended 
difucosylated oligosaccharides. S. mansoni cercarial glycolipids are dominated by 
terminal Lewis x and Fucα1-3Galβ1-4(Fucα1-3)GlcNAc (pseudo Lewis y) structures 
(Figure 6). These glycolipids are not expressed in the adult and egg stages (31). 
Recently the Fucα1-3GalNAc terminal element was demonstrated in S. mansoni egg 
glycolipids, although compared to cercarial glycolipids the Lewis x glycolipids are 
drastically downregulated in the egg (32). F-LDN and F-LDN-F terminal elements 
have been demonstrated on worm, cercariae and egg glycolipids (20;32). The neutral 
glycolipids fraction of S. mansoni adult worms may be useful serodiagnostic antigens 
                                                                                                                                                     General Introduction 
23 
for detection of acute schistosomiasis (33). Lipid extracts of eggs, worms, and 
cercariae of S. mansoni have been shown to contain a large number of highly 
immunogenic glycolipids, many of which remain to be structurally characterized (34). 
Stage specific expression patterns have not only been observed for certain glycan 
elements, but also for the ceramide part of schistosome mono- and dihexosides (35). 
It should be noted that sialic acids, common terminal sugars of mammalian glycans, 
have never been chemically demonstrated as part of schistosome glycoconjugates. 
The only charged monosaccharide demonstrated so far in any schistosome N-, O- or 
lipid-linked glycan is the GlcA residue in the O-glycans of CAA.  
 
 
Figure 6. Glycolipids expressed by Schistosoma mansoni. 
a) glucocerebroside precursor of vertebrates; b) The schisto core; c) egg glycolipid; d) egg 
glycosphingolipid; e) glycolipid with a Lewis x pentasaccharide structure found in cercariae; f) 
glycolipid with the pseudo Lewis y structure found in cercariae; g) glycolipid with a Lewis x 
hexasaccharide found in cercariae.  
Explanation of glycan symbols:     GalNAc;     GlcNAc;      Fucose;      Galactose;     Glucose.
 
 
The immune response 
One of the most fascinating problems in immunology is, understanding how the host 
organism detects the presence of infectious agents such as Schistosoma mansoni and 
disposes of the invader without destroying self-tissues. Schistosomes have evolved 
mechanisms to escape the immune response of the host. It is thought that the 
glycoconjugates that are abundantly expressed throughout all life stages of the 
parasite, play an important role in these escape mechanisms. The first immune cells 
to come in contact with invading pathogens are dendritic cells, the sentinels of the 
immune system. Dendritic cells recognize pathogens and through cell-cell 
interactions with T cells an immune response is elicited. DCs express receptors that 
recognize glycans expressed by pathogens. In the next paragraphs dendritic cells, 
pattern recognition receptors and their role in immune responses will be discussed.  
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Dendritic cells, sentinels of the immune system 
The primary function of the immune system is to protect the host from infectious 
microbes in its environment. Dendritic cells (DCs) are professional antigen-
presenting cells (APCs) which are strategically positioned at the boundaries between 
the inner and the outside world (36). The development of DCs is considered to occur 
in distinct stages. Haematopoietic pluripotential stem cells, under as yet unknown 
influences, constantly generate DC progenitors in the bone marrow, which give rise to 
circulating precursors in the blood (37). These DC precursors are scattered 
throughout the body in virtually all non-lymphoid tissues via the blood circulation 
and function as a continuous surveillance patrol for incoming foreign antigens. DC 
precursors migrate to the peripheral tissues and are then called immature DCs. In the 
peripheral tissues the immature DCs capture antigens. To become licensed to activate 
naïve T helper cells, DCs must undergo a maturation process during the migration 
from the peripheral tissues to the lymph nodes. In the lymph node the captured 
antigen is presented to naïve T cells. Maturation of DCs is characterized by a 
decreased Ag-uptake capacity and an increased cell surface expression of major 
histocompatibility complex (MHC) and co-stimulatory molecules (38-40). In 
addition, rearrangement of cytoskeleton, adhesion molecules and cytokine receptors 
upon maturation, allow DCs to migrate from peripheral tissues to secondary 
lymphoid organs (41-43).  
 
DCs play a pivotal role in the immune response by providing signals that direct naïve 
T helper (TH) cells to proliferate and differentiate into TH1, TH2 or T regulatory cells. 
Three signals are delivered by an APC that are thought to determine the fate of naïve 
T cells (Figure 7) (44). Signal 1 is delivered through the T cell receptor (TCR) when it 
engages an appropriate peptide-MHC complex. Signal 1 alone is thought to promote 
naïve T cell inactivation by anergy, deletion or direction into a regulatory cell fate, 
thereby leading to ‘tolerance’. Accessory signals also referred to as co-stimulation 
(signal 2), together with signal 1 induce ‘immunity’. This is often measured as T cell 
clonal expansion, differentiation into effector cells and a long-term memory (45). 
Signal 2 is often equated with signalling through CD28 when it engages CD80 and/or 
CD86 (46) (Figure 7). However, the actual ‘signal 2’ that favours immunity, is likely 
to be a fine balance of positive and negative co-stimulatory signals emanating from 
many receptors (44). Recently is has been shown that the signals delivered by the 
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APC to the T cell determine its polarization into an specific type of effector cell, are 
referred to as signal 3 (Figure 7). T helper 1 cells activate cytotoxic T cells and 
stimulate the microbicidal properties of macrophages (cell-mediated immune 
response). T helper 2 cells initiate the humoral immune response by activating naïve 
antigen-specific B cells to produce antibodies. The polarizing signals are mediated by 
various soluble and membrane-bound factors, such as interleukine-12 (IL-12) or CC-
chemokine ligand 2 (CCL2) (47).  
Figure 7. T cell polarization requires three dendritic cell-derived signals. 
Signal 1 is an antigen-specific signal that is mediated through T cell receptor (TCR) and MHC class II-
associated peptides. Signal 2 is the co-stimulatory signal, mediated by triggering of CD28 by CD80 and 
CD86. Signal 3 is the polarizing signal mediated by soluble or membrane bound factors like IL-12 
(TH1) or CCL2 (TH2). 
 
Pattern recognition receptors on DCs 
DCs are professional APCs bridging the innate and adaptive immunity. Invading 
pathogens are recognized by pattern recognition receptors (PRRs) expressed on the 
cell surface of DCs. Two main classes of PRRs expressed by DCs are Toll-like 
receptors and C-type lectins. Depending on their tissue localization and 
differentiation state, DCs could be specialized to respond to specific microbes by 
expressing distinct sets of Toll-like receptors and C-type lectin receptors. 
 
Toll-like receptors  
Human Toll-like receptors (TLRs) are type 1 transmembrane glycoproteins 
characterized by an extracellular domain that contains leucine-rich repeat units and 
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cytoplasmic domain of IL-1 receptor, designated as the Toll/IL-1 Receptor (TIR) 
domain. The TIR domain is a conserved protein-protein interacting module, found in 
diverse organisms including humans, plants, insects and nematodes (48). At least ten 
human TLRs have been identified (Figure 8) (49), which are expressed as 
homodimers or heterodimers (TLR-2 with TLR-1 and TLR-6 with TLR2, 
respectively). TLRs are broadly expressed on cells of the immune system (50;51) and 
are arguably the best-studied immune sensors of invading pathogens.  
 
Figure 8. Cellular localization of Toll-like receptors (TLRs). 
TLR1, TLR2, TLR4, TLR5 and TLR 6 reside mainly in the plasma membrane, whereas those TLRs 
recognizing nucleic acid derivatives are localized to intracellular compartments such as endosomes 
(TLR3, TLR7, TLR8 and TLR9). 
 
 
The primary function of the TLRs is to signal that microbes have reached the body’s 
barrier defenses. They appear to do this largely by recognizing common structural 
features of microbes known as pathogen-associated molecular patterns (PAMPs), 
which include modified lipids, proteins and nucleic acids (Figure 8) (52). TLRs are 
particularly found on DC and macrophages, but are also expressed on neutrophils, 
eosinophils, endothelium, epithelial cells and keratinocytes. Most TLRs are expressed 
on the cell surface, others are found almost exclusively in intracellular compartments 
such as endosomes (Figure 8).  Their ligands, mainly nucleic acids, require 
internalization to the endosome before signaling is possible (53). Activation of most 
TLRs induces cellular responses associated with acute and chronic inflammation. 
When TLR ligands interact with their specific TLRs, intracellular adaptor proteins 
transduce signals that lead to enhanced expression of genes encoding cytokines and 
other inflammatory mediators.  
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All members of the TLR super family signal in a similar manner owing to the 
presence of the TIR domain, which activates common signaling pathways, most 
notably those leading to activation of the transcription factor nuclear factor κB (NF-
κB) and stress-activated protein kinases. These pathways are defined as the MyD-88 
dependent and independent pathway (54;55). TLRs relay information about the 
interacting pathogens to DCs through intracellular signaling cascades. TLR triggering 
has versatile effects on DCs such as promoting survival, chemokine secretion, 
expression of chemokine receptors, migration, cytoskeletal and shape changes or 
endocytic remodeling (56). Recently Napolitani and co-workers, showed that TLRs 
can act in synergy to trigger an immune response by activating DCs. TLR ligands 
form a combinatorial code by which DCs discriminate pathogens and this implicates 
a new strategy for priming an immune response (57).  
 
Recent reports indicate that Schistosoma mansoni-derived glycan products can 
interact with TLRs. The Schistosoma mansoni-related glycan lacto-N-fucopentaose 
III (LNFP III) contains the trisaccharide Lewis x, which is expressed by several life-
cycle stages of schistosomes. Thomas et al., showed that LNFP III can directly 
activate murine bone marrow-derived DCs through a TLR4 dependent mechanism. 
DCs mature into a DC2 phenotype, capable of driving naïve T cells to differentiate 
into TH2 cells (58). Aksoy and coworkers investigated whether Schistosoma mansoni 
living eggs activate murine bone marrow-derived DCs through TLR2 and TLR3 
engagement (59). Egg-derived RNA possessed RN-ase A-resistent and RN-ase III-
sensitive structures that are capable of triggering TLR3 activation, suggesting the 
involvement of double-stranded (ds) structures. Thus ds-RNA structures present in 
the eggs of Schistosoma mansoni are able to activate TLR3 (59). Helminth glycolipids 
also interact with TLRs. The schistosome-specific lysophosphatidyl-serine was shown 
to active human monocyte-derived DCs through TLR2, which results in the ability of 
DCs to induce the development of IL-10 producing regulatory T cells as well as the 
induction of a TH2 response (60). 
 
C-type lectins  
The term C-type lectin receptor designates carbohydrate-binding molecules that bind 
their ligands in a Ca2+-dependent manner through a carbohydrate recognition 
domain (CRD). The CRD contains a well-preserved consensus sequence of 
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approximately 115-130 amino acids, which are involved in calcium binding and sugar 
specificity. One calcium ion is essential for proper positioning of the binding site. The 
second calcium ion is situated in the primary binding site and co-ordinates ligand 
binding (61). In addition, the sugar binding to a lectin depends on subtle differences 
in the arrangements of carbohydrate residues and their branching. Furthermore, the 
secondary binding site within the CRD was shown to play an important role in sugar 
binding by mutation studies (62;63)  
 
C-type lectins (CLRs) have diverse functions (64). They recognize endogenous ligands 
and thereby mediate cell-cell interactions during immune responses. CLRs bind to 
soluble self-antigens, leading to immune tolerance and maintenance of endogenous 
glycoprotein homeostasis. CLRs function also as pathogen recognition receptors 
through the recognition of PAMPs. Furthermore, co-operation between TLRs and 
CLRs has been demonstrated and it seems that appropriate immune responses rely 
on the interaction of many different antigen sensing and sampling mechanisms (65).  
 
APCs express CLRs that are predominantly type II transmembrane receptors with a 
single carbohydrate recognition domain, such as DC-SIGN, MGL, dectin-1, Blood DC 
antigen 2 (BDCA2) and Langerin (Figure 9). In addition, there are also type I 
transmembrane receptors, such as the mannose receptor and DEC-205, which have 
multiple CRDs, although not all of these act as functional CRDs (Figure 9) (64). True 
Ca2+-dependent CLRs fall into two broad categories, those recognizing mannose-/ 
fucose-/N-acetylglucosamine-type ligands and those recognizing galactose-/N-
acetylgalactosamine-type ligands, which can be defined by the presence of a 
distinctive triplet of amino acids within the CRD: EPN for mannose-type receptors 
and QPD for galactose-type receptors (61). 
 
The capacity of CLRs to detect microorganisms depends on the degree of 
oligomerization of the lectin receptor, as well as on the PAMP present on the 
microbial surface. By creating multimers, in which several CRDs point towards a 
common direction, the binding valency increases and allows interactions with the 
dense carbohydrate expression on microbial surfaces. To increase their binding 
strength to PAMPs, transmembrane CLRs have developed several strategies. CLRs 
exists as tetramers or trimers on the surface of immature monocyte-derived DCs and 
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this assembly is required for high binding of target proteins (66). The neck portion of 
each CLR molecule adjacent to the CRD is sufficient to mediate the formation of 
dimers, whereas the neck regions near the amino-terminal are required to stabilize 
tetramers (67). The CRDs are flexibly linked to the neck regions, which project CRDs 
from the cell surface and enable CLRs to bind to various glycans on microbial 
surfaces (67). Higher levels of organization can be obtained, due to clustering on the 
cell surface of DCs (68). The organization of CLRs in so-called ‘microdomains’ on the 
plasma membrane is important for the binding and internalization of virus particles, 
suggesting that these multi-molecular assemblies of CLRs act as a docking site for 
pathogens to invade the host (68). In the next paragraph the CLRs used throughout 
this thesis will be described. 
 
Figure 9. Two types of C-type lectins that are present on dendritic cells. 
Type I transmembrane receptors like DEC-205 and MR contain 8-10 carbohydrate recognition 
domains (CRDs) at their extracellular amino-terminus. Type II transmembrane receptors contain only 
one CRD at their carboxy-terminal extracellular domain. 
 
 
DC-SIGN 
Dendritic cell-specific intracellular adhesion molecule 3 (ICAM-3)-grabbing non-
integrin (DC-SIGN, CD209) is a type II membrane C-type lectin with a short amino 
terminal cytoplasmic tail and a single carboxyl terminal carbohydrate recognition 
domain (CRD) (69). The primary structure of the CRD contains conserved residues 
consistent with classical mannose-specific CRDs. The CRD of DC-SIGN recognizes 
both internal branched mannose residues as well as terminal di-mannoses (70;71). 
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The CRD of DC-SIGN also recognizes fucosylated glycan structures preferentially the 
α1-3 and α1-4 fucosylated tri- and tetrasaccharides such as Lewis antigens and LDNF 
(72;73). DC-SIGN is a well known pathogen receptor. DC-SIGN binds HIV-1 gp120 
and facilitates the transport of HIV from mucosal sites to draining lymph nodes 
where infection of T-lymphocytes occurs (74). Since the identification of DC-SIGN as 
HIV-1 receptor on DCs, interactions with other pathogens have been reported 
including Mycobacterium tuberculosis (72;73), Candida albicans (75), Helicobacter 
pylori (76) and Schistosoma mansoni (77) but also viruses like hepatitis C virus (78-
80), Ebola (81;82), Cytomegalovirus (CMV) (83) and Dengue (84;85). These 
interactions are due to the mannose- or fucose-type glycans that these pathogens 
express on their surface or that are present in their secretion products.  
 
The main function of CLRs expressed by DCs is to interact with conserved molecular 
patterns that are shared by a large group of microorganisms, and internalize these 
pathogens for processing and antigen presentation, thereby initiating an immune 
response(86). To internalize pathogens most of these CLRs contain internalization 
motifs. The cytoplasmic tail of DC-SIGN contains three internalization motives, 
namely a tyrosine-based motif of the sequence YKSL, a dileucine motif and a tri-
acidic cluster EEE. Engering and coworkers showed that the tyrosine motif and the 
dileucine motif are involved in the ligand-induced internalization of DC-SIGN (87). 
DC-SIGN delivers antigens to intracellular compartments resembling late 
endosomes/lysosomes for degradation and these antigens are subsequently 
presented to T-cells in vitro (87;88). Whilst data suggest a role for DC-SIGN in host 
defense, evidence is now accumulating that some pathogens may preferentially 
interact with DC-SIGN as part of a pathogenic strategy and exploit the CLR mediated 
uptake to their own benefit, namely to evade the host immune defenses (86). 
 
DC-SIGN recognizes the self glycoproteins ICAM-2 and ICMA-3, and functions as a 
cell-adhesion receptor. As a cell adhesion receptor DC-SIGN mediates interactions 
between dendritic cells (DCs) and resting T cells through binding to ICAM-3 (69).  
Enzymatic removal of the N-linked carbohydrates  abrogates binding to DC-SIGN 
(62). Recently it was reported that besides interactions with T cells, DC-SIGN also 
mediates cell-cell interactions between DCs and neutrophils and interactions between 
DCs and Natural Killer (NK) cells (89;90). DC-SIGN also functions as a rolling 
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receptor, that supports trans-endothelial migration of DC precursors from the blood 
to tissues through interaction with endothelial ICAM-2 (91), however the endogenous 
carbohydrate ligand still remained inconclusive. In chapter 5 we addressed this 
question and found that Lewis y expressed on ICAM-2 on endothelial cells is the 
endogenous ligand for DC-SIGN (Garcia-Vallejo et al., submitted, chapter 5). 
 
DC-SIGN interacts with Schistosoma mansoni SEA. Blocking with anti-glycan 
antibodies showed that Lewis x and LDNF moieties play a role in this interaction 
(77). Reports on the carbohydrate specificity and function within the immune system 
of lectins are emerging the last few years. By using glycan microarray technology the 
carbohydrate specificity of lectins can be identified. Glycan microarray studies 
confirmed that DC-SIGN recognizes two classes of glycans, mannose containing 
glycans terminated with manα1-2 residues and various fucosylated glycans with the 
Fucα1-3GlcNAc and Fucα1-4GlcNAc containing glycans found as terminal sequences 
of N- and O-linked glycans (92). 
 
L-SIGN 
Liver/lymph node specific ICAM-3-grabbing non-integrin (L-SIGN/CD209L/DC-
SIGN-R) is a human homologue of DC-SIGN (93;94). L-SIGN shares 77% amino acid 
sequence identity with DC-SIGN. L-SIGN is not expressed by DCs, but is expressed 
by endothelial cells present in lymph node sinuses and liver sinusoidal endothelial 
cells (LSECs). LSECs function as a liver-resident antigen presenting cell population 
on which L-SIGN could play a role in antigen clearance as well as LSEC-leukocyte 
adhesion (95).  Within the cytoplasmic tail the most differences between DC-SIGN 
and L-SIGN are found. Like DC-SIGN, L-SIGN contains a dileucine motif and a tri-
acidic cluster EED. L-SIGN lacks the tyrosine-based motif (93). In addition, 
elucidation of the crystal structures of the CRDs of both DC-SIGN and L-SIGN, in 
combination with binding studies, revealed that both receptors recognize high-
mannose oligosaccharides (70;71), and showed that L-SIGN has a higher affinity for 
mannose than DC-SIGN (92). Whereas for DC-SIGN increasing evidence indicates, 
that its major ligands are α3/α4-fucosylated glycans, no data so far indicated a role 
for L-SIGN in the binding of fucosylated oligosaccharides. In chapter 4 we showed 
that L-SIGN, like DC-SIGN, can bind to several Lewis antigens, with the exception of 
Lewis x. DC-SIGN and L-SIGN share  functional similarities by recognizing ICAM-2, 
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ICAM-3, HIV-1 gp120 and Ebola. Recent reports indicate that L-SIGN represents a 
liver specific receptor for Hepatitis C virus (HCV) and L-SIGN might play an 
important role in HCV infection and immunity (78;88). L-SIGN also binds to 
Schistosoma mansoni soluble egg antigens (SEA), however the exact ligands have not 
been identified (63; Chapter 4).  
 
MGL 
The macrophage galactose binding lectin MGL (CD301), also called DC-asialoglyco- 
protein receptor (DC-ASGP-R) or human macrophage lectin (HML) is the only 
reported galactose-type C-type lectin on human DCs. MGL consists of one CRD 
domain and contains an YENF internalization motif for endocytosis via clathrin 
coated pits. MGL is expressed as a trimer on human DCs and macrophages at an 
intermediate stage of differentiation from monocytes (96). MGL positive immature 
DCs and macrophages are most abundantly expressed in the dermis and skin. MGL 
expression is also found on DC-like cells in the T cell areas of human lymph node and 
tonsil (96; 97). By using glycan microarray profiling the carbohydrate specificity of 
MGL was characterized (98; Chapter 3). MGL has an exclusive specificity for terminal 
α- and β-linked GalNAc residues that naturally occur as parts of glycoproteins and 
glycosphingolipids. Up till now terminal GalNAc moieties expressed by tumor 
antigens as well as the human parasite Schistosoma mansoni and a subset of 
gangliosides (98; Chapter 3 and 7), are identified as ligands for MGL. Recently the 
interaction of MGL and CD45 on effector T cells has been described (99). 
 
Mannose receptor 
The mannose receptor (MR, CD206) is a type I transmembrane domain that consists 
of eight CRDs, a fibronectin type II domain and a cysteine rich N-terminal domain. 
The mannose receptor is expressed on macrophage subsets, in vitro cultured DCs and 
certain DC populations from inflamed skin as well as lymphatic and hepatic 
sinusoidal endothelium (100-102). The MR has been shown to recycle constitutively 
while releasing its cargo (103). It has been implicated in homeostatic processes, such 
as clearance of endogenous products, cell adhesion, as well as pathogen recognition 
and antigen presentation (104). 
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Recombinant domain deletion studies have demonstrated that CRD 4 and to a lesser 
extent CRD 5 are the only domains showing true affinity for N-acetylglucosamine, 
mannose and fucose-terminating oligosaccharides (105). Although all eight CRDs 
contain conserved residues responsible for formation of the hydrophobic fold, only 
CRD 4 and 5 retain residues needed for Ca2+ coordination and consequent 
carbohydrate binding. The role of the MR as a pattern recognition receptor has been 
well studied and it has been reported to bind to a wide variety of pathogens like HIV-1 
(106), Mycobacterium tuberculosis (107), Candida albicans (108), Trypanosoma 
cruzi (109), Pneumocystis carinii (110) and Streptococcus pneumoniae (111). It 
preferentially targets mannose-containing structures and differs from DC-SIGN, as it 
does not interact with Lewis x, despite having affinity for fucose (112). This can be 
explained by the differences in arrangement of CRDs, as DC-SIGN has one CRD and 
needs tetramerization for multivalent binding of its ligands, whereas the MR has 
eight CRDs. The cysteine rich N-terminal was recently shown to be involved in the 
binding of sulphated oligosaccharides (111), while the fibronectin type II domain 
mediates the activity of the MR to bind collagen (113). 
 
Cross talk between C-type lectins and Toll-like receptors 
Pathogens have evolved strategies to evade the hosts’ immune response by subverting 
the function of pattern recognition receptors. Certain PAMPs are recognized by TLRs 
and CLRs simultaneously, and although the signal transduction route upon TLR 
activation are well documented, CLR may also signal and thus influence DC 
functions. C-type lectin stimulation can either enhance or inhibit TLR signaling. 
Although C-type lectins do not seem to directly stimulate the immune system, they 
affect the balance between immunity and tolerance by influencing TLR signaling 
(114). 
 
Mycobacterium tuberculosis is a potent inducer of T helper 1 (TH1)-polarized 
immune response, and mycobacterial components have often been shown to 
stimulate expression of co-stimulatory molecules and IL-12 production in DCs 
through TLR2 and TLR4 triggering (115). M. tuberculosis strongly binds to DC-SIGN 
through their mannose-capped cell-wall component lipoarabinomannan (ManLAM). 
ManLAM targets CLRs to alter the immune response though cross talk between TLRs 
and CLRs. In particular, binding of the mycobacterial component ManLAM to 
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immature DCs inhibited LPS-induced maturation and subsequent LPS-mediated IL-
12 induction. Inhibitory anti-DC-SIGN antibodies could restore maturation of DCs in 
the presence of ManLAM. The inhibition of DC maturation and the induction of IL-10 
may contribute to the virulence of mycobacteria (115). Thus pathogen recognition by 
DC-SIGN may modulate DC-induced immune responses, shifting the balance from 
immune activation toward impairment of the immune response, which would be 
beneficial to pathogen survival. How DC-SIGN signals are propagated within DCs is 
not clear. Recently, Caparros and coworkers, revealed the first clues on signaling 
transduction pathways upon DC-SIGN-ligation. They showed that DC-SIGN induces 
the phosphorylation of ERK and Akt, without the concomitant p38MAPK activation 
(116).  
 
Dectin-1, a β-glucan receptor that is expressed on DCs and macrophages, and TLR-2 
synergize in yeast recognition. The collaborative signaling of these two receptors 
induces enhanced production of IL-12 and TNF-α in DCs and subsequently facilitates 
a TH1 response (117). Studies showed that the cytoplasmic tail in particular the ITAM 
motif, is involved in generating enhanced stimulatory capacity (118). Interestingly, a 
similar motif that mediates signaling in dectin-1 is present in the cytoplasmic tail of 
DC-SIGN, however there is no evidence yet for DC-SIGN that it can signal through 
this motif in a similar manner. 
 
The studies described above demonstrate that the collaborative recognition of 
distinct microbial components or a pathogen by different classes of innate immune 
receptors (TLRs and CLRs) is crucial for orchestrating inflammatory or inhibitory 
responses. The balance between CLR binding and TLR stimulation may fine-tune 
regulatory mechanisms to allow appropriate immune responses. To maintain 
homeostatic control and silence immune activation pathogens have evolved a survival 
strategy within the host environment. CLRs can induce unique intracellular signals 
that modulate DC function, although the precise signaling pathways need further 
investigation. Signals derived from CLRs and TLRs will determine whether pathogens 
escape immunity or are eliminated (119).  
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Immune response to Schistosomes 
Schistosome infection presents a complex challenge to the immune system. Many 
helminth parasites are long-lived and cause chronic infections. The immune response 
that develops during this time often proceeds to cause pathologic changes that in 
many helminth infections are the primary cause of the disease. 
 
Schistosomes use a wide array of strategies to evade the host immune system. They 
use molecular mimicry to evade the immune defense of the snail host (120). In 
humans schistosomes have an impressive array of immune evasion and repair 
mechanisms, which include the ability to mask their surface by the acquisition of host 
molecules, to enzymatically cleave antibodies, and to rapidly replace their surface 
with unique double membranes using pre-formed membrane vesicles (121-124).  
 
The infective stage, cercariae stimulate the onset of a TH1 response during the first 5 
weeks of infection, which is maintained during the schistosomula and worm stage of 
the life cycle. As infection progresses and eggs are released by the adult worms, the 
response switches towards a TH2 response, driven by schistosome-egg antigens and 
the TH1 responses declines (8;9). Increased numbers of eosinophils, basophils and 
mast cells, and high circulating levels of IgE accompany the TH2 response. The 
antigens released by the eggs orchestrate the development of granulomatous lesions 
in the liver (125). By surrounding the egg, the granuloma segregates the egg from 
hepatic tissue and allows continuing liver function. In the long term as the egg dies 
and the granuloma resolves, fibrosis can develop (125). This can result in increased 
portal blood pressure and bleedings, which are the most common death-cause during 
schistosomiasis. In mouse models it has been shown that granulomas are not formed 
in CD4 T cell deficient mice. These mice die of the toxic effect that certain egg 
proteins have on the hepatocytes (126;127). 
 
Glycosylated components of schistosome eggs have been shown to affect the 
production of cytokines by DCs (128) and DCs stimulated by egg-derived antigens in 
vitro can promote TH2-cell responses both in vitro and in vivo (129). Several 
helminth-derived structures, including glycans have been identified to interact with 
TLRs and induce innate immune responses. Lacto-N-fucopentaose III (LNFPIII), a 
milk sugar terminating in Lewis x conjugated to human serum albumin, has been 
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shown to activate murine dendritic cells via TLR4, whereas the non-fucosylated 
analogue lacks this activity. The activation of TLR4 by LPS leads to the activation of 
three MAP-Kinase intracellular pathways: via ERK, P38 and JNK, whereas activation 
of TLR4 via LNFPIII leads to the activation of the ERK pathway only (58). When 
lipids from schistosome eggs were fractionated into different classes and their effect 
on DCs were analyzed, it became clear that the fraction containing 
phosphatidylserines could interact with DCs and affect their T cell polarizing 
capacity. Lysophosphatidylserine from helminth eggs activates TLR-2 at the cell 
surface of DCs and influence their functional maturation such that they induce IL-10-
secreting regulatory T cells (60;130). Glycoconjugates within the soluble egg antigen 
preparation containing β2-xylose and core α3-fucose, but possibly also other glycan 
antigens, seem to play an important role in TH2 polarization in vivo (131).  
 
While the role of DCs as the initiators of egg-antigen specific responses during 
infection has not been established, it is clear that DCs pulsed with SEA in vitro are 
capable of inducing TH2 responses. The interaction between host lectins and 
schistosome antigens seem to play an important role. Several lectins that bind to 
schistosome glycans have been described. Galectin-3 has been shown to bind to both 
LN and LDN and to be capable of stimulating the uptake of LN and LDN containing 
particles by macrophages (132). DC-SIGN binds to schistosome soluble egg antigens 
via the Lewis x and LDNF epitope (77). DC-SIGN also interacts with cercarial 
glycolipids of Schistosoma mansoni expressing Lewis x and pseudo-Lewis y (133). 
The C-type lectin MGL binds to terminal α- and β-linked GalNAc and interacts with 
SEA through the β-linked GalNAc in LDN and its derivates (98). The murine 
mannose receptor was shown to interact with SEA by using a chimera consisting of 
CRDs 4-7.  In Chapter 7 we show that the interaction of SEA with DCs is dependent of 
multiple C-type lectins, DC-SIGN, MGL and mannose receptor respectively (134). 
However, at this moment it remains unclear whether these interactions have 
implications for the immunomodulatory and/or stimulatory effects of schistosome 
glycans in the immune response to Schistosoma mansoni, nor is it clear whether 
these CLRs stimulate or inhibit each others functions. 
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Outline of this thesis 
The studies described in this thesis have been performed to gain more insight in the 
recognition of Schistosoma mansoni glycans by C-type lectins and the consequences 
for dendritic cell mediated immune responses. As a first approach to understand the 
molecular interactions of schistosome glycans and dendritic cells that lead to TH2 cell 
polarization, the recognition of schistosome glycan antigens by DCs were 
investigated. In chapter 2 and 3 we describe the carbohydrate specificity of DC-
SIGN and MGL respectively, by performing a glycan array using an Fc-chimera. Next, 
the molecular basis of differences in carbohydrate binding properties of DC-SIGN 
and its homologue L-SIGN were investigated in chapter 4. The interaction of DC-
SIGN with self- glycoproteins was analyzed in chapter 5, by determining the DC-
SIGN ligands that are crucial for the adhesion and rolling of dendritic cells on 
endothelial cells, a prerequisite for migration of DCs to the lymph node. The 
interactions of DC-SIGN with glycolipids of different life stages of the human parasite 
Schistosoma mansoni were investigated in chapter 6. In chapter 7 we demonstrate 
that Schistosoma mansoni soluble egg antigens are recognized by several C-type 
lectins on dendritic cells and suppress TLR- induced DC maturation. Finally, the 
results presented in this thesis are integrated in a general discussion and main 
perspectives for future studies are discussed in chapter 8. 
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Abstract  
The dendritic cell specific C-type lectin dendritic cell specific ICAM_ grabbing non-
integrin (DC-SIGN) binds to “self” glycan ligands found on human cells and to 
“foreign” glycans of bacterial or parasitic pathogens. Here, we investigated the 
binding properties of DC-SIGN to a large array of potential ligands in a glycan array 
format. Our data indicate that DC-SIGN binds with Kd < 2 μM to a neoglycoconjugate 
in which Galβ1-4(Fucα1-3)GlcNAc (Lex) trisaccharides are expressed multivalently. A 
lower selective binding was observed to oligomannose-type N-glycans, diantennary 
N-glycans expressing Lex and GalNAcβ1-4(Fucα1-3)GlcNAc (Lac-di-Nac-fucose), 
whereas no binding was observed to N-glycans expressing core-fucose linked either 
α1-6 or α1-3 to the Asn-linked GlcNAc of N-glycans. These results demonstrate that 
DC-SIGN is selective in its recognition of specific types of fucosylated glycans and 
subsets of oligomannose- and complex-type N-glycans.  
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Introduction 
The innate immune system provides the first line of defense by detecting the 
immediate presence of pathogens and determining the nature of subsequent immune 
events. Recognition of invading pathogens by macrophages and dendritic cells (DCs) 
is mediated by pattern-recognition receptors (PRR), including Toll-like Receptors (1) 
and C-type lectins (2). C-type lectins bind carbohydrates in a Ca2+-dependent 
manner, using conserved carbohydrate recognition domains (CRDs). The binding of a 
glycan to the CRD may depend on more than one monosaccharide and on subtle 
differences in the spatial arrangements of these monosaccharides. C-type lectins 
containing CRDs with similar monosaccharide selectivity can also bind their ligands 
in distinct ways. In addition, oligomerization of CRD domains may alter the affinity 
and specificity of binding. The differential expression of many different (C-type) 
lectins in combination with their binding properties, thus create unique sets of 
carbohydrate recognition profiles on DCs (3;4).  
 
DC-SIGN (Dendritic Cell-Specific ICAM-3-Grabbing Non-integrin; CD209), is a type 
II transmembrane C-type lectin with a single C-terminal CRD (5). The CRD is 
separated from the transmembrane region by a neck domain that is thought to affect 
the formation of oligomers (6). DC-SIGN binds to “self” glycan ligands found on 
human cells (7;8) as well as to “foreign” glycans derived from bacterial or parasitic 
pathogens (9-11). The results from several studies using recombinant or cell surface 
expressed DC-SIGN, indicate that DC-SIGN typically recognizes at least two classes 
of glycans, mannose rich, and fucosylated glycans (9, 12-14). To increase our 
understanding of the function of DC-SIGN, we report here a detailed and (semi-) 
quantitative characterization of the glycan binding specificity and properties of DC-
SIGN-Fc to more than 100 glycans, including several complex-type N-linked glycans 
not tested previously. 
 
Materials and methods 
Antibodies and cells. Anti-core fucose polyclonal antibodies were obtained as 
described previously (15). The monoclonal antibody (mAb) G8G12 recognizes Lex 
(16), mAb SMLDN1.1 recognizes GalNAcβ1-4GlcNAc (Lac-di-Nac, LDN) (17) and 
mAb SMFG4.1 binds GalNAcβ1-4(Fucα1-3)GlcNAc (Lac-di-Nac-fucose, LDNF) 
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glycan antigens (11). DC-SIGN-Fc has been described previously (18). Chinese 
hamster ovary (CHO) cells were cultured in RPMI-1640 (Gibco, BRL, USA) with 10% 
FCS (BioWithaker, Verviers, Belgium) 100 units/ml penicillin and 100 μg/ml 
streptomycin (Pen/Strep). CHO cells stably expressing the Polyoma virus large T 
antigen (CHOP2) were kindly provided by Dr. James Dennis (Toronto, Canada) (19). 
CHOP2 cells are deficient in sialic acid transport, resulting in >90% reduction in 
sialic acid content (20). CHOP8 cells derived from CHO glycosylation mutant Lec8 
are defective in UDP-galactose transport, resulting in truncated glycans without 
galactose (21). CHO PIR-P3 cells, were kindly provided by Dr. Mark Lehrman (Dallas, 
Texas) (22). Lec8 cells stably transfected with Caenorhabditis elegans β1-4-N-
acetylgalactosaminyltransferase (β1-4GalNAcT) expressing poly-LDN glycans, and 
Lec8 cells stable transfected with β1-4GalNAcT and fucosyltransferase IX (FUT 9), 
expressing poly-LDNF glycans, have been described previously (23). Where 
indicated, cells were cultured during 5 days in the presence of the α-mannosidase-I 
inhibitor kifunensine (2 μg/ml; Calbiochem, USA). Efficiency of treatment was 
assessed by flow cytometry analysis using Concanavalin A AlexaFluor-488 (Molecular 
probes, Inc., Eugene, OR).  
Transient transfection and flow cytometry. Cells were incubated until 50-80% 
confluency. Transfection was performed according to the manufacturer’s protocol. In 
short, both DNA and LipofectAMINE (Invitrogen, Carlsbad, CA) were diluted in 
serum-free medium and combined to allow DNA-liposome complexes to form and 
subsequently added to the cells. After 24 h the medium was replaced with fresh, 
complete medium. Forty-eight hours after transfection cells were used for flow 
cytometry (FACSscan, BD Pharmingen, San Diego, CA) to detect binding of anti-
glycan antibodies and DC-SIGN-Fc in TSM (20 mM Tris HCl pH 7.4, containing 150 
mM NaCl, 2mM CaCl2 and 2mM MgCl2) with 0.5% BSA (TSA), using FITC or 
AlexaFluor-conjugated anti-human or anti-mouse secondary antibodies.  
Glycosidase treatment of cell-lysates, SDS-PAGE and Western Blotting. Cells were 
lysed in 50mM Tris-HCl pH 7.4, containing 0.1% sodium dodecyl sulfate (SDS) and 
protease inhibitors. Where indicated lyophilised lysates were treated by 
endoglycosidase H (EndoH, recombinant Escherichia coli, Boehringer, Mannheim 
GmbH, Germany) or α-mannosidase (from Jack Beans, Sigma-Aldrich, St Louis, MO) 
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according to the manufacturer’s protocol. The proteins within the lysates were 
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 12.5 % gels, 
using the Mini-Protean III system (Biorad, Hercules, CA) and blotted onto a 
nitrocellulose membrane (Schleicher and Schuell, Bioscience Inc, Dassel, Germany). 
After blocking the membrane with 5 % BSA (Fluka Biochemica) in TSM, the blots 
were incubated with DC-SIGN-Fc (5 μg/ml) in TSA, washed in TSM containing 0.1 % 
Tween-20 (ICN Biomedicals Inc., Aurora, Ohio) and incubated with peroxidase-
labeled goat-anti-human IgG-Fc (Jackson, West Grove, PA). Bound DC-SIGN-Fc was 
detected by measuring chemiluminescence, using Supersignal WestPico 
Chemiluminescence substrate (Pierce, Rockford, IL), in an Epi Chemi II Darkroom 
(UVP bioimaging systems, Upland, CA) and Labworks Software (UVP, USA). 
 
Fluorescence solid phase glycan array. Streptavidin-coated high binding capacity 
black plates (Pierce, Rockford, IL) were washed three times with 200 μl TSM and 
coated at saturating densities with biotinylated oligosaccharides, glycopeptides or 
polyacrylamide (PAA) coupled glycoconjugates (~20% substitution, Lectinity, 
Lappeenranta, Finland) in TSA. After washing with TSM, purified DC-SIGN-Fc (5 
μg/ml in TSA) or an antiglycan antibody (to determine coating efficiency) was added. 
Bound DC-SIGN-Fc was detected after incubation with AlexaFluor-488 goat anti-
human- or mouse-IgG (5 μg/ml; Molecular Probes) by measuring fluorescence 
(FluoStar, BMG Labtech GmbH, Offenburg, Germany). The assays were performed in 
triplicate and background fluorescence was subtracted from each sample. The glycan 
array screening (ELISA-based) was performed by Core H of the Consortium of 
Functional Glycomics. The array used was Version 1.1.a. containing glycan structures 
with the CFG numbers (#) 1-89, as described in supplemental data of Bochner et al., 
(24). In addition, a secondary screening was performed with in addition glycans with 
the CFG # 112, 114, 129-132, 185 and 186, which are described in supplemental data 
by Coombs et al., (25) . The structure Bi-Lex was synthesized starting with 
desialylated human transferrin, which was fucosylated using recombinant 
fucosyltransferase VI (Calbiochem, Germany) and GDP-fucose. All used glycan 
structures and their CFG numbers, as well as standard procedures for glycan array 
testing by the Consortium for Functional Glycomics are available at 
http://web.mit.edu/glycomics/consortium.
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Surface plasmon resonance. All surface plasmon resonance (SPR) experiments were 
performed at 25ºC on a Biacore 3000 instrument (Biacore Inc., Piscataway, NJ). The 
running buffer used was TSM containing 0.005 % Tween20. Biotinylated glycans 
were captured on research grade streptavidin-coated sensor chips (Sensor Chip SA, 
Biacore Inc.) that were pretreated with three 1 min infusions of 1M NaCl in 50 mM 
NaOH. A 10 fmol/μl solution of each biotinylated glycan was injected at 2 μl/min for 
7.5 min to capture each glycan on an independent surface. In total, 3 different glycans 
and a control (non-binding) glycan, were studied using one SA sensor chip. Specific 
binding of DC-SIGN-Fc to the test glycans was measured using the in-line reference 
subtraction feature of the Biacore 3000 instrument. Increasing concentrations of DC-
SIGN-Fc were injected at a flow-rate of 35 μl/min over all four surfaces of the sensor 
chip. The equilibrium binding data of DC-SIGN-Fc were analysed by non-linear curve 
fitting of the Langmuir binding isotherm using the BIAevaluation software (Biacore 
Inc., Piscataway, NJ).  
 
Results 
Analysis of the glycan-binding specificity of DC-SIGN-Fc by glycan array screening. 
Binding of the chimeric DC-SIGN-Fc to a total of 100 different glycan structures was 
analyzed using glycan-array technology. In these arrays, similar amounts of 
individual biotinylated glycans or glycopeptides were immobilized on streptavidin-
coated plates, allowing semi-quantitative binding analysis (Consortium for 
Functional Glycomics). The consolidated data of the glycan array are shown in Figure 
1. DC-SIGN-Fc binds to N-linked oligomannose with the highest apparent affinity for 
the structure Man9GlcNAc2, and decreasing binding apparent affinity as the number 
of mannoses decreases, as shown in Figure 1A. DC-SIGN-Fc shows binding to several 
fucosylated glycans. Of the glycans tested, Lewis b (Fucα1-2Galβ1-3(Fucα1-
4)GlcNAcβ; Leb) shows the highest relative binding, followed by Lewis y (Fucα1-
2Galβ1-4(Fucα1-3)GlcNAcβ; Ley) and Lewis a (Galβ1-3(Fucα1-4)GlcNAcβ; Lea). The 
trisaccharides Lewis x (Galβ1-4(Fucα1-3)GlcNAcβ;Lex) and LDNF (GalNAcβ1-
4(Fucα1,3)GlcNAc) are bound slightly less efficiently, however diantennary N-glycans 
containing these epitopes (bi-Lex and bi-LDNF) show a 4-fold increase in binding of 
DC-SIGN-Fc over the terminal trisaccharides alone (Figure 1B). The α1-6 core-
fucosylated Man3GlcNAc2 is not bound by DC-SIGN. From these results it can be 
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concluded that presentation of DC-SIGN glycan ligands, such as Lex or LDNF, within 
a diantennary N-glycan clearly enhances binding as compared to the individual 
glycan determinants. 
 
 
 
Figure 1. Consolidated data of glycan array. 
A glycan array was probed with DC-SIGN-Fc (5 μg/ml). After subtraction of the background signal, the 
level of fluorescence for each sample was determined by taking the average ± standard deviation of 
three wells tested. NC, negative control (biotinylated spacer).  A) Binding of DC-SIGN-Fc to 
oligomannose-type N-glycans. B) Consolidated data of the glycan array. A Schematic representation is 
given of the carbohydrate structure, the common name, the signal/noise ratio (S/N) and the relative 
binding affinity, calculated as relative to the glycan with highest binding (bi-LDNF). A relative binding 
of 10% or lower was considered as background based on the values of the negative controls. 
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Binding of DC-SIGN-Fc to multivalent neoglycoconjugates 
The binding of DC-SIGN to multivalent glycans was tested in a similar solid phase 
assay by using biotinylated polyacrylamide (PAA) that is modified to contain 
monosaccharides or fucose- or mannose-containing glycans. By titrating DC-SIGN-Fc 
in the binding assays, the IC50 was established, with the IC50 being the 
concentration that shows 50 % of the maximal binding to the different PAA-
neoglycoconjugates. Figure 2A shows the titration curves for some of the glycans 
tested. Based on their binding properties, the PAA-linked glycans tested in this assay 
can be divided into four groups (Figure 2B). The first group contains 
neoglycoconjugates carrying Lea or Leb, which show binding even when low 
concentrations DC-SIGN-Fc are used (IC50 between 2 and 4 μg/ml). 
Neoglycoconjugates containing Lex, Ley, 6-sulfo-Lea and mannotriose 
(Manα1,3(Manα1,6)Man) showed binding at intermediate DC-SIGN concentrations 
(IC50 between 5 -6 μg/ml), whereas H-type-2 antigen (Fucα1-2Galβ1-4GlcNAc) and 
α-L-fucose, showed only a low binding when high DC-SIGN-Fc concentrations were 
used (IC 50 between 8 and 15 μg/ml). The last group consists of neoglycoconjugates 
carrying sialyl-Lex, 6-sulfo-Lex and α-D-mannose, which were not bound by DC-
SIGN-Fc (Figure 2B). 
DC-SIGN binds to glycan epitopes on the surface of cells 
To study the binding of DC-SIGN to cell-surface expressed glycoconjugates, which 
more likely represents the natural presentation, the binding capacity of recombinant 
DC-SIGN-Fc to CHO cells and CHO-glycosylation mutants was determined by FACS 
analysis. The results show that DC-SIGN-Fc does not bind to wild-type CHO cells or 
to CHOP2 cells (CHO cells that carry glycans lacking sialic acid) (Figure 3). By 
contrast, low binding was observed to CHOP8 cells, CHO cells that are deficient in 
UDP-galactose transport due to a lec8 mutation (Figure 3) (21). These cells express 
N-glycans with terminal GlcNAc, and truncated O-glycans with terminal GalNAc (Tn 
antigen). The glycan-array studies described above, as well as previous studies of 
others, have shown that oligomannose-type N-glycans are recognized by DC-SIGN in 
vitro (6, 26-28). To analyze the binding of DC-SIGN to whole cells carrying 
oligomannose-type N-glycans on glycoproteins, we cultured CHOP2 cells in the 
presence of kifunensine, an inhibitor of α-mannosidase I, which causes expression of 
mainly Man9GlcNAc2. DC-SIGN-Fc binds very well to CHOP2 cells cultured with 
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kifunensine, suggesting that oligomannose-type N-glycans on cell-surface expressed 
proteins are recognized ligands within the context of cellular expression (Figure 3).  
 
Figure 2. Binding of DC-SIGN-Fc to multivalent neoglycoconjugates. 
A) A quantitative fluorescent solid phase assay was performed with different PAA-biotinylated 
glycoconjugates (1 μg/ml) coated on a streptavidin coated high binding capacity black plate. DC-SIGN-
Fc was titrated on to the plate (ranging from 0 to 15 μg/ml) and detected with goat anti-human Alexa 
Fluor-488-labeled. Samples were tested in triplicate and the average is shown as relative fluorescence 
units (RFU). One representative experiment out of three is shown. B) The concentration of DC-SIGN-
Fc that shows 50% of the maximal binding (IC50) was determined. ND means that the IC50 could not 
be determined.
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Figure 3. Binding capacity of DC-SIGN-Fc to CHO glycosylation mutants. 
In the left panel, the black histogram shows the binding of DC-SIGN-Fc  (goat anti-human Alexa 
Fluor) to these cells and the middle panel shows whether the binding is Ca2+-dependent (binding in 
the presence of EDTA). In grey non-stained cells are shown. In the last panel a typical N-glycan 
structure for each cell-line is shown. One representative experiment out of three is shown.  
 
To investigate whether the binding of DC-SIGN-Fc to CHOP2 cells cultured in the 
presence of kifunensine was indeed dependent on binding to the oligomannose-type 
glycans, the cells were lysed and proteins were separated by SDS-page followed by 
Western blotting and binding of DC-SIGN-Fc was detected. No binding of DC-SIGN-
Fc to CHOP2 cells was observed on Western blots. Analysis of the binding of DC-
SIGN-Fc to kifunensine-treated CHOP2 cells revealed binding to a wide array of 
glycoproteins with apparent Mr between 70 –120 kD (Figure 4). Treatment of the 
cell-lysate with endoglycosidase H, an enzyme that removes oligomannose-type 
glycans, or alternatively with α-mannosidase, that cleaves terminal α-linked mannose 
residues, abolished binding of DC-SIGN-Fc completely (Figure 4, data not shown). 
This indicates that the oligomannose-type glycans in the cell-lysate are the ligands of 
DC-SIGN. CHO-cells PIR-P3, which are resistant to the plant lectin Phaseolus 
vulgaris erythroagglutinin primarily express N-glycans of the Man3GlcNAc2 type (70-
75%) (22). DC-SIGN-Fc bound well to these CHO PIR-P3 cells, which can be blocked 
by EDTA, indicating that the binding is Ca2+-dependent as would be expected (Figure 
3). In conclusion, whereas DC-SIGN-Fc does not bind to wild-type CHO cells or 
CHOP2 cells, it binds to both oligomannose-type N-linked glycans or N-glycans with 
the structure Man3GlcNAc2 on the cell surface. 
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Figure 4. Binding of DC-SIGN-Fc to 
CHOP2 cells cultured with kifunensine on 
Western blot.  
Cell-lysates were made of CHOP2 cells cultured 
with or without kifunensine. Cell-lysates were 
treated with endoglycosidases as indicated. The 
proteins of the lysate were separated by SDS-
PAGE and transferred to a membrane for 
Western blotting. The binding of DC-SIGN-Fc to 
CHOP2 cells cultured with kifunensine was 
abolished after treatment with Endo H, 
indicating that DC-SIGN-Fc binds to 
oligomannose-type glycans expressed by CHOP2 
cells.
 
 
Transfection of specific glycosyltransferases can induce the expression of DC-SIGN 
ligands on CHOP2 cells 
To modify the cellular glycans expressed by CHOP2 cells, the cells were transiently 
transfected with different glycosyltransferase cDNAs and the binding of DC-SIGN-Fc 
to these cells was analyzed. CHOP2 cells were transfected with the cDNA of human 
fucosyltransferase IV (FUT IV) (29) and Arabidopsis thaliana core α1-3fucosyltrans- 
ferase (C3FT)  (30), respectively. The expression of the induced glycan antigens and 
the binding of DC-SIGN-Fc were determined by FACS analysis. FUT-IV adds a fucose 
in an α1-3 linkage to Galβ1-4GlcNAc, generating the Lex epitope (Figure 5).  Using an 
anti-Lex antibody it was demonstrated that 35% of the cell population following 
transfection carried the Lex epitope. DC-SIGN-Fc binds to the CHOP2 cell fraction 
expressing FUT-IV (Figure 5). CFT3 adds a fucose in α1−3 linkage to the Asn-linked 
GlcNAc of N-glycans, thus forming a highly immunogenic glycan epitope such as 
found in plant- and insect allergens, as well as in parasitic helminthes (15). FACS-
analysis clearly showed that the core α1-3fucose is present in 30% of the cells, 
reflecting the transfected population, however no binding of DC-SIGN-Fc could be 
detected (Figure 5). To analyze the binding of DC-SIGN to LDNF-containing 
glycoproteins expressed on the surface of cells, stably transfected CHO cells 
expressing either poly-LDN or poly-LDNF glycans (23) were tested for their ability to 
bind DC-SIGN-Fc. CHO cells expressing poly-LDNF glycans showed strong binding 
of DC-SIGN-Fc (Figure 5) in a Ca2+-dependent manner, whereas no binding of DC-
SIGN-Fc was detected to CHO cells expressing poly-LDN. These results demonstrate 
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that DC-SIGN binds to Lex-expressing and LDNF-expressing glycans on cell surfaces 
but not to surface glycans lacking these epitopes in CHO cells. 
 
 
Figure 5. The binding capacity of DC-SIGN-Fc to CHOP2 cells transfected with 
glycosyltransferases. 
The binding of DC-SIGN-Fc to CHOP2 cells transfected with cDNAs of glycosyltransferases was 
analyzed by flow cytometry. In the left panel, the binding to DC-SIGN-Fc (secondary antibody goat-
anti human Alexa Fluor 488) is shown in black and non-stained cells are shown as grey lines. In the 
second panel, the expression was determined by staining the cells with a specific anti-glycan-antibody 
(goat-anti mouse Alexa Fluor 488). The parental CHO cells are all negative in staining with the anti-
glycan antibodies (results not shown). The second and third rows indicate CHOP2 cells that are 
transiently transfected with cDNAs encoding for, respectively, FUT VI and core α1-3-
fucosyltransferase (CFT3), resulting in approx. 35% of the cells being transfected. The fourth (poly-
LDN) and fifth row (poly-LDNF) show stably transfected cells (100 % of the cells expressing the 
glycosyltransferases). In the right panel a typical N-glycan structure for each cell is depicted. The 
arrows indicate the monosaccharides added by the different glycosyltransferases. Cells were gated on 
forward and side scatter and the mean fluorescence of one representative experiment out of three is 
shown.  
 
Affinity of DC-SIGN-Fc binding 
The binding affinities of DC-SIGN-Fc for Man8GlcNAc2, bi-LDNF and Lex-PAA 
biotinylated neoglycoconjugates were determined by Surface Plasmon Resonance 
(SPR) using a streptavidin-coated sensor chip. Bi-LDN was captured on one surface 
of the sensor chip and used as negative control. DC-SIGN-Fc showed specific binding 
to all three glycans tested (Figure 6A). The sensorgram shows that upon injection, the 
binding of DC-SIGN-Fc to Lex-PAA neoglycoconjugate slowly reached equilibrium 
and the bound DC-SIGN-Fc slowly dissociated after injection was stopped. By 
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contrast, DC-SIGN-Fc binding to Man8GlcNAc2 and bi-LDNF rapidly reached 
equilibrium in the first few seconds after injection, and fast dissociation of the bound 
DC-SIGN-Fc was observed. The apparent dissociation constant (Kd) for DC-SIGN-Fc 
to the three test glycans was determined in triplicate by varying the concentration of 
DC-SIGN-Fc from 0 – 12 μM. For Lex-PAA the apparent Kd is 1.74 μM (Figure 6B), 
whereas the apparent Kd to Man8GlcNAc2 and bi-LDNF is at least 2 times lower than 
the Kd measured for Lex-PAA neoglycoconjugate (results not shown).  
 
 
Figure 6.  Binding of DC-SIGN-Fc to bi-LDNF, Man8GlcNAc2 and Lex-PAA as assessed by 
Surface Plasmon Resonance (SPR) 
A) Specific binding is shown of DC-SIGN-Fc to bi-LDNF, Man8GlcNAc2 and Lex-PAA. The SPR-
response (in resonance units) versus time (in seconds) is shown using 6 μM DC-SIGN-Fc. 
B) Affinity of DC-SIGN-Fc binding to Lex-PAA as measured by SPR. The equilibrium SPR response is 
plotted versus the DC-SIGN-Fc concentration, using DC-SIGN-Fc concentrations of 0 – 12 μM. The 
data were analyzed by non-linear curve fitting and one representative experiment out of four is shown. 
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Discussion 
Recent evidence indicates that dendritic cell associated DC-SIGN may have a dual 
function in the induction of tolerance to self-antigens and recognition of pathogens, 
respectively. Because the function of dendritic cells may be dependent on their 
binding properties to self-antigens and pathogens, it is essential to obtain detailed 
insight in the carbohydrate-binding properties of DC-SIGN. In this report, we 
describe the glycan-binding profile of DC-SIGN by determining its binding properties 
to a library of glycan structures and glycopeptides on a glycan array, as well as to 
glycans expressed multivalently, and cell-surface expressed glycans. For these studies 
we used an Ig fusion protein, DC-SIGN-Fc, which has a binding site on each arm of 
the IgG chimera, and is therefore bivalent (18). Using glycan arrays assembled by the 
Consortium for Functional Glycomics, we showed that DC-SIGN-Fc interacts with 
various α1-3 and α1-4 fucosylated tri- and tetrasaccharides, such as the monovalent 
Lewis antigens and LDNF, and with increased affinity to mannose type N-glycans 
carrying 5 – 9 mannose residues and diantennary glycans comprising a Lex or LDNF 
antigen within each of the branches. Although some slight differences are seen, the 
general conclusion is that the binding properties of DC-SIGN-Fc are very similar to 
those of the renatured tetramer of DC-SIGN, as reported recently by Guo et al. (13). 
In previous studies we already demonstrated that bivalent DC-SIGN-Fc and natural, 
cell-surface expressed DC-SIGN that is understood to be tetrameric (31, 28), show 
very similar binding properties (9, 14). Together, these data indicate that DC-SIGN-
Fc is a reliable tool to study the binding properties of DC-SIGN to its glycan ligands.  
 
Using extended glycan arrays from the Consortium of Functional Glycomics and 
cellular adhesion assays, we show here for the first time that DC-SIGN is able to bind 
LDNF present within N-glycans. The difference in structure between Lex and LDNF is 
the N-acetyl group of the GalNAc residue in LDNF.  Apparently, this additional N-
acetyl group does not interfere with DC-SIGN binding, similar to the situation in Ley 
where an additional fucose occurs that is linked to the 2 position of Gal (14). 
However, in contrast to the situation for Lewis structures or LDNF, DC-SIGN is 
highly specific for the nature of the glycans expressing Fucα1-3GlcNAc moieties, 
since it does not bind to that structure when it is part of the core structure of an N-
glycan. This may be due to the lack of a GlcNAc linked Gal or GalNAc that contributes 
to the binding to the CRD domain of DC-SIGN and/or spatial interference of the 
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distal aspects of the N-glycan (13, 14). This lack of binding to core α1-3-fucose 
residues indicates that DC-SIGN is not directly involved in the induction of immune 
responses to this glycan epitope or glycotope that have been demonstrated to occur in 
plant- and insect induced allergies (32). 
 
The glycan array data indicate that a 4-fold increase in binding affinity of DC-SIGN-
Fc was found towards a diantennary N-glycan containing Lex (bi-Lex) and a 
diantennary N-glycan containing LDNF (bi-LDNF), compared to the respective 
trisaccharide determinants. Considering the bivalent nature of DC-SIGN-Fc it would 
in principle be possible that the two binding sites on each arm of the IgG chimera 
associate and dissociate from the two Lex/LDNF units of the diantennary glycan with 
the same binding parameters. To test if a multivalent presentation would increase the 
affinity even further, we used SPR to analyze the specificity and affinity of the binding 
of DC-SIGN-Fc to a neoglycoconjugate where Lex is coupled multivalently to 
polyacrylamide (Lex-PAA), and compared the binding properties to those towards bi-
LDNF and the oligomannose-type glycan Man8GlcNAc2. The SPR data show that 
binding of DC-SIGN-Fc to all three ligands is specific.  By analysis of the DC-SIGN-Fc 
data for equilibrium binding responses, an apparent Kd of 1.7 μM was found towards 
Lex-PAA, whereas the apparent Kd for Man8GlcNAc2 and bi-LDNF was at least 5 μM. 
Whereas these experiments give insight in the affinity range of DC-SIGN binding to 
its ligands, it should be noted that the data cannot directly be compared 
quantitatively, since the polyvalent nature of the ligand Lex-PAA will introduce 
avidity effects, whereas Man8GlcNAc2 is a monovalent ligand by contrast.  In 
addition, and in contrast to the binding pattern to Lex-PAA and Man8GlcNAc2, we 
could not determine a consistent binding pattern of DC-SIGN-Fc to bi-LDNF by SPR. 
It may be that both DC-SIGN subunits differentially interact with the bi-LDNF 
structure because the spacing or orientation of both branches does not allow proper 
bivalent binding to both LDNF units.   
 
The affinity of DC-SIGN binding in the low μM range (2 - 10 μM) to its glycan ligands 
is in the same range to those found for other mammalian lectins of biological 
importance. For example, both Siglec 8 and galectin 1 bind to their respective ligands 
with apparent Kd ~ 2-4 μM (24, 33). In vivo, we propose that a high degree of glycan 
binding can be achieved through tetramerisation of DC-SIGN at the cell surface (31, 
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28), which for example facilitates binding to oligomannose glycans as found on HIV-1 
(34). In addition, other pathogens are strongly recognized by DC-SIGN, which is 
likely to occur by combining an intermediate affinity with varying avidity effects, such 
as Schistosoma mansoni that expresses both Lex and LDNF antigens (35). We show 
here that DC-SIGN-Fc strongly binds to mammalian cells engineered to express N-
glycans carrying antennae with repeating LDNF units (23) structures that are indeed 
found within Schistosoma mansoni worms (36). These LDNF-expressing 
glycoproteins as well as Lex and pseudo-Ley expressing glycoproteins and/or 
glycolipids found in schistosomes are expected to be targets of humoral and cellular 
immune reponses during schistosome infection, in which DC-SIGN might play an 
important role (10, 11). 
 
It is becoming increasingly clear that an important aspect of DC-SIGN binding may 
also be provided by its potential to bind with high avidity to glycan ligands that are 
bound with very low relative affinity in their monovalent context. In the glycan array, 
we showed that DC-SIGN-Fc has no significant affinity to truncated N-glycans 
(Manα1-3(Manα1-6)Manβ1-2GlcNAcβ1-4GlcNAc-R, Man3). However significant DC-
SIGN-Fc binding was observed to glycosylation mutant cells expressing mainly 
Man3GlcNAc2 on their cell-surface, or to Manα1-3(Manα1-6)Man linked to PAA. 
Similar observations were obtained with H-type 2 glycans, carrying a α1-2-linked 
fucose. Interestingly, it was recently reported that a Neisseria meningitides LPS 
oligosaccharide mutant IgtB, which expresses GlcNAcβ1-3Galβ1-4-Glc-R outer core 
units, targets dendritic cells through DC-SIGN, thereby mediating highly efficient 
bacterial uptake and skewing of the immune response into a TH1 direction (37). 
Although our current glycan array data do not reveal GlcNAc as a ligand for DC-SIGN 
(13), we show here that DC-SIGN-Fc exhibits binding to the CHO glycosylation 
mutant Lec8 that expresses N-glycans carrying a terminal GlcNAc on its cell-surface. 
These data suggest that DC-SIGN may bind to terminal GlcNAc residues when they 
are presented at high density. Since a high density of repeating glycan moieties is 
generally lacking on mammalian cell surfaces or glycoproteins, this feature of DC-
SIGN binding through avidity and possibly clustering of DC-SIGN on the cell surface 
(31) may be of particular importance for pathogen recognition.  
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Our data show that DC-SIGN can bind various ligands in different ways, which may 
have consequences for how the pathogen or antigen is processed by DCs. Many 
pathogens exploit self-glycans or glycans that specifically target C-type lectins 
including DC-SIGN to direct the immune response in favor of their own survival and 
thus evade host immunity (38). The detailed dissection of molecular interactions 
between DC lectins and its glycan ligands as described here will, facilitate future 
studies to clarify the role of these lectins in modulation of dendritic cell functions. 
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Abstract 
Dendritic cells are key to the maintenance of peripheral tolerance to self-antigens and 
the orchestration of an immune reaction to foreign antigens. C-type lectins, expressed 
by dendritic cells, recognize carbohydrate moieties on antigens that can be 
internalized for processing and presentation. Little is known about the exact glycan 
structures on self-antigens and pathogens that are specifically recognized by the 
different C-type lectins and how this interaction influences dendritic cell function. We 
have analyzed the carbohydrate specificity of the human C-type lectin MGL using 
glycan micro array profiling and identified an exclusive specificity for terminal α- and 
β-linked GalNAc residues that naturally occur as parts of glycoproteins or 
glycosphingolipids. Specific glycan structures containing terminal GalNAc moieties, 
expressed by the human helminth parasite Schistosoma mansoni as well as tumor 
antigens and a subset of gangliosides, were identified as ligands for MGL. Our results 
indicate an endogenous function for dendritic cell expressed MGL in the clearance 
and tolerance to self-gangliosides, and in the pattern recognition of tumor antigens 
and foreign glycoproteins derived from helminth parasites.  
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Introduction 
Antigen presenting cells (APC), such as dendritic cells (DC) and macrophages (MØ) 
are the key players in the initiation and control of innate and adaptive immune 
responses. In order to perform their function both DC and MØ are equipped with a 
full array of specialized receptors, including adhesion receptors, costimulatory 
molecules and several pattern recognition receptors, such as C-type lectins and Toll-
like receptors (1). 
 
Within the last few years several C-type lectins, which recognize specific carbohydrate 
structures in a Ca2+-dependent manner, C-type lectin-like molecules and Selectins 
have been identified on both DC and MØ, including DC-SIGN (2), Mannose Receptor, 
Langerin, DEC205 and L-selectin (3). Specific glycosylation patterns regulate 
leukocyte homing and trafficking processes within the immune system (4). Changes 
in glycosylation can similarly control the interaction of DC with other cell types, 
thereby modulating migration and immune responses (5). Most C-type lectins, with 
the exception of DC-SIGN and Mannose Receptor, have been poorly characterized 
with respect to their carbohydrate specificity and function within the immune system. 
It has been postulated that C-type lectins function in cell-cell adhesion, antigen 
recognition and serve as signaling molecules influencing the balance between 
tolerance and immunity (6). C-type lectin stimulation can either enhance or inhibit 
TLR signaling thereby modulating DC phenotype and outcome of immune responses 
(7;8). The cytoplasmic tail of C-type lectins often contains signaling motifs or 
internalization motifs for processing of antigens (9).  
 
Predictions on carbohydrate specificities of C-type lectins for either Galactose-type or 
Mannose-type glycans can be made based on the primary amino acid sequence. 
However, knowledge on the exact carbohydrate recognition profile is essential to 
understand the importance of these receptors in immune related functions. Studies 
on carbohydrate recognition have long been hampered due to the complexity of 
glycan synthesis and the limited availability of isolated or synthesized glycans.  
Recognition of mannose- and fucose structures by DC-SIGN and Mannose Receptor 
on DC has been widely investigated. However, studies on Galactose or GalNAc 
recognition by DC are limited. One Galactose-type C- type lectin has been reported to 
be expressed by human DC, namely the Macrophage Galactose-type lectin (MGL, also 
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called DC-ASGPR or HML) (10-12). MGL is a member of the type II family of C- type 
lectins. MGL and is expressed on human and mouse immature DC and MØ in skin 
and lymph node (13). No natural ligand or function for MGL has been established yet 
(14). Mice contain two functional copies of the MGL gene, mMGL1 and mMGL2, 
whereas in humans only one MGL gene is found. mMGL1 and mMGL2 have different 
carbohydrate specificities for respectively Lewis X and α/β-GalNAc structures (15). 
Earlier studies on COS-1 transfectants of MGL suggested a specificity for the 
monosaccharides Galactose and GalNAc (16). In contrast, recombinant MGL 
produced in a bacterial expression system displayed restricted binding to GalNAc 
(17). The recognition of more complex oligosaccharides by human MGL has not been 
thoroughly investigated yet. 
 
To gain more insight in the function and carbohydrate specificity of MGL and 
Galactose/GalNAc recognition by human DC we set out to identify the carbohydrate 
recognition profile of human MGL using glycan microarray screening. The glycan 
array was developed by the Consortium for Functional Glycomics 
(http://web.mit.edu/glycomics/consortium) and consists of more than one hundred 
synthetic and natural glycan structures. The use of glycan arrays for the elucidation of 
carbohydrate recognition profiles of individual C-type lectins has been applied to 
Selectins, langerin and DC-SIGN homologues (18-20). 
 
Using a MGL-Fc chimeric protein, we identified oligosaccharides containing terminal 
α- or β-linked GalNAc residues as high affinity ligands for MGL. Such terminal 
GalNAc residues can be part of protein N- or O-linked glycans, or glycosphingolipids. 
Identification of this specificity led to the discovery of glycan antigens within egg 
glycoproteins of the pathogenic helminth Schistosoma mansoni as counterstructures 
for MGL. In addition MGL strongly interacted with tumor cells in a GalNAc-specific 
manner. Our results strongly implicate a role for MGL in recognition of self-
gangliosides, tumor antigens and pathogenic helminths by DC. 
Methods 
Cells. The adenocarcinoma cell lines SW948, SKBR3 and ZR75.1, CHO and CHO-
MGL cells and the melanoma cell lines BLM, FM3.29, FM6, SK23mel, 90.07 and 
00.09 were maintained in RPMI or DMEM medium (Invitrogen, Carlsbad, CA) 
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containing 8-10% fetal calf's serum. Immature monocyte derived DC were cultured 
for 5-7 days from monocytes obtained from buffy coats of healthy donors (Sanquin, 
Amsterdam) in the presence of IL-4 (500 U/ml) and GM-CSF (800 U/ml).  
Antibodies and reagents. The following mAbs were used: MLD-1 (anti-MGL (21)), 
AZN-D1 (anti-DC-SIGN), SMLDN1.1 and SMFG4.1 (anti-LDN (22) and anti-LDNF, 
respectively, kindly provided by dr. A. Nyame and dr. R. Cummings, University of 
Oklahoma Health Sciences Center, USA) and 6H3 (anti-Lewis X). Biotinylated 
polyacrylamide coupled glycoconjugates were obtained from Lectinity (~20% 
substitution, Lappeenranta, Finland). Crude Schistosoma mansoni soluble egg 
antigen extract was prepared as previously described (kindly provided by Dr. F. 
Lewis) (23). Forssman glycolipid was a kind gift from Dr. R. Geyer (University of 
Giessen, Germany). DC-SIGN-Fc has been described previously (24). The peroxidase 
labeled or biotinylated lectins Con A (Canavalia ensiformis), HPA (Helix pomatia), 
MAA (Maackia amurensis), PNA (Arachis hypogaea), SBA (Glycin max), SNA 
(Sambucus nigra) and WGA (Triticum vulgaris), were obtained from Sigma-Aldrich 
(St. Louis, MO). 
Isolation and expression of the cDNA encoding MGL and MGL-Fc. The cDNA 
encoding human MGL (25) was amplified on total RNA from immature DC, cloned 
into expression vector pRc/CMV and confirmed by sequence analysis. Stable CHO 
transfectants were generated using lipofectamin (Invitrogen). MGL positive cells 
were sorted using the MoFlo (DAKOcytomation, Glostrup, Denmark).The 
extracellular part of MGL (amino acids 61-289) was amplified on pRc/CMV-MGL 
with PCR, confirmed by sequence analysis and fused at the C-terminus to human 
IgG1-Fc in the Sig-pIgG1-Fc-vector. MGL-Fc was produced by transient transfection 
of CHO cells. MGL-Fc concentrations were determined by ELISA. 
Glycan array (Consortium for Functional Glycomics). Biotinylated synthetic or 
natural glycan structures were coated at saturating densities to streptavidin coated 
high binding capacity black plates (Pierce, Rockford, IL) and probed with MGL-Fc 
(2.5 μg/ml). Bound MGL-Fc was detected using a FITC-labeled anti-human IgG-Fc 
antibody. Plates were read at 485-535 nm on a Wallac Victor2 1420 multi-label 
counter (Perkin Elmer, Wellesley, MA). Standard procedures for glycan array testing 
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are available at (http://web.mit.edu/glycomics/consortium). The repertoire of glycan 
structures probed are described elsewhere (26;27). 
MGL-Fc adhesion assay. Schistosoma mansoni soluble egg antigens and biotinylated 
polyacrylamide-coupled glycoconjugates were coated (5 μg/ml or as indicated) on 
streptavidin coated plates (Pierce) or NUNC maxisorb plates (Roskilde, Denmark) 
overnight at room temperature. Plates were blocked with 1% BSA and MGL-Fc was 
added (1 μg/ml) for 2 hours at room temperature in the presence or absence of 10 
mM EGTA or 20 μg/ml mAbs. Binding was detected using a peroxidase labeled anti-
human IgG-Fc antibody (Jackson, West grove, PA). To identify the carbohydrate 
nature of the MGL ligands, NUNC maxisorb plates were coated with goat anti-human 
Fc antibody (4 μg/ml, Jackson), followed by a 1% BSA blocking step (30 minutes at 
37°C) and MGL-Fc (1 μg/ml for 1 hour at 37°C). MGL-Fc coated plates were 
incubated overnight at 4°C with tumor cell lysates (10.106 cells/ml). After extensive 
washing 1 mg/ml biotinylated or peroxidase labeled lectins (Sigma) were added for 2 
hours at room temperature. Binding of biotinylated lectins was detected using 
peroxidase-labeled avidin (Vector Laboratories, Burlingham, CA). 
Flowcytometry and cellular adhesion assays. Cells were incubated with primary 
antibody (5 μg/ml), followed by staining with a secondary FITC-labeled anti-mouse 
antibody (Zymed, San Francisco, CA) and analyzed on FACScalibur (BD Pharmingen, 
San Diego, CA).Streptavidin coated fluorescent beads (488/645 nm, Molecular 
Probes, Eugene, OR) were incubated with 1 μg of the PAA-coupled glycoconjugates or 
biotinylated soluble egg antigens. Fluorescent bead adhesion assay was performed as 
previously described (28) and analyzed on FACScalibur and presented as the 
percentage of cells which have bound the fluorescent beads. 96-well plates (NUNC 
maxisorb) were coated overnight at room temperature with biotinylated PAA-
glycoconjugates (5 μg/ml) or SEA (2 μg/ml) and afterwards blocked with 1% BSA. 
Calceine AM labeled DC (Molecular probes) were added for 1.5 hours at 37ºC in the 
presence or absence of 10 mM EGTA or 10 μg/ml mAbs. Non-adherent cells were 
removed by gentle washing. Adherent cells were lysed and fluorescence was 
quantified on a Fluorstar spectrofluorimeter (BMG Labtech, Offenburg, Germany). 
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Results 
MGL specifically recognizes terminal α- or β-linked GalNAc residues that naturally 
occur as part of glycoproteins or glycosphingolipids 
To allow efficient screening of multiple potential carbohydrate ligands, we 
constructed a MGL-Fc chimeric protein, with the extracellular portion of human 
MGL (amino acids 61-289) fused to a human IgG1-Fc tail. Recombinant MGL-Fc was 
produced in CHO cells and using an ELISA based method we show that MGL-Fc 
indeed comprises of the extracellular domains of MGL fused to the human IgG1-tail 
(Fig. 1A).  
 
Figure 1. MGL specifically 
recognizes GalNAc residues. 
(A) MGL-Fc comprises of a human 
IgG1 tail and the extracellular 
domains of MGL. MGL-Fc was 
detected in ELISA by anti-MGL 
and anti-human IgG-Fc Abs. DC-
SIGN-Fc was used as a control. (B) 
MGL interacts with GalNAc 
residues. MGL-Fc binding to 
monosaccharides coated on the 
glycan array was detected by FITC-
labeled anti human Fc-antibody. 
(C) MGL recognizes multivalent 
GalNAc. Streptavidin plates were 
coated with biotinylated PAA-
glycoconjugates. MGL-Fc binding 
was determined by ELISA. 
Standard deviation <0.02 OD 450 
nm. One representative 
experiment out of three is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                        MGL recognition of terminal GalNAc residues 
73
To identify the carbohydrate recognition profile and potential function of MGL, the 
MGL-Fc chimera was used to screen for carbohydrate ligands on the glycan array of 
the Consortium for Functional Glycomics (29;30). MGL-Fc strongly bound the 
monosaccharides α-GalNAc and β-GalNAc, whereas no interaction was observed with 
the related sugar Galactose, or other monosaccharides tested (Fig. 1B). The exclusive 
specificity of MGL for GalNAc was confirmed using α- and β-GalNAc 
monosaccharides multivalently linked to polyacrylamide (PAA) (Fig. 1C). Our results 
demonstrate that MGL exclusively recognizes GalNAc, both in α- or β-linked 
configuration, whereas no specificity for either α- or β-Galactose is observed. 
 
We next investigated whether MGL recognizes GalNAc moieties present in extended 
oligosaccharides. During O-glycan synthesis α-GalNAc is substituted with other 
monosaccharides to form several O-glycan core structures. Using the glycan array we 
investigated whether MGL recognizes specific O-glycan core-structures (Fig. 2A). 
MGL specifically interacted with a single α-GalNAc residue, also known as the Tn-
antigen. Sialylation of the α-GalNAc residue completely abrogated MGL binding, 
whereas sulfation did not alter the MGL reactivity. Substitution on position 3 of the 
α-GalNAc, as found in the core 1-4 structures, abrogated MGL binding. In contrast, 
addition of another α-GalNac-residue to position 3 (core 5) or a β-GlcNAc to position 
6 (core 6) did not affect MGL binding activity (Fig. 2A). Thus, MGL-Fc specifically 
recognizes Tn-antigen and core 5 and 6 O-glycan structures.  
Glycan antigens with terminal β-GalNAc residues, such as the LDN (LacdiNAc, 
GalNAcβ1-4GlcNAc) glycan epitope and its derivate LDNF (GalNAcβ1-4(Fucα1-
3)GlcNAc) are found in humans, but are much more abundantly expressed by human 
helminth parasites such as Schistosoma mansoni (31;32). In humans complex-type 
glycans usually contain a Lactosamine unit (LacNAc, Galβ1-4GlcNAc) or Lewis X 
(Galβ1-4(Fucα1-3)GlcNAc). Indeed MGL recognized both LDN and LDNF 
oligosaccharides, but not their Galactose-containing counterparts Lactosamine or 
Lewis X (Fig. 2B). 
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Figure 2. MGL recognizes terminal GalNAc residues in O-glycans, helminth associated 
glycans and glycans that are part of glycosphingolipids.  
MGL-Fc binding was determined by glycan array analysis of (A) O-glycan core structures, (B) LDN and 
LDNF glycans, and the related oligosaccharides LacNAc and Lewis X and (C) ganglioside glycan 
structures. Schematic representation of all carbohydrate structures tested is indicated in the figures. 
Certain glycosphingolipids contain terminal GalNAc residues, such as the 
gangliosides GM2, GD2 and the Forssman glycolipid (globopentosylceramide, 
GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4GlcCer). MGL strongly interacted with the 
oligosaccharide component of GM2 and GD2, whereas no binding was observed to 
oligosaccharides that do not contain a terminal GalNAc, as found in GM3 and GD3 
(Fig. 2C). In addition, MGL-Fc recognized the Forssman glycolipid in a glycolipid 
ELISA (results not shown). Our results strongly support a MGL recognition profile of 
terminal α- and β-linked GalNAc residues (Table 1).  
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Table 1. Overview of carbohydrate structures recognized by the C-type lectin MGL.  
a Signal to noise ratio. Signal ratios (S) were determined by dividing the fluorescence value obtained 
for each carbohydrate by the background fluorescence level (497 fluorescence units). All signal ratios 
were averaged out to a noise ratio (N) of 4.04. Individual signals (S) were then divided by 4.04 to give 
the listed signal to noise ratio (S/N).  
High affinity S/N>3*N; medium affinity S/N>2*N, low affinity S/N>1*N. 
MGL is the major GalNAc-receptor on human dendritic cells 
To confirm the GalNAc-specificity of MGL-Fc, MGL-expressing cells were analyzed 
for their carbohydrate binding characteristics. CHO-MGL transfectants expressed 
high levels of MGL on its cell surface (Fig. 3A). Both α-GalNAc and β-GalNAc-PAA 
coupled beads showed strong binding activity to CHO-MGL, but not to the parental 
CHO cells. MGL-mediated adhesion is completely inhibited by the Ca2+-chelator 
EGTA or an anti-MGL antibody, but not by an isotype control antibody. Neither α- 
nor β-Galactose was recognized by CHO-MGL (Fig. 3B), indicating that cell surface 
expressed MGL exhibits a similar GalNAc specificity as recombinant MGL-Fc.  
 
Human immature DC naturally express MGL on the cell surface (Fig. 3A). Despite the 
fact that DC express multiple C- type lectins, binding of α- or β-GalNAc to DC was 
substantially blocked by anti-MGL antibodies and not by the anti-DC-SIGN antibody 
(Fig. 3C). DC displayed only low binding to Galactose, which could not be attributed 
to MGL, as the interaction could not be blocked by anti-MGL antibodies. DC-
expressed MGL displayed an exclusive GalNAc-specificity and our results clearly 
indicate a major role for MGL in GalNAc recognition by DC.  
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Figure 3. Both cellular and 
recombinant MGL have identical 
specificities for α- and b-linked 
GalNAc. 
A) MGL expression on CHO transfectants 
and immature DCs. Open histograms 
represent the isotype control and filled 
histograms represent anti-MGL mAb 
staining. B) CHO-MGL strongly interacts 
with GalNAc but not with Galactose in the 
bead adhesion assay. Specificity was 
determined in the presence of the Ca2+-
chelator EGTA, blocking antibodies to MGL 
or isotype control antibody (anti-DC-SIGN). 
Standard deviation for the bead adhesion 
assay is <5%. C) MGL is the major GalNAc 
receptor on immature DC. Binding of DC to 
PAA-coupled carbohydrates was determined 
using plate adhesion assay in the presence or 
absence of EGTA, blocking antibodies to 
MGL or DC-SIGN. All results are 
representative for three independent 
experiments. 
 
MGL functions as a pattern recognition receptor for helminth antigens 
The specific recognition of LDN and LDNF by MGL (Fig. 2) prompted us to look at 
the interaction of MGL with helminth glycan antigens. The soluble egg antigens 
(SEA) of the human parasite Schistosoma mansoni were selected as a natural source 
for LDN- and LDNF-glycans. Both LDN-PAA and SEA-coupled beads showed high 
binding activity to CHO-MGL, but not to parental CHO cells (Fig. 4A). MGL-
mediated adhesion was specific, as shown by the complete block with anti-MGL 
antibodies or EGTA, but not with an isotype control antibody. Since SEA is composed 
of a several glycoproteins, monoclonal antibodies against carbohydrate epitopes were 
used to determine the relative contribution of LDN and LDNF in the binding of MGL 
to SEA (Fig. 4B). Binding of MGL to SEA was substantially blocked by anti-LDN 
mAbs (38% reduction) and to a lesser extent by anti-LDNF mAbs (22% reduction), 
whereas a combination of both anti-LDN and anti-LDNF mAbs further reduced MGL 
reactivity (46% inhibition), indicating that MGL recognizes both terminal β-GalNAc 
residues of LDN and LDNF structures present in SEA.  
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Figure 4. MGL strongly interacts 
with soluble egg glycoproteins of 
Schistosoma mansoni. 
A) CHO-MGL binds to LDN glycans and 
SEA as measured by bead adhesion 
assay. Specificity was determined in the 
presence of the Ca2+-chelator EGTA, 
blocking antibodies to MGL or isotype 
control antibody (anti-DC-SIGN). 
Standard deviation for the bead 
adhesion assay is <5%. B) MGL 
interacts with LDN and LDNF glycans 
present in the SEA. Binding of MGL-Fc 
to SEA was determined by ELISA in the 
presence or absence of EGTA, blocking 
mAbs to MGL and DC-SIGN (isotype 
control) or specific anti-glycan mAbs. C) 
Binding of SEA to immature DC is 
mediated by both MGL and DC-SIGN. 
Binding of DC was determined by plate 
adhesion assay in the presence or 
absence of EGTA, blocking mAbs to 
MGL or DC-SIGN. NT, not tested. All 
results are representative for three 
independent experiments.
 
 
 
 
 
 
 
 
 
 
 
 
Next, blocking antibodies were used to determine the relative contribution of MGL in 
relation to other DC expressed C-type lectins, in the binding of LDN and SEA. MGL 
mediated 50% of the adhesion of DC to LDN, as shown by the significant reduction in 
binding with anti-MGL antibodies (Fig. 4C). Since other C-type lectins on DC, such as 
DC-SIGN, are reported to be involved in binding SEA through Lewis X structures 
(33), the interaction of DC with SEA was further analyzed using blocking anti-MGL 
and anti-DC-SIGN antibodies. Both MGL and DC-SIGN are responsible for 30% of 
the DC reactivity, whereas a combination of anti-DC-SIGN and anti-MGL antibodies 
reduced adhesion by 50% (Fig. 4C). Therefore, DC-expressed MGL functions as a 
pattern recognition receptor for helminth parasites.  
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The tumor specific Tn-antigen is bound with high affinity by MGL 
Tumorigenicity is associated with an increased degree of sialylation and a reduction 
in length of the O-glycans expressed (34). Tumor cells, especially of adenocarcinoma 
origin, are frequently positive for the Tn-antigen (single α-GalNAc linked to Serine or 
Threonine). The tumor-associated Tn-antigen was preferentially recognized by MGL 
(Fig. 2A), therefore several adenocarcinoma cell lines and melanoma cell lines were 
analyzed for specific recognition by MGL. All adenocarcinoma cell lines tested and 3 
out of 6 melanoma cell lines displayed a strong interaction with MGL-Fc (Fig. 5A).  
 
One high binding adenocarcinoma cell line, ZR75-1, and one melanoma cell line, 
00.09, were selected to investigate the nature of the recognized carbohydrates on 
tumor glycoproteins. Carbohydrate ligands were captured from tumor cell lysates 
with MGL-Fc and probed with commercially available plant/invertebrate lectins with 
known specificities. The lectins, SBA and HPA, which both have specificity for α-
GalNAc residues, showed consistent reaction with glycoproteins, captured by MGL 
from tumor cells (Fig. 5B), indicating the presence of terminal α-GalNAc residues on 
the tumor antigens recognized by MGL. Since our previous data showed that 
recombinant and cellular MGL have identical carbohydrate recognition profiles, these 
results indicate that MGL might function as a DC-specific receptor for tumor derived 
cell types.  
Figure 5. MGL recognizes α-GalNAc residues on tumor cells.  
A) MGL recognizes both adenocarcinoma and melanoma tumor cells. Binding of MGL-Fc to tumor cell 
lines was determined by flowcytometry. B) MGL recognizes GalNAc residues on tumor glycoproteins. 
Presence of specific carbohydrate structures on glycoproteins captured by MGL was determined using 
biotinylated plant/invertebrate lectins with known specificities in an ELISA based assay. Values were 
normalized to the HPA reactivity. Standard deviation <0.02 OD 450 nm. All results are representative 
for three independent experiments. 
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Discussion 
Here we report the carbohydrate recognition profile of the C-type lectin MGL and the 
implications these results may have for the recognition of self-gangliosides, helminth 
parasites and tumor cells by DC. 
 
Using a high throughput glycan array screening, developed by the Consortium of 
Functional Glycomics, terminal α-and β-linked GalNAc residues were identified as 
the main carbohydrate determinants for MGL recognition. Carbohydrate mircoarrays 
for studying protein-carbohydrate interactions are just emerging and most of them 
work as a proof-of- principle, using lectins with known specificities to validate the 
array system (35). To our knowledge this is one of the first reports describing the 
identification of the carbohydrate recognition profile of a single C-type lectin with the 
use of a carbohydrate array. Carbohydrate recognition profiles of Selectins, Langerin 
and DC-SIGN homologues have been further refined with the use of glycan arrays 
(36-38). 
Both Galactose/GalNAc and GalNAc specificity have been reported for human MGL 
(39;40). Initially the specificity of MGL was evaluated using lysates of MGL 
transfected into COS-1. Purification on a Galactose-Sepharose column showed that 
Galactose, GalNAc and even fucose were able to elute MGL from the purification 
column (12). However subsequent binding studies with recombinant MGL produced 
in a bacterial expression system identified a restricted GalNAc specificity (16). 
Moreover the MGL specificity was not confirmed for cells naturally expressing MGL. 
In this article we define the carbohydrate recognition profile of human MGL-Fc 
chimeric protein by glycan array and confirm this profile using MGL transfectants 
and MGL positive immature dendritic cells.  
Our data clearly demonstrates that both recombinant MGL-Fc and MGL expressed by 
transfectants and DC have an identical and exclusive specificity for terminal α- or β-
linked GalNAc residues and no specificity for Galactose. Substitution on position 3 or 
4 of the GalNAc residue and sialylation, either on position 3 or 6 of the GalNAc, 
completely eliminates MGL recognition. The effect of the sialylation could be due to 
the addition of a dominant negative charge, which has been described for other C-
type lectins to interfere in binding (41). However addition of a negative charge in the 
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form of a sulfate group on position 6 does not affect MGL binding (Fig. 2A). The 
blocking effect of sialic acid on position 6 of the GalNAc is unlikely to be due to steric 
hindrance, since the addition of GlcNAc on this position does not preclude MGL 
recognition. The exclusive GalNAc specificity indicates that human MGL is 
functionally most closely related to mouse mMGL2, which shares the GalNAc 
specificity with human MGL (42). 
Our finding that anti-MGL antibodies do not completely block binding of α-GalNAc 
or LDN to DC, suggests that DC express next to MGL another receptor with GalNAc 
specificity. No candidate C-type lectins have been reported to be expressed by 
immature DC, since the well known Galactose/GalNAc-specific lectin ASGP-R (43), 
abundantly expressed by liver parenchymal cells, is not expressed by DC (data not 
shown). Although MGL and ASGP-R have partially overlapping carbohydrate 
recognition profiles (GalNAc and Galactose/GalNAc respectively), the exclusive 
expression of MGL on immature DC and MØ, implicates non-redundant cellular 
functions for these C-type lectins. Recently Galectin-3 was shown to be involved in 
uptake of SEA by MØ through recognition of LDN (44). Since Galectin-3 is expressed 
by DC (45), Galectin-3 might be a promising candidate receptor. Recognition of LDN 
by DC could therefore be mediated by both MGL and Galectin-3 simultaneously.  
Most C-type lectins contain special motifs within their cytoplasmic tails, which 
facilitate antigen uptake and thereby enhance antigen processing and presentation. 
Although C-type lectins do not directly stimulate the immune system, they affect the 
balance between immunity and tolerance by influencing Toll-like receptor signaling 
(46;47). C-type lectins probably have an important endogenous role in maintaining 
tolerance towards self-glycoproteins (48).  
 
The specific interaction of MGL with SEA glycoproteins containing LDN and LDNF, 
demonstrates that MGL functions as a pattern recognition receptor for the human 
helminth parasite Schistosoma mansoni. SEA are known to skew the immune system 
towards a TH2-type response (49). Recently Ebola and Marburg filoviruses have been 
reported as pathogenic ligands for human MGL (50). Interestingly both SEA and 
filoviruses target DC-SIGN as well, in a fucose and high-mannose type manner 
respectively (51;52). In addition the mouse Mannose Receptor recognizes SEA in a 
mannose dependent fashion (53). The residual binding of DC to SEA, after complete 
                                                                                                        MGL recognition of terminal GalNAc residues 
81
block of MGL and DC-SIGN, might therefore be mediated by the human Mannose 
Receptor. Since several pathogens misuse the tolerogenic pathway induced by C- type 
lectins for their own survival (54), it will be interesting to pursue how targeting of 
pathogens to MGL and other cooperating C-type lectins may modulate DC 
maturation and the induction of adaptive immune responses. 
Furthermore, MGL recognized glycosphingolipids, mainly of the ganglioside subtype. 
As MGL has the capacity to internalize synthetic glycoconjugates (55), it might 
internalize glycolipids for loading onto CD1 molecules, similarly as reported for the C-
type lectin Langerin (56). Langerin is capable of loading CD1a molecules with foreign 
glycolipids derived from Mycobacteria leprae, however the gangliosides which bind 
MGL are normally expressed in the spleen (57). The fact that gangliosides inhibit APC 
function (58), may hint to a possible function of MGL in antigen presentation and 
maintenance of tolerance to self-glycolipids. 
Our data demonstrates that MGL might be involved in the recognition of tumor cells 
by DC. In normal leukocytes and epithelial cells O-glycans are essentially all of core 1 
or extended core 2 subtype. Tumorigenicity is associated with increased sialylation 
and a reduction in length of the O-glycans expressed (59). Tumor cells, especially of 
adenocarcinoma origin, are frequently positive for the Tn-antigen (single α-GalNAc) 
or TF-antigen (Galβ1-3GalNAc). Positivity for the Tn-antigen specific lectin HPA 
serves as a diagnostic marker for a wide range of adenocarcinomas and 
coloncarinomas and is associated with lymph node metastases, poor prognosis and 
lower survival rates (60). A high correlation was found between the GalNAc-specific 
lectins HPA/SBA, and MGL recognition of α-GalNAc in tumor glycoproteins. 
Recently cytotoxic T cells have been described with specificity for the Tn-antigen (61), 
indicating that it is possible to generate a T cell response against carbohydrate 
antigens. Targeting of tumor antigens containing the Tn-antigen to MGL on DC can 
potentially result in enhanced presentation in MHC I and II. Yet targeting of antigens 
to C- type lectins without any additional DC activation may have tolerizing effects and 
inhibit anti-tumor responses (6;62). We postulate that the expression of Tn-antigen 
by tumors might modulate immune responses via targeting to C-type lectins, such as 
MGL. 
 
 Chapter 3                                                                                                                                                                      _ 
82
Our data shows that MGL specifically recognizes terminal α- and β-linked GalNAc 
moieties that are present on tumor derived cell types, pathogens such as helminth 
parasites and self-antigens, such as glycosphingolipids. Future studies should address 
whether antigen targeting to MGL on APC, such as DC and MØ, leads to antigen 
presentation as well as immune modulation. 
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Abstract 
The dendritic cell specific C-type lectin DC-SIGN functions as a pathogen receptor 
that recognizes Schistosoma mansoni egg antigens (SEA) through its major glycan 
epitope Galβ1,4(Fucα1,3)GlcNAc (Lex). Here we report that L-SIGN, a highly related 
homologue of DC-SIGN found on liver sinusoidal endothelial cells, binds to S. 
mansoni SEA but not to the Lex epitope. L-SIGN does bind the Lewis antigens Lea, 
Leb and Ley, similar as DC-SIGN. A specific mutation in the carbohydrate recognition 
domain (CRD) of DC-SIGN (V351G) abrogates binding to all Lewis antigens. In L-
SIGN Ser363 is present at the corresponding position of Val351 in DC-SIGN. 
Replacement of this Ser into Val resulted in a “gain of function” L-SIGN mutant that 
binds Lex, and shows increased binding to the other Lewis antigens. These data 
indicate that Val351 is important for the fucose-specificity of DC-SIGN. Molecular 
modeling, and docking of the different Lewis antigens in the CRDs of L-SIGN, DC-
SIGN, and their mutant forms, demonstrate that Val351 in DC-SIGN creates a 
hydrophobic pocket that strongly interacts with the Fucα1,3/4-GlcNAc moiety of the 
Lewis antigens. The equivalent amino acid residue Ser363 in L-SIGN creates a 
hydrophilic pocket that prevents interaction with Fucα1,3-GlcNAc in Lex but supports 
interactions with the Fucα1,4-GlcNAc moiety in Lea and Leb antigens. These data 
demonstrate for the first time that DC-SIGN and L-SIGN differ in their carbohydrate 
binding profiles, and will contribute to our understanding of the functional roles of 
these C-type lectin receptors, both in recognition of pathogen and self glycan 
antigens.
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Introduction 
Dendritic cell specific intercellular adhesion molecule-3 (ICAM-3) grabbing 
nonintegrin (DC-SIGN, CD209), is a type II membrane C-type lectin with a short 
amino terminal cytoplasmic tail and a single carboxyl terminal carbohydrate 
recognition domain (CRD). DC-SIGN is a cell adhesion receptor that mediates 
interactions between dendritic cells (DCs) and resting T cells through binding to 
ICAM-3 and supports trans-endothelial migration through interaction with ICAM-2 
(1-3). DC-SIGN has also been described as a pathogen receptor. It binds HIV-1 gp120 
and facilitates the transport of HIV from mucosal sites to draining lymph nodes 
where infection of T-lymphocytes occurs (2). Recent reports show that DC-SIGN 
binds to other viruses like hepatitis C (4;5), Ebola (6), CMV (7) and Dengue (8), as 
well as other pathogens such as Mycobacterium (9-11), Leishmania (12;13) and 
Candida albicans (14). Recently we showed that DC-SIGN binds soluble egg 
glycoproteins (SEA) of the helminth parasite Schistosoma mansoni through the 
Lewis x (Lex, CD15) glycan antigen (15). This binding to Lex and SEA was abrogated 
by mutation of the Val at position 351 in the CRD of DC-SIGN. 
 
Liver/lymph node specific ICAM-3-grabbing nonintegrin (L-SIGN/CD209L/DC-
SIGN-R) is a human homologue of DC-SIGN. L-SIGN shares 77% amino acid 
sequence identity with DC-SIGN and has functional similarity by recognizing ICAM-
2, ICAM-3 and HIV-1 gp120.  In addition, elucidation of the crystal structures of the 
CRDs of both DC-SIGN and L-SIGN, in combination with binding studies revealed 
that both receptors recognize high-mannose oligosaccharides (16;17). Whereas for 
DC-SIGN increasing evidence indicates that its major ligands are α3/α4-fucosylated 
glycans (15,18,19), no data so far indicate a role for L-SIGN in the binding of 
fucosylated oligosaccharides. L-SIGN is not expressed by DCs, but is expressed by 
endothelial cells present in lymph node sinuses, capillary endothelial cells of the 
placenta and liver sinusoidal endothelial cells (LSECs)(18-21). Since LSECs function 
as a liver-resident antigen presenting cell population (24), it is of particular interest 
to investigate whether L-SIGN plays a role in the recognition and uptake of 
glycosylated Schistosome egg antigens that are secreted by eggs trapped in the liver of 
Schistosome infected hosts. 
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Here we demonstrate that L-SIGN interacts with S. mansoni SEA, but recognizes 
another glycoprotein fraction than DC-SIGN, suggesting that L-SIGN does not 
recognize Lex. Indeed, binding assays with L-SIGN demonstrated a lack of binding of 
L-SIGN to neoglycoconjugates carrying Lex, but show that L-SIGN recognizes other 
fucosylated glycans, i.e. Lewis a (Lea), Lewis b (Leb) and Lewis y (Ley). Site-specific 
mutagenesis of the amino acid residue Ser363 in L-SIGN into a Val, as is present in 
DC-SIGN at this position, resulted in a “gain of function” mutant that binds to 
neoglycoconjugates carrying Lex, and shows increased binding to the other Lewis 
antigens. Molecular modeling of the CRDs of the wild-type and mutant lectins 
demonstrated that Val351 in DC-SIGN, which is lacking in L-SIGN, may be critically 
involved in the binding to Lex and Lea by creating a strong hydrophobic contact with 
the fucose. These data show for the first time that DC-SIGN and L-SIGN differ in 
their carbohydrate recognition profiles, and propose a molecular model that explains 
the observed differential binding of these lectins to fucosylated glycan antigens.
 
Experimental Procedures 
Antibodies and neoglycoconjugates.  The following antibodies were used: AZN-D1 
(IgG1, anti-DC-SIGN), AZN-D2 (anti-DC-SIGN/anti-L-SIGN) (22), anti-LDN mAb 
SMLDN1.1 (23). Crude Schistosoma mansoni soluble egg (SEA) extract was 
centrifuged for 90 min. at 100,000 x g at 4ºC and sterilized by passing through a 0.2 
μM filter, essentially as described by Nyame et al., (26). Neoglycoconjugates, 
containing glycans multivalently coupled to biotinylated polyacrylamide (PAA) were 
from Lectinity (Finland).
  
Mutagenesis. Mutations in the cDNA encoding L-SIGN were generated using the 
QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and pRc/CMV-
L-SIGN plasmid according to the manufacturers protocol. Plasmid sequencing 
confirmed the introduction of a mutation in the Ser residue at position 363 into Val 
(S363V) or Gly (S363G), respectively. Stable K562 cell lines expressing L-SIGN 
mutants were generated by transfection of K562 cells with 10 μg of plasmid as 
described previously (24). Positive cells were sorted several times with the antibody 
AZN-D2, to obtain stable transfectants with similar expression levels (> 85%, Figure 
3B). 
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Binding assay. Stable K562 cells expressing different wild-type and mutant C-type 
lectins  (5 x 104 cells) were incubated in a total volume of 25 μl with biotinylated 
polyacrylamide (PAA)-linked glycoconjugates (5 μg/ml) in adhesion buffer (20 mM 
Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM CaCl2, 2mM MgCl2 and 0.5% BSA) for 30 
min at 37ºC. Cells were washed with adhesion buffer and incubated with 
streptavidine-alexa fluor 488 secondary antibody (Molecular Probes, Inc., Eugene, 
OR) for 20 min at room temperature and analyzed using flow cytometry in the FL-1 
channel (FACScan, Becton Dickinson, Oxnard, CA). 
 
Fluorescent bead adhesion assay.  For measuring SEA binding to whole cells, a bead 
adhesion assay was used as described previously (25). Streptavidin was covalently 
coupled to TransFluorSpheres, fluorescent beads with a size of 1.0 μm and 
fluorescence at 488/654 nm (Molecular Probes Inc., Eugene, OR). The streptavidin-
coated beads were incubated with biotinylated F(ab’)2 fragment of goat anti-mouse 
IgG (6 μg/ml); Jackson Immunoresearch), followed by an overnight incubation at 
4ºC with anti-LDN mAb. The beads were washed and incubated with 1 μg/ml SEA 
overnight at 4ºC (26). Alternatively, SEA was biotinylated with EZ-linkTM NHS-LC-
LC-Biotin, according to the manufacturers protocol (Pierce, Rockford, IL). 
Biotinylated SEA (SEA-bio) was directly coupled to the streptavidin coated 
fluorescent beads. HIV gp120 fluorescent beads were prepared as described 
previously (2). Briefly, for the fluorescent beads adhesion assay 50 x 103 cells were 
resuspended in adhesion buffer (20 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM 
CaCl2, 2mM MgCl2 and 0.5% BSA). Ligand-coated fluorescent beads (20 beads/cell) 
were added to the cells and the suspension was incubated for 45 minutes at 37ºC. 
Cells were washed and adhesion was determined using flow cytometry (FACScan, 
Becton Dickinson, Oxnard, CA), by measuring the percentage of cells that had bound 
fluorescent beads in the FL-3 channel. 
 
Molecular modelling. The starting coordinates of human DC-SIGN and L-SIGN (17) 
were taken from the Protein Data Bank (29), using files with code 1K9I and 1K9J, 
respectively. Using the Sybyl software (Tripos Inc., St Louis), the structures were 
edited in order to contain only one protein monomer together with calcium ions. 
Protein hydrogen atoms were added, the peptide atoms partial charges were 
calculated using the Pullman procedure and the calcium ions were given a charge of 
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2. The positions of the hydrogen atoms were refined with the use of the Tripos force 
field (30). Lewis oligosaccharides were built from a database of 3D-structures of 
monosaccharides, with their glycosidic torsion angles corresponding to the lowest 
energy conformation previously determined (31). Atom types and charges for 
oligosaccharides were defined using the PIM parameters developed for carbohydrates 
(32). Docking of oligosaccharides in the binding sites was performed by testing the 
several possible orientations of the fucose hydroxyl groups in the coordination sphere 
of the calcium ion. Energy minimization was performed using the Tripos force-field 
(30) with geometry optimization of the sugar and the side chains of amino acids in 
the binding sites. A distance dependent dielectric constant was used in the 
calculations. Energy minimizations were carried out using the Powell procedure until 
a gradient deviation of 0.05 kcal·mol-1·Å-1 was attained. 
 
Results 
L-SIGN shows binding to Schistosoma mansoni SEA  
In a previous study, we showed that DC-SIGN binds S. mansoni soluble egg antigens 
(SEA) through the recognition of Lex antigens. To investigate the binding properties 
of L-SIGN to SEA, we used a fluorescent bead adhesion assay with K562 transfectants 
stably expressing L-SIGN or DC-SIGN (Figure 1A). Streptavidin coated fluorescent 
beads were precoated with monoclonal antibodies recognizing LDN glycan antigens 
(25) that occur on a SEA glycoprotein fraction that simultaneously carries Lex glycan 
antigens (15). These LDN coated fluorescent beads were then used to capture SEA, 
and incubated with K562 cells expressing L-SIGN as described previously for DC-
SIGN (27). The LDN captured SEA beads interacted with K562 cells expressing DC-
SIGN, however we could not observe any binding to L-SIGN (Figure 1C). However, by 
using this approach only a fraction of the SEA was coated on the beads (i.e. only SEA 
containing LDN glycans carrying also Lex (15)). To investigate binding of L-SIGN to 
the whole SEA population, SEA was biotinylated and directly coated on streptavidin 
coated fluorescent beads. Interestingly, K562 cells expressing L-SIGN bound to beads 
carrying biotinylated SEA (Figure 1B,C). In agreement with previous results L-SIGN 
was able to bind HIV-1 gp120 beads in a manner similar to DC-SIGN (Figure 1C) 
(28). The binding of beads coated with biotinylated SEA to both DC-SIGN and L-
SIGN could be blocked by the anti-DC-SIGN/L-SIGN antibody AZN-D2 and by 
EDTA, which removes the Ca2+ ions that are essential for carbohydrate binding, 
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indicating that the carbohydrate recognition domains (CRDs) of the lectins are 
involved in binding of SEA (Figure 1D). These data show that L-SIGN binds S. 
mansoni SEA, but recognizes a different subset of SEA compared to DC-SIGN, which 
suggests that L-SIGN differs from DC-SIGN in its ability to bind Lex glycan antigens. 
 
Figure 1. Fluorescent beads adhesion assays of S. mansoni SEA with K562 cells 
expressing L-SIGN or DC-SIGN. 
(A) K562 cells stable transfected with L-SIGN or DC-SIGN have similar expression levels as 
determined by FACScan analysis using mAb AZN-D2 that recognizes a common epitope on L-SIGN 
and DC-SIGN. (B) SEA was biotinylated and coupled to streptavidin-coated fluorescent beads (SEA-
bio). Binding of the beads to the cells was measured by FACScan analysis using Cellquest (Becton 
Dickinson, Oxnard, CA). The dotplots (left panel) show the forward-side scatter (FSC) of the cells in 
the presence of SEA-bio. The adhesion of the beads to the cells is measured in the FL-3 channel and 
shown as histoplots (right panel). (C) Binding of HIV-1 gp120 and SEA coated beads to the cells was 
measured using the fluorescent bead adhesion assay as in B and shown as % binding. In addition to 
SEA-bio (see B), fluorescent beads coupled to an anti-LDN-mAb (25) were used to capture SEA (SEA-
LDN). One representative experiment out of three is shown. (D) The binding of fluorescent beads 
coated with biotinylated SEA (SEA-bio) was blocked by AZN-D2 (20 μg/ml) and EGTA (5mM). One 
representative experiment out of three is shown. 
 
 
 
 
 
                                                                        Differential binding of DC-SIGN and L-SIGN to Lewis antigens 
95
L-SIGN does not bind to Lex, but recognizes other Lewis antigens 
As our previous data indicated that the trisaccharide Lex on schistosome SEA is a 
ligand for DC-SIGN, we next investigated whether L-SIGN binds to Lex glycans linked 
to biotinylated polyacrylamide (PAA). The results in Figure 2 show that K562 cells 
expressing L-SIGN did not bind Lex-PAA, in contrast to K562 cells expressing DC-
SIGN that strongly bound to Lex-PAA. The binding of DC-SIGN to Lex-PAA could be 
inhibited by a blocking antibody against DC-SIGN (AZN-D2) and by the calcium 
chelator EGTA (Figure 2B).         
 
Figure 2.  Binding of Lex coupled to biotinylated polyacrylamide (Lex-PAA-bio) to K562 
cells expressing L-SIGN or DC-SIGN.  
(A) Cells were incubated with Lex-PAA-bio in adhesion buffer for 30 min at 37ºC. After incubation 
with goat-anti-mouse streptavidin Alexa Fluor488, the binding was measured by FACScan analysis, 
and shown as a histoplot. The white graphs  represent control cells, the black graphs show binding of 
the cells to Lex-PAA-bio. One representative experiment out of three is shown. (B) Binding of K562 
cells expressing L-SIGN or DC-SIGN to Lex-PAA-bio (indicated as Lex) was measured as outlined in A, 
but shown here as % of binding. Binding of Lex–PAA-bio to DC-SIGN could be blocked by EGTA and 
the anti-L-SIGN/DC-SIGN antibody AZN-D2. One representative experiment out of three is shown. 
 
It has been described that the CRD of DC-SIGN binds two Ca2+ ions and that amino 
acids in close contact with these Ca2+ binding sites are essential for ligand binding 
(1,28). The amino acid sequences of the CRD domains of L-SIGN and DC-SIGN show 
a high identity (Figure 3A). Recently we showed that mutation of amino acid residue 
Val351 into a Gly in DC-SIGN (V351G, Figure 3A) abrogated binding to SEA and Lex, 
whereas binding to HIV gp120 was not affected (15,28). This suggests that Val351 
within the CRD of DC-SIGN is important for binding of DC-SIGN to Lex. In L-SIGN, a 
Ser is located at the position of Val in DC-SIGN. To determine the molecular basis for 
the difference in carbohydrate specificity between L-SIGN and DC-SIGN, two 
mutations were made in the CRD domain of L-SIGN in which Ser at position 363 is 
converted into a Val (S363V) or alternatively into a Gly (S363G) (Figure 3A). The 
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carbohydrate binding capacity of K562 cells expressing these L-SIGN mutant forms 
was compared to K562 cells expressing similar levels of wild type L-SIGN, DC-SIGN 
and the DC-SIGN V351G mutant, respectively (Figure 3B). Both wild type L-SIGN 
and DC-SIGN showed binding to biotinylated neoglycoconjugates containing Lea, Leb 
and Ley, but not to sialyl Lex (sLex) (Table 1, Figure 3C). EGTA and a blocking anti-
DC-SIGN/L-SIGN antibody could inhibit this binding (data not shown). Remarkably, 
the L-SIGN mutant S363V showed binding to Lex, in contrast to the wild type L-SIGN 
(Figure 3C). The introduction of this Val residue also induced increased binding of 
the L-SIGN S363V mutant to Lea, Leb and Ley (Figure 3C), and to S. mansoni SEA 
(data not shown). The conversion of Val351 into a Gly in DC-SIGN (DC-SIGN V351G) 
abrogated binding to all Lewis antigens. Similarly, the L-SIGN S363G mutant showed 
no binding to any of the Lewis antigens tested (Figure 3C). These results demonstrate 
that cell-surface expressed L-SIGN and DC-SIGN differ in their binding properties to 
Lex. Both lectins, however, show a functional similarity in their capacity to bind to 
Lea, Leb and Ley glycan antigens, and their lack of binding to sLex. Our data indicate 
that amino acid residue Val351 in DC-SIGN, which is lacking in L-SIGN, is critically 
involved in the binding of DC-SIGN to Lex glycan structures. 
 
     Table 1: Structures of Lewis glycan antigens.   
Lewis antigen Carbohydrate structure 
Lewis x (Lex)                    Galβ1→4GlcNAc-R 
                                    3 
                                    ↑
                            Fucα1  
                 
Lewis y (Ley)     Fucα1→2Galβ1→4GlcNAc-R 
                                     3 
                                     ↑
                             Fucα1 
Lewis a (Lea)                    Galβ1→3GlcNAc-R 
                                     4 
                                     ↑
                             Fucα1 
Lewis b (Leb)     Fucα1→2Galβ1→3GlcNAc-R 
                                      4 
                                      ↑
                              Fucα1 
sialyl-Lewis x (sLex) NeuAcα1→3Galβ1→4GlcNAc-R 
                                       3 
                                       ↑
                               Fucα1  
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Figure 3. Binding of different Lewis antigens coupled to biotinylated polyacrylamide 
(PAA-bio) to K562 cells expressing L-SIGN, DC-SIGN or mutant forms of the lectins. 
(A) Amino acid sequence alignment of part of the carbohydrate recognition domains (CRDs) of L-
SIGN (AAK20998) and DC-SIGN (AAK20997) is depicted. The CRD sequences are very similar as is 
shown by the black boxes. Mutations in the CRD of L-SIGN have been introduced at position Ser363, as 
indicated by an arrow. (B) Stable K562 transfectants express similar levels of L-SIGN, DC-SIGN and 
different mutant forms of L-SIGN and DC-SIGN, as determined by FACScan analysis using mAb AZN-
D2. One representative experiment out of three is shown. (C) Binding of different Lewis antigens 
coupled to PAA-bio to K562 cells expressing wild-type or mutant forms of L-SIGN and DC-SIGN. Cells 
were incubated with the PAA-bio-neoglycoconjugates in adhesion buffer for 30 min at 37ºC. After 
incubation with goat-anti-mouse streptavidin Alexa Fluor 488, the binding was measured by FACScan 
analysis as in Figure 2A, and shown as % of binding. One representative experiment out of three is 
shown. 
 
Remarkably, the L-SIGN mutant S363V showed binding to Lex, in contrast to the wild 
type L-SIGN (Figure 3C). The introduction of this Val residue also induced increased 
binding of the L-SIGN S363V mutant to Lea, Leb and Ley (Figure 3C), and to S. 
mansoni SEA (data not shown). The conversion of Val351 into a Gly in DC-SIGN (DC-
SIGN V351G) abrogated binding to all Lewis antigens. Similarly, the L-SIGN S363G 
mutant showed no binding to any of the Lewis antigens tested (Figure 3C). These 
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results demonstrate that cell-surface expressed L-SIGN and DC-SIGN differ in their 
binding properties to Lex. Both lectins, however, show a functional similarity in their 
capacity to bind to Lea, Leb and Ley glycan antigens, and their lack of binding to sLex. 
Our data indicate that amino acid residue Val351 in DC-SIGN, which is lacking in L-
SIGN, is critically involved in the binding of DC-SIGN to Lex glycan structures. 
 
Docking of Lewis x in DC-SIGN 
To gain more insight in the molecular basis that determines the differences in 
binding properties of DC-SIGN and L-SIGN to Lex, molecular modelling studies were 
undertaken. Since DC-SIGN and L-SIGN have been crystallized with mannose-
containing oligosaccharides (17), but not with fucose containing ones, the possible 
interactions of Lex with the CRD of DC-SIGN was determined first.  Several binding 
modes of fucose, or fucose-containing oligosaccharides, have been observed when 
comparing crystal structures of the whole C-type lectin family. sLex is bound to E- 
and P-selectin with oxygen O3 and O4 of fucose interacting with the calcium ion (33). 
Alternatively, fucose and several sialyl and sulfo-Lex derivatives are bound to 
mannose-binding protein (MBP) with O2 and O3 of fucose involved in calcium 
coordination (34-36).  
 
Four docking modes were tested in the present study for Lex interaction with DC-
SIGN: the two described above, and two additional ones, with inversion of the fucose 
orientation (i.e. inversion of O4 and O3 in the first binding mode, and inversion of O2 
and O3 in the second one). Only the two binding modes previously observed in C-type 
lectins yielded stable interactions without steric or hydrophobic conflict (Figure 4). 
Binding mode A, which corresponds to the interaction observed for sLex in E- and P-
selectin, is energetically favoured since it is stabilized by five hydrogen bonds 
between the fucose and the protein, and an additional one between O6 of galactose 
and an acidic group (Figure 5). This particular hydrogen bond is also observed in 
selectins with a conserved glutamate residue (33). The second binding mode (Figure 
4B), corresponding to sulfo and sLex in MBP mutants (35), only displays four 
hydrogen bonds. Thus it is proposed that DC-SIGN and L-SIGN bind fucosylated 
oligosaccharides with similar orientations as found in the selectins (Figure 4A). 
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Figure 4. Two proposed binding modes for Lex trisaccharide with DC-SIGN. 
Ribbon presentation of the binding modes of Lex trisaccharide to DC-SIGN. The bound calcium ions in 
the structure are represented as grey spheres. (A) Similar to the observed binding of sialyl-Lex in E-
selectin (33). (B) Similar to the observed binding site of 3-sulfo-Lewis x in modified MBPA (35).  
All drawings were performed with the MOLSCRIPT program (37). 
 
Docking of other oligosaccharides in DC-SIGN  
Energy minimized structures of DC-SIGN in complex with Lex and Lea trisaccharides, 
and Ley and Leb tetrasaccharides have been calculated. The six hydrogen bonds 
described above are conserved in all of these complexes (Table 2). In addition, 
hydrophobic contact can be predicted between galactose aliphatic groups and the 
aromatic ring of the amino acid residue Phe313. Val351 of DC-SIGN is close to the 
fucose binding site and makes strong hydrophobic contact with CH at position 1 and 
2 of fucose. For Lex, the methyl group of GlcNAc is also involved in this hydrophobic 
patch (Figure 5A), whereas for Lea, the CH2 of the hydroxymethyl group plays the 
same role, albeit at slightly longer distance (Figure 5B). No additional contacts are 
observed for Leb and Ley. This model is fully compatible with the observed binding of 
DC-SIGN to all Lewis antigens. In addition, sLex has been docked in the binding site 
of DC-SIGN with the same conformation as observed in E- and P-selectin crystals 
(33). In the latter structures, the acidic group of NeuAc closely interacts with amino 
acid residue Tyr48, allowing for the occurrence of a strong hydrogen bond between 
the acidic group of NeuAc monosaccharide and the hydroxyl group of the Tyr. 
However, in DC-SIGN the equivalent position is occupied by Phe313. There is no 
favourable interaction between the acidic group of NeuAc and the hydrophobic 
aromatic group of Phe313, which may explain the lack of binding of DC-SIGN to sLex. 
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Docking of oligosaccharides in L-SIGN 
The hydrophilic amino acids of the L-SIGN binding site are identical to the ones in 
DC-SIGN, and the Lewis oligosaccharides can be docked with establishing the same 
network of 6 hydrogen bonds (Table 2). The only difference is Ser363 that replaces 
Val351 in DC-SIGN. The substitution of a Val by a Ser destroys the hydrophobic wall 
that was adjacent to the fucose residue, and creates a hydrophilic pocket that is not 
favourable for the methyl group of GlcNAc in Lex (Figure 5C). This may explain the 
lack of binding of L-SIGN to Lex. However, when Lea is docked, Ser363 can establish a 
hydrogen bond with the O6 of GlcNAc, thereby restoring part of the contacts that are 
lost (Figure 5D), resulting in binding of Lea. Leb and Ley have been modeled and did 
not present additional interactions compared to their corresponding trisaccharides 
Lea and Lex, respectively (data not shown). Whereas this model explains binding of L-
SIGN to Leb, the observed binding of L-SIGN to Ley is not supported by the model 
proposed. 
 
Docking of oligosaccharides in mutant forms of L-SIGN and DC-SIGN 
When Val351 of DC-SIGN is substituted by a Gly residue, the hydrophobic interaction 
with the fucose residue is lost. Furthermore, the GlcNAc residue does not interact at 
all with the protein surface in this mutant, neither for Lex, nor for Lea (Figure 5E and 
F). The loop that contains this Gly appears to be stable in our calculations, but it 
could have greater mobility in solution, which will be entropically unfavorable for the 
binding of oligosaccharides. The same observations are made for the S363G mutant 
in L-SIGN (data not shown). These data are compatible with the observed lack of 
binding of both the DC-SIGN V351G and L-SIGN S363G mutant to all Lewis antigens. 
By contrast, the L-SIGN S363V mutant displays the same strong hydrophobic 
stabilization of the fucose and the methyl (or hydroxymethyl group) of GlcNAc as is 
observed in DC-SIGN (data not shown), which corresponds with the observed 
increase in binding of this mutant to all Lewis antigens and S. mansoni SEA. 
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Figure 5.  Models of the interaction of DC-SIGN, L-SIGN and DC-SIGN/V351G with Lex 
and Lea. 
Models of the interaction of DC-SIGN with Lex (A) and Lea trisaccharides (B); L-SIGN with  Lex (C) 
and Lea trisaccharides (D); and DC-SIGN (V351G) with Lex  (E) and Lea trisaccharides (F). The calcium 
ion is represented by a grey sphere. Only the amino acids interacting directly with the sugars have 
been displayed.  
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Table II Hydrogen bonds involved in the binding of Lewis oligosaccharides by DC-SIGN 
and L-SIGN. 
Discussion 
L-SIGN and DC-SIGN contain a single carbohydrate recognition domain (CRD), 
which mediates recognition of either self-glycoproteins or carbohydrate antigens on 
pathogens (38,39). The CRDs of L-SIGN and DC-SIGN show a high amino acid 
sequence identity, suggesting that their carbohydrate recognition profiles may be 
similar. Recently we have demonstrated that DC-SIGN binds to Schistosoma 
mansoni soluble egg antigens (SEA) through recognition of Lex antigens (15). Here 
we show that L-SIGN binds to a different subset of SEA than DC-SIGN, and does not 
bind Lex antigens. These data show for the first time a clear difference in binding 
properties between L-SIGN and DC-SIGN, which may have important consequences 
for their functions. In S. mansoni infections, egg antigens and their major glycan 
antigen Lex are able to cause a switch toward TH2-mediated immune responses (40). 
Although direct evidence is still lacking, we consider it possible that the interaction 
between Lex and DC-SIGN may contribute to a shift in the TH1/TH2 balance in favor 
of persistence of the pathogen. The binding of L-SIGN to SEA suggests that also this 
C-type lectin could play an important role in the recognition of S. mansoni egg 
antigens. However, the specific antigens within SEA that are involved in interaction 
with L-SIGN as well as the functional relevance of this interaction need to be further 
investigated.  
 
Our previous studies suggested that amino acid residue Val351 in DC-SIGN may have 
a crucial role in binding the Lex antigen (15). Here we show that mutation of Val351 
into Gly in DC-SIGN not only abrogated binding of DC-SIGN to Lex, but also to Lea, 
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Leb and Ley glycan antigens. L-SIGN has Ser363 in the position equivalent to Val351 of 
DC-SIGN. Remarkably, although L-SIGN does not bind to Lex, it shows binding to 
other Lewis antigens. Docking of the Lewis oligosaccharides into molecular models of 
the CRDs of L-SIGN and DC-SIGN indicated that the Lewis antigens most likely dock 
in a mode similar to sLex in E-selectin (Figure 4). Apart from being energetically the 
most favorable mode, only this mode is in agreement with the data demonstrating 
that DC-SIGN and L-SIGN do not bind sLex.  In the docking mode based on MBP-A, 
sialic acid does not make any additional contacts compared to Lex, which would 
predict binding of DC-SIGN and L-SIGN to both Lex and sLex and contradicts binding 
studies.  
 
From the proposed models it appears that Val351 in DC-SIGN is close to the fucose 
binding site and makes a strong hydrophobic contact with CH at position 1 and 2 of 
fucose. In L-SIGN the presence of a Ser instead of a Val creates a hydrophilic pocket 
that is not favorable for the methyl group of GlcNAc in Lex, but can establish a 
hydrogen bond with the O6 of GlcNAc. This may explain the observed differences of 
L-SIGN binding to Lex and Lea.  However, changing L-SIGN Ser363 into a Val not only 
did allow binding to Lex but also increased binding to all Lewis antigens, showing that 
a Val residue is favored for binding the fucose containing oligosaccharides in the CRD 
domain.   
 
All binding assays in this study have been performed with cells expressing the 
recombinant C-type lectins or their mutant forms at the cell surface, where they may 
be assembled into tetramers and interact with glycan ligands presented in 
multivalent form (16). The models that show docking of Lex, Lea, Leb and sLex in the 
CRDs of DC-SIGN, L-SIGN, and their mutant forms, correspond very well to the 
observed results of the binding assays. However, comparison of the docking of Ley 
with Lex in L-SIGN did not reveal additional interactions that would explain binding 
of Ley, but not Lex, by L-SIGN. It is possible that either additional contacts between 
Ley and the CRD of L-SIGN are introduced in the tetrameric form of L-SIGN, or that 
more than one CRD is involved in the binding of the oligosaccharide, which may 
result in another binding mode of Ley in L-SIGN than proposed from the model.  
It is remarkable, that DC-SIGN and L-SIGN interact with such different 
oligosaccharide ligands, i.e. high mannose-type N-glycans and Lewis antigens using 
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the same region in their CRDs. Many of the amino acid residues that interact with the 
mannose-type glycans, i.e. Phe313 Glu347, Asn349, Val351, Glu354 and Asn365 in DC-SIGN, 
and their corresponding residues in L-SIGN (16), are proposed here to be also 
involved in binding to the Lewis structures. Interestingly, these amino acid residues 
clearly interact with different monosaccharides, and the individual importance of 
each of these contacts in the binding pocket may vary dependent on the glycan 
bound. Recently it was shown that mutating Gly346 in DC-SIGN abrogated gp120 
binding but enhanced ICAM-2 and ICAM-3 binding (41), whereas mutation of Val351 
abrogates binding to ICAM-3 and Lex, but not to HIV-1 gp120 (15, 28). Thus, DC-
SIGN appears to bind in a distinct but overlapping manner to gp120 when compared 
to ICAM-2, ICAM-3, and Lex. Differential recognition of carbohydrate ligands by DC-
SIGN and L-SIGN will be crucially involved in the functional consequences of these 
interactions, which may lead to either immune activation or immune suppression. 
Detailed structural knowledge of the molecular interactions of DC-SIGN and L-SIGN 
with their carbohydrate ligands may be exploited to develop strategies for immune 
intervention, such as HIV-1 dissemination by DC-SIGN, or dendritic cell-induced 
immunity. 
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Abstract 
Immature dendritic cells (DCs) are recruited from blood into tissues to patrol for 
foreign antigens. After antigen uptake and processing, DCs mature and migrate to the 
secondary lymphoid organs where they initiate immune responses. DC-SIGN is a DC-
specific C-type lectin that acts both as a pattern recognition receptor and as an 
adhesion molecule. As an adhesion molecule, DC-SIGN is able to mediate rolling and 
adhesion over endothelial cells under shear flow. The binding partner of DC-SIGN on 
endothelial cells is the carbohydrate epitope LewisY (LeY), expressed on ICAM-2. 
ICAM-2 expressed on CHO cells only served as a ligand for DC-SIGN when properly 
glycosylated, underscoring its function as a scaffolding protein. The expression of LeY 
on endothelial cells is directed by the enzyme FUT1. Silencing of FUT1 results in an 
inhibition of the rolling and adhesion of immature DCs over endothelial cells. The 
identification of LeY as the carbohydrate ligand of DC-SIGN in endothelial cells opens 
new possibilities for the manipulation of DC migration.
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Introduction 
Dendritic cells (DC) have a key role in the control of immunity by surveying 
peripheral tissues in the search for pathogens (1). In order to create a network of 
tissue-resident DCs, precursor DCs continuously migrate from the blood into 
peripheral tissues, where they are highly efficient in capturing and processing 
antigens as immature DCs (2, 3). Once activated, immature DCs mature and migrate 
from the peripheral tissues to secondary lymphoid organs in order to interact with 
specific T-cells and initiate an immune response (1). The molecular basis for the 
migratory capacity of DCs is starting to be unraveled (4, 5), and several molecules 
have been described to be involved, such as DC-SIGN (6), MR (7, 8), and selectins 
(4). DC-SIGN (CD209) is a C-type lectin expressed by precursor and immature DCs 
that was primarily identified through its high affinity interaction with ICAM-3 (9). In 
addition, DC-SIGN also functions as an HIV-1 trans-receptor important in the 
dissemination of HIV-1 (10). Importantly, DC-SIGN mediates rolling and adhesion of 
precursor DC over the endothelium, which is suggested to be mediated through 
interactions with ICAM-2 (6). 
 
Thus DC-SIGN appears as a molecule with a dual role, acting as a pattern recognition 
receptor and as an adhesion molecule. As a pattern recognition receptor, the 
carbohydrate specificity of DC-SIGN has been carefully evaluated. It is now clear that 
DC-SIGN is able to recognize high-mannose type N-glycans, as well as 
glycoconjugates carrying non-sialylated, non-sulfated Lewis antigens (11-16). This 
relatively large recognition profile converts DC-SIGN into a sort of broad-spectrum 
pattern recognition receptor. Many pathogens have been found to be recognized and 
internalized by DC-SIGN (4) and, although this mechanism is meant to allow the 
development of an immune response, often is used by the pathogen to escape 
immune surveillance (17). As an adhesion molecule, however, the identity of the 
endogenous carbohydrate ligand(s) of DC-SIGN, especially in endothelial cells, still 
remains inconclusive.  
 
The present study was undertaken to identify the DC-SIGN ligands that are crucial 
for the adhesion and rolling of dendritic cells on endothelial cells. We show here that 
ICAM-2 expressed on endothelial cells constitutes the major scaffold protein ligand 
for DC-SIGN. Importantly, the interaction of DC-SIGN with ICAM-2 is carbohydrate-
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dependent, and we provide evidence that LeY antigens within ICAM-2 are of crucial 
importance for the binding of DC-SIGN to endothelial cells, as well as for the rolling 
and adhesion of dendritic cells over endothelial cells. 
 
Materials and Methods 
Cell lines and primary cells Human umbilical vein endothelial cells (HUVEC) were 
isolated from 5 healthy donors by a modification of the method of Jaffe et al (18), as 
previously described (19). The cells were resuspended in M199 (Biowhittaker, USA) 
supplemented with 100 U/mL Penicilin-Streptomycin (Biowhittaker, USA), 10 % 
human serum (Biowhittaker, USA), 10 % new born calf serum (Biowhittaker, USA), 5 
U/ml heparin (Leo Pharmaceutical Products, The Netherlands), and 150 μg/mL 
bFGF (Sigma, The Netherlands) and plated in gelatin coated plates. The cells were 
cultured to confluency in the mentioned media in a 5 % CO2 atmosphere at 37 °C. 
When confluency was reached, cells were trypsinized (0.18 % trypsin, 10 mM EDTA) 
and plated again to 1/3 of their density. All endothelial cells used displayed the 
presence of Von Willebrand factor, platelet endothelial cell adhesion molecule-1 
(CD31), and VE-Cadherin (20). No immunoreactivity to the anti-cytokeratin 20 
antibody or the anti-α-smooth muscle actin antibody was observed. 
 
Chinese Hamster Ovary (CHO) cells were cultured in RPMI-1640 (Gibco BRL, USA) 
supplemented with 10% FCS and 100 U/ml Penicillin-Streptomycin. Where 
indicated, cells were cultured during 5 days in the presence of kifunensine 
(Kitasatosporia kifunense, 2 μg/ml; Calbiochem, USA). Efficiency of treatment was 
assessed by flow cytometry analysis using Con A as described under Flow cytometry. 
 
Immature DCs were obtained from a buffycoat as previously described (21). In short, 
human peripheral blood mononuclear cells (PBMCs) were isolated from a buffycoat 
by a Ficoll gradient and followed by a CD14 magnetic microbeads isolation (MACS; 
Miltenyibiotec, USA). The obtained CD14+ monocytes were differentiated into 
immature DCs in the presence of interleukine-4 and granulocyte-macrophage colony 
stimulating factor (500 and 800 U/ml, respectively; Schering-Plough, Belgium). At 
day 6, the phenotype of the cultured DCs was confirmed by flow cytometric analysis. 
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The immature DCs expressed high levels of major histocompatibility complex class I 
and II, CD11b, CD11c, and ICAM-1; and low levels of CD80 and CD86. 
 
Western blotting DC-SIGN-Fc consists of the extracellular portion of DC-SIGN 
(amino acid residues 64-404) fused at the C-terminus to a human IgG1-Fc fragment 
into the Sig-pIgG1-Fc vector (22). DC-SIGN-Fc was produced in Chinese hamster 
ovary K1 cells by cotransfection of DC-SIGN-Sig-pIgG1 Fc (20 μg) and pEE14 (5 μg) 
vector. DC-SIGN-Fc concentrations in the supernatant were determined by an anti-
IgG1 Fc ELISA. Cells were grown to confluency in a T175 flask (Corning, USA), 
washed and resuspended in TSM, and lysed in 0.1 M Tris-HCl (pH 7.4), 0.05 M 
CHAPS. Lysate was centrifuged and the supernatant incubated with DC-SIGN-Fc (0.5 
mg/ml) at 4 °C in a rotating device (18 h). Subsequently, 20 μl protA/G-agarose 
beads (Santa Cruz, USA) were added and incubated at 4 °C in a rotating device (4 h). 
The beads were washed twice in TSM, resuspended in Laemmli sample buffer and 
incubated at 95°C for 5 minutes prior to resolving in 10 % SDS-PAGE, according to 
Laemmli (23).  
 
After electrophoresis, the gel was blotted on to a PVDF (Millipore, The Netherlands) 
membrane and stained with DC-SIGN-Fc or mouse anti-human-ICAM-2 (12A2) 
using peroxidase-labeled goat anti-human (Jackson, USA) and rabbit anti-mouse 
immunoglobulins (DakoCytomation, Denmark). The membrane was developed using 
SuperSignal WestPico Chemiluminescence substrate (Pierce, USA) and the 
chemiluminescence detected in an Epi Chemi II Darkroom (UVP, USA) using the 
Labworks (UVP, USA) software. 
 
Transient transfection of CHO cells Cells were incubated until 50-80 % confluent. 
The transfection was performed according to the manufacturer’s protocol. In short, 
both DNA (5 μg pcDM8-ICAM2 or pcDNA1-FUT4) and LipofectAMINE (Gibco BRL, 
USA) were diluted in serum free medium and combined. After 30 min the cells were 
washed with serum free medium and the complex solution was added to the cells. 
After 5 h serum-enriched medium (20 %) was added. The medium was replaced with 
fresh, complete medium 24 h after transfection. 24 h later the cells (5·104) were 
resuspended, washed with TSM and analyzed by flow cytometry as indicated under 
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Flow cytometry. Alternatively, cells (106) were lysed in 0.1 M Tris-HCl (pH 7.4), 0.05 
M CHAPS and analyzed by ELISA as indicated under ELISA.  
 
Capture ELISA Goat anti-mouse-Fc was coated on ELISA plates (Nunc, USA; 2 
μg/ml, 100 μl/well), followed by mouse anti-human ICAM2 (12A2) antibodies (1 
μg/ml, 50 μl/well). Plates were blocked with 1 % ELISA grade BSA (Fraction V, Fatty 
acid free; Calbiochem, USA), cell lysates were added, and incubated overnight at 4 °C. 
After washing, the wells were incubated with DC-SIGN-Fc (5 μg/ml), anti-LewisY (5 
μg/ml , clone F3, Calbiochem, USA) and digoxin-labeled Con A (5 μg/ml, Roche, 
Switzerland), in the presence or absence of 50 mM α-D-CH3-Mannose/α-D-CH3-
Glucose (both Sigma, The Netherlands). Binding was detected using a peroxidase 
labeled anti-human IgG-Fc, goat anti-mouse IgM (both Jackson, West Grove, PA) or 
sheep anti-digoxin (Roche, Switzerland), respectively. Color development after 
adding POD substrate (Roche, Switzerland) was measured in a spectrophotometer 
(BioRad, USA) at 410 nm. 
 
Flow cytometry Cells were washed twice in cold TSM (20 mM Tris, pH 7.4, 150 mM 
NaCl, 1 mM CaCl2 and 2 mM MgCl2), resuspended in 1 % BSA/TSM and incubated 30 
minutes at room temperature with 25 μL of 1 % BSA-TSM diluted primary 
antibody/lectin (10 μg/ml), washed twice with TSM and incubated 30 minutes at 
room temperature with secondary antibody according to manufacturers instructions. 
After the second incubation, cells were washed twice with PBS and resuspended in a 
final volume of 100 μL 1 % BSA/TSM for analysis in the FACS-Calibur (Becton-
Dickinson, USA). The primary monoclonal antibodies (mouse IgM) used were 
specific for LewisX (DakoCytomation, Denmark), LewisY (clone F3, Calbiochem, 
USA), Lewisa (clone T174, Calbiochem, USA), Lewisb (clone T128, Calbiochem, USA). 
The lectins used were Con A (concanavalin A, digoxin-labeled, Roche, Switzerland), 
UEA-I (Ulex europaeus agglutinin, biotin-labeled, EY Labs, USA), and AAL (Aleuria 
aurantia, digoxin-labeled, Roche, Switzerland). The anti-carbohydrate antibodies, 
were counter-stained with Alexa 488-labeled goat-anti-mouse secondary antibody 
(Molecular Probes, The Netherlands). For the secondary staining of the biotin-labeled 
lectins Alexa 488-streptavidin (Vector Laboratories, USA) and FITC-labeled anti-
digoxin (Sigma, USA) were used. Cells were analyzed for immunofluorescence on a 
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FACS-Calibur flow cytometer by collecting data for 104 cells per histogram. 
Corresponding negative controls were performed by omitting the antibody or lectin of 
interest. 
 
mRNA isolation and cDNA synthesis mRNA was isolated by capturing of poly(A+) 
RNA in streptavidin-coated tubes with an mRNA Capture kit (Roche, Switzerland) 
and cDNA was synthesized with the Reverse Transcription System kit (Promega, 
USA) following manufacturer’s guidelines. Cells (2·105/well) were washed twice with 
ice-cold PBS and harvested with 200 μL of lysis buffer. Lysates were incubated with 
biotin-labeled oligo(dT)20 for 5 min at 37 ºC and then 50 μL of the mix were 
transferred to streptavidin-coated tubes and incubated for 5 min at 37 ºC. After 
washing 3 times with 250 μL of washing buffer, 30 μL of the reverse transcription 
mix (5 mM MgCl2, 1x reverse transcription buffer, 1 mM dNTP, 0.4 U recombinant 
RNasin ribonuclease inhibitor, 0.4 U AMV reverse transcriptase, 0.5 μg random 
hexamers in nuclease-free water) were added to the tubes and incubated for 10 min at 
room temperature followed by 45 min at 42 ºC. To inactivate AMV reverse 
transcriptase and separate mRNA from the streptavidin-biotin complex, samples 
were heated at 99 ºC for 5 min, transferred to microcentrifuge tubes and incubated 
on ice for 5 min, diluted 1:2 in nuclease-free water and stored at –20 ºC until 
analysis. 
 
Quantitative real-time PCR Oligonucleotides (Table 1) have been designed by using 
the computer software Primer Express 2.0 (Applied Biosystems, USA). All 
oligonucleotides were synthesized by Invitrogen (Invitrogen, Belgium). 
Oligonucleotide specificity was computer tested (BLAST, NCBI) by homology search 
with the human genome and specifically, with all the known galactosyltransferases 
(CLUSTALW, EMBL), and later confirmed by dissociation curve analysis and 
resolving the PCR products in agarose electrophoresis. In the case of FUT3, FUT5 
and FUT6, genes with a high homology, the specificity of the primers was tested using 
plasmids (kindly provided by Dr. JB Lowe) encoding for each of the fucosyltrans-
ferases. The efficiency (24) of the oligonucleotides was determined using the 
computer program LinReg (25) and resulted in an average of 90 %. PCR reactions 
were performed with the SYBR Green method in an ABI 7900HT sequence detection 
system (Applied Biosystems, USA). The reactions were set on a 96 well-plate by 
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mixing 4 μL of the 2 times concentrated SYBR Green Master Mix (Applied 
Biosystems, USA) with 2 μL of a oligonucleotide solution containing 5 nmol/μL of 
both oligonucleotides and 2 μL of a cDNA solution corresponding to 1/60 of the 
cDNA synthesis product. The thermal profile for all the reactions was 2 min at 50 ºC, 
followed by 10 min at 95 ºC and then 40 cycles of 15 sec at 95 ºC and 1 min at 60 ºC. 
The fluorescence monitoring occurred at the end of each cycle. Additionally, 
dissociation curve analysis was performed at the end of every run by increasing the 
temperature of the block from 60 to 95 ºC at a rate of 1.75 ºC/min while continuously 
monitoring fluorescence. The plot of the first derivative of the decrease in 
fluorescence with respect to temperature showed in all cases one single peak at the 
Tm predicted by the Primer Express 2.0 software. The Ct value is defined as the 
number of PCR cycles where the fluorescence signal exceeds the detection threshold 
value, which is fixed above 10 times the standard deviation of the fluorescence during 
the first 15 cycles and typically corresponds to 0.2 relative fluorescence units. This 
threshold is set constant throughout the study and corresponds to the log linear range 
of the amplification curve. The normalized amount of target, or relative abundance 
(26), reflects the relative amount of target transcripts with respect to the expression 
of the endogenous reference gene. Due to the low expression of glycosyltransferases, 
the results are shown as 100-times the relative abundance. In this study, the 
endogenous reference gene chosen was GAPDH, based on previous results (19). 
 
RNA interference The mammalian expression vector, pSUPER.retro.puro (27, 28) (a 
kind gift of Dr. R. Agami, Netherlands Cancer Institute, Amsterdam, The 
Netherlands) was used for expression of siRNA in HUVEC. The gene-specific insert 
identifies a 19-nucleotide sequence corresponding to nucleotides 272-291 
(tcagatgggacagtatgcc) of FUT-1 (NM_000148), nucleotides 362-381 
(gacgacctacccgatagat) of FX (NM_003313), or the sequence 5’-ctgaatgaatcgtgacacg 
with no significant similarity to any human gene sequence, therefore used as a non-
silencing control. The gene-specific insert was separated by a 9-nucleotide non-
complementary spacer (ttcaagaga) from the reverse complement of the same 19-
nucleotide sequence, and flanked by restriction sites for the enzymes Bgl II and Hind 
III, producing a final insert of 60 nucleotides. These sequences were inserted into the 
pSUPER.retro.puro backbone. The different vectors were referred to as 
pSUPER/FUT-1, pSUPER/FX, and pSUPER/Scrambled, respectively. Plasmids were 
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transfected into HUVEC using the Basic Nucleofector Kit for Primary Mammalian 
Endothelial Cells (Amaxa, Germany) in an Amaxa Nucleofector (Amaxa, Germany), 
according to manufacturer´s instructions. Immediately after transfection, cells were 
seeded in glass coverslips coated with crosslinked gelatin (1 %) and fibronectin (5 
mg/ml). Transfection efficiency was higher than 90 % as evaluated by flow cytometry 
analysis of HUVEC co-transfected pmax/GFP (Amaxa, Germany) and the different 
pSUPER constructs (data not shown). To test the efficiency of RNA interference, cells 
were lysed after 48 h, mRNA isolated (mRNA Capture Kit, Roche, Switzerland) and 
retrotranscribed into cDNA (Reverse Transcription System, Promega, USA), 
according to manufacturer’s instructions. Gene expression of FUT-1, FX, and ICAM-2 
was assessed by means of quantitative real-time PCR in an ABI 7900HT platform 
(Applied Biosystems, USA) using the SYBR Green I chemistry (Applied Biosystems, 
USA), as previously described (19), using the primers described in Table 1. The 
silencing resulted in a decrease in gene expression higher than 80 % (data not 
shown). 
 
Table 1. Oligonucleotides used in the present study. 
Gene GeneID Oligonucleotides 
GAPDH 2597 Fwd: aggtcatccctgagctgaacgg Rev: cgcctgcttcaccaccttcttg 
FX 7264 Fwd: agccatccagaaggtggtagc Rev: gacgtgtgtgggttggacc 
FUT1 2523 Fwd: gcaggccatggactggtt Rev: cctgggaggtgtcgatgttt 
FUT2 2524 Fwd: ctcgctacagctccctcatctt Rev: cgtgggaggtgtcaatgttct 
FUT3 2525 Fwd: ccagtgggtcctcccga Rev: gccatgtccatagcaggatca 
FUT4 2526 Fwd: gagctacgctgtccacatcacc Rev: cagctggccaagttccgtatg 
FUT5 2527 Fwd: gtcccgagacgatgccact Rev: ccggtgacaggttccactg 
FUT6 2528 Fwd: atcccactgtgtaccctaatgg Rev: tgccaggcaccatctctgag 
FUT7 2529 Fwd: tccgcgtgcgactgttc Rev: accctcaaggtcctcatagacttg 
FUT8 2530 Fwd: tcttcatccccgtcctcca Rev: gagacacccaccacactgca 
FUT9 10690 Fwd: caaatcccatgcagttctgatc Rev: gtggcctagcttgctgaggta 
 
 
Immature DC perfusion and evaluation of adhesion and rolling velocity 
Immature DCs in suspension (2·106 cells/ml in incubation buffer) were aspirated 
from a reservoir through plastic tubing and perfused through a chamber with a 
Harvard syringe pump (Harvard Apparatus, South Natic, MA). The flow rate through 
the chamber was precisely controlled and the immature DCs were perfused over 
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endothelial cells at 0.8 dyn/cm2. During perfusions the flow chamber was mounted 
on a microscope stage (Axiovert 25, Zeiss, Germany), equipped with a B/W CCD 
video camera (Sanyo, Osaka, Japan), and coupled to a VHS video recorder (29, 30). 
Video images were evaluated for the number of adherent monocytes and the rolling 
velocity per cell, with dedicated routines made in the image analysis software 
Optimas 6.1 (Media Cybernetics Systems, Silverspring, MD, USA). The immature 
dendritic cells that were in contact with the surface appeared as bright white-centered 
cells after proper adjustment of the microscope during recording. The number of 
surface-adherent immature dendritic cells was measured after 5 min of perfusion at a 
minimum of 25 randomized high-power fields. To automatically determine the 
velocity of rolling cells, custom-made software was developed in Optimas 6.1. A 
sequence of 50 frames representing an adjustable time interval (δt, with a minimal 
interval of 80 milliseconds) was digitally captured. The position of every cell was 
detected in each frame, and for all subsequent frames the distance traveled by each 
cell and the number of images in which a cell appears in focus was measured. The 
cut-off value to distinguish between rolling and static adherent cells was set at 1 
μm/s. With this method, static adherent, rolling and free flowing cells (which were 
not in focus) could be clearly distinguished.
Results 
ICAM-2 is the major DC-SIGN ligand on endothelial cells 
Precursor DCs continuously traffic to peripheral tissues (1). The migration process is 
highly dependent on the interaction of DC-SIGN with its ligand. In earlier studies, 
ICAM-2 was identified as a ligand for DC-SIGN that supports binding under shear 
stress conditions using a chimeric construct produced in CHO cells (ICAM-2-Fc) (6). 
To identify counter receptors for DC-SIGN on primary endothelial cells, chimeric DC-
SIGN-Fc protein was used to immunoprecipitate ligands from a HUVEC cell lysate of 
which the surface proteins had been labeled by biotin. Subsequently, the 
immunoprecipitate and the supernatant were subjected to SDS-PAGE under reducing 
conditions, and the isolated proteins analyzed by western blot. As shown in Fig 1A 
and Fig 1C, the major surface-labeled protein that was selectively precipitated by DC-
SIGN-Fc has an apparent molecular weight of 55-60 KDa, which coincides with the 
molecular weight of ICAM-2 (31, 32). The selective precipitation of ICAM-2 could be 
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confirmed after western blotting analysis using an anti-ICAM-2 antibody for 
immunodetection (Fig. 1B). 
Figure 1. DC-SIGN binds to ICAM-2 in endothelial cells.  
HUVECs were labeled with biotin prior to lysis. DC-SIGN ligands were immunoprecipitated in a 
HUVEC lysate by incubation with DC-SIGN-Fc and Prot-A/G agarose beads as described in Materials 
and Methods. A. 10 % SDS-PAGE. One major band of approximately 55-60 KDa was detected in the 
immunoprecipitated fraction. B. Western Blot, immunodetection with anti-ICAM-2 antibody (12A2). 
The main immunoprecipitated band corresponds to ICAM-2. C. Western Blot, immunodetection with 
Streptavidin. The immunoprecipitated band identified as ICAM-2, is present in the extracellular 
membrane of HUVECs. Results are representative of 3 experiments. 
 
 
DC-SIGN–ICAM-2 interaction is carbohydrate-dependent 
ICAM-2 is also a ligand for LFA-1 and this interaction is carbohydrate-independent 
(33). To investigate whether the DC-SIGN–ICAM-2 interaction is carbohydrate 
dependent, CHO cells were transfected with a cDNA coding for ICAM-2, and either 
grown in the presence of kifunensine or co-transfected with a cDNA coding for FUT4. 
Kifunensine is an α-mannosidase I inhibitor that stops the processing of N-glycans at 
the Man9-GlcNAc2-Asn stage (34). Cells grown in the presence of kifunensine 
produce mainly high-mannose type N-glycans. FUT4 is an α1,3-fucosyltransferase 
implicated in the synthesis of LeX (35). Both LeX and high-mannose N-glycans are 
recognized by DC-SIGN (11, 13). 
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Figure 2. The DC-SIGN–ICAM-2 interaction is carbohydrate dependent.  
CHO cells were transfected with the plasmid pcDM8-ICAM-2 and either left untreated, treated with 
kifunensine or co-transfected with the plasmid pcDNA1-FUT4. Untreated or kifunensine-treated mock 
transfectant were used as controls. A. Flow cytometry analysis using an anti-ICAM-2 antibody (12A2) 
or the DC-SIGN-Fc chimeric protein (+ EDTA as a negative control). Gray lines denote the isotype 
control, while solid areas represent the staining with the above mentioned antibody or chimeric 
molecule. B. The binding of DC-SIGN-Fc, Con A and anti-LeX to ICAM-2 captured from the CHO cells 
transfected with the plasmid pcDM8-ICAM-2 was analyzed by ELISA in plates coated with the 
antibody 12A2. Results are representative of 3 experiments. 
 
As shown in Fig. 2A, the DC-SIGN-Fc chimera does not bind to ICAM-2 expressed in 
untreated cells, whereas it binds with high affinity to ICAM-2 expressing CHO cells 
that were grown in the presence of kifunensine. Remarkably, DC-SIGN-Fc also 
recognized glycoproteins other than ICAM-2 on the CHO cells that were grown in the 
presence of kifunensine, as can be observed in the mock transfected CHO cells. In an 
ICAM-2–immobilizing ELISA (Fig. 2B), we could show that the kifunensine 
treatment resulted in an ICAM-2 population that showed increased binding of the 
lectin Con A, as well as an increased DC-SIGN-Fc binding (Fig. 2B). 
 
The co-transfection with FUT4 also resulted in an increase in the binding of DC-
SIGN-Fc, which correlated with an increase in the expression of LeX-containing 
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ICAM-2 (Fig. 2A and B). Together, these data demonstrate that binding of DC-SIGN-
Fc to ICAM-2 is strictly carbohydrate dependent, and that the glycosylation potential 
of the cells expressing ICAM-2 determines whether or not ICAM-2 can function as a 
counter receptor for DC-SIGN. 
 
ICAM-2 carries LeY in endothelial cells 
In order to explore the glycosylation of ICAM-2 in endothelial cells, HUVECs were 
analyzed by flow cytometry, ELISA, and western blotting. Using antibodies specific 
for the Lewis antigens LeX, LeY, Lea, and Leb, it was demonstrated that HUVEC 
expressed significant amounts of LeY (Fig 3A). Presence of the other Lewis antigens 
could not be detected on HUVECs, whereas all antibodies showed specific binding to 
control neoglycoconjugates expressing the respective Lewis antigens (data not 
shown).  Con A was also able to bind to endothelial cells (Fig. 3A). Con A recognizes 
unsubstituted hydroxyl groups in mannose, as those present in high-mannose 
structures, hybrid-type N-glycans and diantennary N-glycans (with this order of 
affinity) (36, 37). Using increasing concentrations of methyl-mannoside it is possible 
to discriminate whether Con A binds to the high affinity ligand (high-mannose 
glycans) or to the low affinity ligands (diantennary N-glycans). A priori, as indicated 
by previous in vitro studies (11, 13), both LeY and mannose-rich structures are 
potential ligands for DC-SIGN. 
 
To identify the carbohydrates present in ICAM-2, immobilized ICAM-2 from an 
endothelial cell extract was tested for binding with anti-LeY antibodies and Con A in 
ELISA. The data in Fig. 3B show that both anti-LeY antibodies and Con A bound to 
the captured ICAM-2. Binding of Con A, however, could be completely abolished by 
addition of low concentrations of methyl-mannoside (Fig. 3B), indicating that the low 
affinity Con A-reactive glycans on ICAM-2 most likely correspond to diantennary N-
glycans, rather than high-mannose type N-glycans. This indicates that LeY most likely 
represents the ligand for DC-SIGN on ICAM-2. Interestingly, there are other 
glycoproteins on HUVEC carrying the LeY carbohydrate epitope (Fig. 3C), however, 
they do not support an interaction with DC-SIGN, as previously shown (Fig. 1). 
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Figure 3. Endothelial cells express LeY and Con A-reactive epitopes.  
A. HUVEC were grown to confluency, mechanically detached, incubated with the corresponding lectin 
or antibody, and analyzed by flow cytometry. Gray lines denote the isotype control, while solid areas 
represent the staining with the above mentioned lectin or antibody. B. Alternatively, HUVEC were 
lysed and the binding of DC-SIGN-Fc (+ EDTA as a negative control), anti-LeY, Con A, and Con A + 50 
mM methyl-mannoside to captured ICAM-2 was analyzed by ELISA in plates coated with anti-ICAM-2 
(12A2). C. HUVEC were lysed, resolved by SDS-PAGE and blotted onto a PVDF membrane. The 
membrane was stained with an anti-LeY antibody (F3). Results are representative of 3 experiments. 
 
HUVEC express FUT1 and FUT4 as the main α2- and α3-fucosyltransferases, 
respectively 
The expression of fucosylated carbohydrates depends upon the expression of 
fucosyltransferases (38). To identify the fucosyltransferases that are involved in the 
synthesis of LeY structures in HUVEC, a highly sensitive and specific real-time PCR 
assay was designed. Special care was taken to design oligonucleotides able to 
discriminate FUT3, FUT5 and FUT6, which have a large sequence identity. Plasmids 
encoding for FUT3, FUT5 and FUT6 were used as positive control (data not shown). 
The results showed significant mRNA levels for only three fucosyltransferase genes in 
HUVEC. Amongst them, FUT4, which encodes an α3-fucosyltransferase involved in 
the synthesis of Lewis-type structures, as well as the VIM-2 antigen (35), and FUT1 
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that encodes an α2-fucosyltransferase (39), can contribute to the biosynthesis of LeY. 
The third fucosyltransferase, FUT8, encodes for an α6-fucosyltransferase that 
catalyzes the transfer of fucose to the first N-acetylglucosamine of the chitobiose core 
of an N-glycan (40). 
 
Figure 4. Fucosyltransferase gene expression profile.  
HUVEC were grown to confluency and assayed for the expression of a panel of fucosyltransferases 
(FUT1-9) using real-time PCR. GAPDH was used as an endogenous reference. Results are shown as the 
average ± SE of 5 experiments. 
  
DC-SIGN interacts with the LeY structure on ICAM-2 expressed by endothelial cells 
Based on the fucosyltransferase gene expression profile, FUT1 was the a priori 
candidate to direct the synthesis of the DC-SIGN ligand LeY in HUVEC. To further 
investigate this point, a silencing approach was followed (27, 28) to knock down the 
expression of the enzymes that are expected to be crucial for the synthesis of LeY. 
HUVECs were transfected with either pSUPER/Scrambled (non-silencing control), 
pSUPER/FX or pSUPER/FUT-1. The plasmid pSUPER/FX targets the expression of 
the gene FX, which encodes GDP-4-keto-6-deoxymannose 3,5-epimerase-4-
reductase, one of the enzymes necessary for the synthesis GDP-fucose from GDP-
mannose (41, 42). This pathway accounts for the vast majority of cellular GDP-fucose 
production (43). GDP-fucose is the sugar donor used in the reactions catalyzed by 
fucosyltransferases. In the absence of this enzyme, the pool of GDP-Fucose can be 
rescued by adding fucose to the culture media, which is then metabolized to GDP-
Fucose via the salvage pathway (44). The efficiency of the silencing was evaluated by 
assessing the transcript levels of FX and FUT-1 in HUVECs transfected with the 
pSUPER/Scrambled plasmid, pSUPER/FX, or pSUPER/FUT-1 (Fig. 5A) and by flow 
cytometric analysis of the transfected HUVEC using an anti-LeY antibody (data not 
shown). As shown in Fig. 5B, the rolling velocity of immature DCs on a cell-layer of 
                                                                                                             DC-SIGN binds LewisY present on ICAM-2 
123
primary HUVEC is increased when either FX or FUT1 were silenced. Simultaneously, 
the tethering and adhesion (C) of the immature DCs to HUVEC is decreased. The 
degree of increase in rolling velocity and decrease in tethering and adhesion was to 
the same extend as was achieved using the monoclonal antibody AZN-D1, which is a 
DC-SIGN blocking antibody. Furthermore, the effects obtained with pSUPER/FX 
could be rescued by adding fucose to the HUVECs. 
Figure 5. The binding of DC-SIGN to ICAM-2 in endothelial cells is blocked by silencing 
the expression of LeY using RNA interference.  
(A) The expression of FX and FUT-1 was reduced to less than 30 %. The rolling velocity (B) and 
adhesion (C) of monocyte-derived DCs over the transfected HUVEC was measured as indicated in 
Materials and Methods. Results are shown as the average ± SE of 3 experiments. 
 
 
Discussion 
Immature DCs use DC-SIGN as an adhesion molecule to recognize a counter-receptor 
in endothelial cells. As a result of this interaction, immature DCs tether and adhere to 
endothelial cells, starting the migration to the underlying tissue. In this study we have 
shown that ICAM-2 expressed in endothelial cells constitutes the major scaffold 
protein ligand for DC-SIGN. Furthermore, we have demonstrated that LeY present on 
ICAM-2 acts as the major carbohydrate ligand that mediates DC-SIGN adhesion and 
tethering to HUVEC. 
 
ICAM-2 was identified as the major endothelial ligand for DC-SIGN employing a DC-
SIGN-Fc immune precipitation from HUVEC lysates (Fig. 1). Although the main 
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visible band is situated around 55-60 KDa (Fig. 1A), coinciding with ICAM-2 as 
detected by Western-Blot (Fig. 1B), two other minor bands (molecular weight > 100 
KDa) are visible that are surface located (Fig. 1C), indicating that other proteins 
expressed by HUVEC may contribute to the binding. It was also demonstrated that 
the ICAM-2–DC-SIGN interaction is carbohydrate-dependent, as ICAM-2 expressed 
in CHO cells is only able to be recognized by DC-SIGN when is properly glycosylated, 
excluding an integrin-like interaction (Fig. 2). This system illustrates a complex 
model in which both interaction partners perform dual functions, DC-SIGN as a 
pattern-recognition receptor and an adhesion molecule, and ICAM-2 as an integrin 
and a scaffold molecule for a lectin-ligand. 
 
In this study, we have identified LeY as the major carbohydrate ligand for DC-SIGN 
on endothelial cell-expressed ICAM-2, as is suggested by the flow cytometry analysis 
of endothelial cells, and further demonstrated by an ICAM-2 specific capture ELISA 
(Fig. 3), and the FUT-1 silencing experiments (Fig. 5). Recently, it was published that 
ICAM-2 presents high-mannose N-glycans, which serve as carbohydrate ligands for 
DC-SIGN (45). However, the work of Jiménez et al. has a serious technical 
disadvantage, the conclusions are based on ICAM-2 produced in large amounts in 
COS cells. It is very well known that glycosylation is a species and cell-type specific 
property (46-48). This has also been evidenced in this study (Fig. 2). Additionally, 
our rolling/adhesion assays demonstrate that fucosylation is essential for the rolling 
and adhesion of monocyte-derived DCs (Fig. 5). Additionally, the silencing of FUT-1 
results in a reduction in rolling and adhesion analogue to the inhibition obtained with 
the anti-DC-SIGN antibody AZN-D1 (Fig. 5). In our opinion, this unequivocally 
proves the identity of LeY as the carbohydrate ligand of DC-SIGN in HUVEC.  
 
Interestingly, LeY is expressed by many endothelial cell glycoproteins (Fig. 3), 
however only ICAM-2, and perhaps other high-molecular weight minor ligands, can 
support the binding of DC-SIGN. This may be explained by spatial considerations, 
since there is no evidence so far in other post-translational modifications being 
necessary for the DC-SIGN-carbohydrate ligand interaction (11, 12, 15), as is the case 
for P-Selectin (49). The discovery of FUT-1 as a key enzyme in the synthesis of the 
endothelial DC-SIGN-ligand opens new possibilities in the manipulation of DC 
migration. 
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Abstract 
During schistosomiasis, parasite-derived glycoconjugates play a key role in 
manipulation of the host’s immune response, associated with persistence of the 
parasite. Among the candidate host receptors that are triggered by glycoconjugates 
are C-type lectins (CLRs) on dendritic cells (DCs), which in concerted action with 
Toll-like receptors determine the balance in DCs between induction of immunity 
versus tolerance. Here we report that the CLR DC-SIGN mediates adhesion of DCs to 
authentic glycolipids derived from Schistosoma mansoni cercariae and their 
excretory/secretory products. Structural characterization of the glycolipids, in 
combination with solid-phase and cellular binding studies revealed that DC-SIGN 
binds to the carbohydrate moieties of both glycosphingolipid species with Galβ1-
4(Fucα1-3)GlcNAc (Lewisx) and Fucα1-3Galβ1-4(Fucα1-3)GlcNAc (pseudo-Lewisy) 
determinants. Importantly, these data indicate that surveying DCs in the skin may 
encounter schistosome-derived glycolipids immediately after infection. Recent 
analysis of crystals of the carbohydrate binding domain of DC-SIGN bound to Lewisx 
provided insight into the ability of DC-SIGN to bind fucosylated ligands. Using 
molecular modeling we showed that the observed binding of the schistosome-specific 
pseudo-Lewisy to DC-SIGN is not directly compatible with the model described. To fit 
pseudo-Lewisy into the model, the orientation of the side chain of Phe313 in the 
secondary binding site of DC-SIGN was slightly changed, which results in a perfect 
stacking of Phe313 with the hydrophobic side of the galactose-linked fucose of 
pseudo- Lewisy. We propose that pathogens such as S. mansoni may use the observed 
flexibility in the secondary binding site of DC-SIGN to target DCs, which may 
contribute to immune escape. 
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Introduction 
Schistosomiasis is a human parasitic disease caused by helminths of the genus 
Schistosoma that affect more than 200 million people worldwide (1). One of the most 
striking features of schistosomiasis is that the worms are experts in modulation and 
evasion of the host´s immune response, to enable their survival, migration and 
development in different host tissues.  Schistosomes have a complicated life cycle, 
requiring both a vertebrate and a snail host. Infection starts when cercariae released 
by the snail penetrate the host via the skin and transform into schistosomula. 
Schistosomula migrate to the portal system and develop to mature adult worms that 
mate and produce eggs. The eggs that become lodged within host tissues are 
primarily responsible for the development of a strong anti-inflammatory TH2 
response that enables parasite survival and induces granuloma formation around the 
eggs, which is a major cause of pathology (1). 
 
During infection the immune system is continuously challenged with an array of 
molecules associated with parasite metabolism and reproduction. However, little is 
known about the molecular mechanism behind this challenging of host immune 
responses nor which cellular receptors are involved. Schistosomal glycoconjugates 
(glycoproteins and glycolipids) are shown to play important roles in host-parasite 
interactions (2), which may include evasion mechanisms exploited by the parasites. 
These glycoconjugates are often developmentally regulated antigens that are 
expressed during different life-cycle stages. Proteins of different schistosoma life-
cycle stages carry both N- and O-glycans (2;3). In addition, schistosomes synthesize 
highly immunogenic glycosphingolipids, especially in the egg and cercarial stage 
(4;5). The stage-associated synthesis of carbohydrate structures on these glycolipids 
is paralleled by changes in the ceramide structures during the life cycle (6-8). 
Schistosome glycosphingolipids have a typical core structure that differs from that in 
vertebrates. Remarkably, the glucocerebroside is not galactosylated to make 
lactosylceramide as in vertebrates, but is instead modified by addition of a GalNAc 
residue to generate GalNAcβ1-4Glcβ1-ceramide, the so-called “schisto-core” (4). Both 
protein-linked glycans and glycosphingolipids contain a variety of terminal glycan 
epitopes, many of which are highly fucosylated and include glycan antigens such as 
GalNAcβ1-4GlcNAc (LacdiNac, LDN), Fucα1-3GalNAcβ1-4GlcNAc (F-LDN), 
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GalNAcβ1-4(Fucα1-3)GlcNAc (LDN-F), GalNAcβ1-4(Fucα1-2Fucα1-3)GlcNAc (LDN-
DF) and Galβ1-4(Fucα1-3)GlcNAc (Lewisx, Lex) (2; 9-14).  
 
Several findings indicate important roles for Lex antigens in host-schistosome 
interactions. Lex antigens have been found in glycoconjugates of all life-cycle stages, 
such as membrane-bound glycoproteins of adult schistosomes, secreted egg and gut 
glycoproteins (15) and cercarial glycolipids (5). Interestingly, Lex containing 
glycoconjugates are shown to induce proliferation of B-cells from infected animals, 
which secrete interleukin-10 (IL-10) and prostaglandine E2 (PGE2), and to induce the 
production of IL-10 by peripheral blood mononuclear cells from schistosome-infected 
individuals (16;17). In a murine schistosome model, Lex is an effective adjuvant for 
induction of a TH2 response (18).  
Recognition of an invading pathogen by cells of the immune system is mediated by 
receptors on antigen presenting cells. On dendritic cells (DCs) two receptor families 
are involved in the recognition of pathogens, Toll-like receptors (TLRs) that recognize 
common pathogen-associated molecular patterns, and C-type lectins (CLRs) that 
bind to glycan antigens (19). DCs express several TLRs, depending on their 
developmental stage and lineage (20).  Several studies have shown that bacterial 
products induce maturation of DCs via TLRs (21-23). Recently it was shown that the 
schistosome-specific phosphatidyl-serine (PS) activates TLR2 and induces mature 
DCs to activate IL-10-producing regulatory T cells (24). DCs also express a variety of 
CLRs that recognize glycan antigens in a Ca2+ dependent manner using highly 
conserved carbohydrate recognition domains (19;25). Several CLRs have been 
implicated to play a role in the recognition of pathogens. An important question still 
remaining is whether the principle function of CLRs is to capture pathogens, or to 
recognize self-antigens and suppress immunity (26).  Current views are that the 
balance between triggering TLRs and CLRs may fine-tune the immune response 
towards immune activation or tolerance. Recognition of glycans alone by DC-lectins 
may favor immune suppression, whereas pathogen-recognition in a situation of 
“danger” (when TLRs are triggered) induces immune activation (26;27).  
As a first approach to understand the molecular basis of the role of Lex and other 
schistosome glycan antigens in interactions with their host, we set out to investigate 
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the receptors on antigen presenting cells that recognize the schistosome glycan 
antigens. Recently we showed that the DC specific C-type lectin DC-SIGN (dendritic 
cell- specific ICAM-3 grabbing non-integrin, CD209) binds to S. mansoni soluble egg 
antigens (SEA) via Lex, but the actual ligands within SEA have not yet been identified 
(28). DC-SIGN is a human type II transmembrane CLR  that contains only one C-
terminal CRD and is abundantly expressed on immature DCs (iDCs). DC-SIGN has 
affinity for glycoconjugates containing mannose, N-acetylglucosamine and fucose and 
interacts with many pathogens. Multivalent binding of its ligands is thought to be 
achieved by the formation of tetramers (29;30). Using site-directed mutagenesis, 
molecular modeling, and docking of different Lewis antigens in the CRD of DC-SIGN 
we could demonstrate that the amino acid Val351 in DC-SIGN is essential for binding 
the Fucα1-3/4-GlcNAc moiety of the Lewis antigens Lex, Lea, Leb and Ley (28;31;32). 
In this study we have demonstrated that DC-SIGN strongly binds to authentic 
cercarial glycosphingolipids of S. mansoni, but not to egg glycolipids. Structural 
characterization of the glycan moieties of the glycosphingolipid species revealed that 
a pentasaccharide containing Lex is one of the main ligands recognized by DC-SIGN.  
Unexpectedly, we found that DC-SIGN also binds to glycosphingolipid species 
carrying a hexasaccharide terminating with Fucα1-3Gal(β1-4)(Fucα1-3)GlcNAc-R 
(pseudo-Ley), a glycan antigen that so far only has been found within schistosomes. 
Experimental procedures 
Cells and antibodies. Immature DCs (iDCs) were obtained from human peripheral 
blood mononuclear cells (PBMCs) by a CD14 magnetic microbeads isolation (MACS; 
Miltenyibiotec, USA) (33). The obtained CD14+ monocytes were differentiated into 
iDCs in the presence of IL-4 and granulocyte-macrophage colony stimulating factor 
(500 and 800 U/ml, respectively; Schering-Plough, Belgium). At day 6, the 
phenotype of the cultured DCs was confirmed by flow cytometric analysis. The DCs 
expressed high levels of major histocompatibility complex class I and II, CD11b, 
CD11c, and ICAM-1 and low levels of CD80 and CD86. Stable transfectants of K562 
cells expressing DC-SIGN (34) were kindly provided by Dr. T. Geijtenbeek. The mAb 
AZN-D1 is a blocking anti-DC-SIGN antibody described previously (35). DC-SIGN-Fc 
consists of the extracellular portion of DC-SIGN (amino acid residues 64-404) fused 
at the C-terminus to a human IgG1-Fc fragment into the Sig-pIgG1-Fc vector (32). 
The peroxidase-labelled goat anti-human IgG-Fc or goat anti-mouse IgM were both 
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from Jackson, West Grove, PA. The goat anti- mouse Alexa Fluor 488 secondary anti-
body was obtained from Molecular Probes, Inc., Eugene, OR. 
Glycolipid purification. Lyophilized S.mansoni cercariae and eggs were kindly 
provided by Dr. Michael J. Doenhoff (School of Biological Science, University of 
Wales, Bangor, UK). S. mansoni  excretory/secretory (ES) products were kindly 
provided by Dr. M. de Jong-Brink (FALW, VU University, Amsterdam, NL). The 
cercarial and egg glycolipids were purified by organic solvent extraction, 
saponification, desalting and anion-exchange chromatography as described 
previously (5). Neutral glycolipids were separated by HPLC (latrobeads 6RS-8010, 
10µm, 4,6 mm × 500mm; Macherey and Nagel, Düren, Germany) at a flow rate of 1 
ml/min using a binary linear gradient from 100% solvent A 
(chloroform:methanol:water 83:16:1, by volume) in 60 minutes to 60% solvent B 
(chloroform:methanol:water 10:70:20, by volume) followed by a 20 minute elution 
step with 100% solvent B. 
Release and purification of Lex and pseudo-Ley oligosaccharides from the ceramide 
moieties. Oligosaccharides were released from cercarial and ES glycolipids by 
treatment with recombinant endoglycoceramidase II (from Rhodococcus spp., Takara 
Shuzu Co., Otsu, Shiga, Japan). Released oligosaccharides were separated from 
ceramide moieties by reversed-phase (RP-) chromatography as described previously 
(45). Lex and pseudo-Ley glycans were fractionated and separated from remaining 
glycolipid-derived oligosaccharide species by HPLC on a TSK-Amide 80 column (4 
mm × 250 mm; Tosoh, Amsterdam, NL) using a linear gradient from 100% solvent A 
(35% acetic acid, buffered with triethylamine to pH 7.3 and 65% acetonitrile) to 100% 
solvent B (50% acetic acid, buffered with triethylamine to pH 7.3 and 50% 
acetonitrile) at a flow rate of 1 ml/min. Fractions (500 μl) were analyzed by MALDI-
TOF-MS and MS/MS.  
Neoglycolipid synthesis. Pure glycolipid-derived oligosaccharide fractions containing 
either Lex or pseudo-Ley glycans (80 μg each) as well as lacto-N-fucopentaose III 
(LNFPIII; 100 μg; Dextra Laboratories, Reading, UK) were used for synthesis of 
neoglycolipids by coupling to 1,2-sn-dipalmitoylphosphatidylethanolamine via 
reductive amination (36). Resulting products were analyzed by MALDI-TOF-MS.  
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Enzyme-linked immunosorbent assay (ELISA). Total egg and cercarial glycolipids 
were diluted in ethanol on NUNC maxisorb plates (Roskilde, Denmark), and 
incubated for 60 min. at 37ºC to coat the glycolipids to the plate. Plates were blocked 
with 1 % ELISA grade BSA (Fraction V, fatty acid free; Calbiochem, USA) and 
incubated with DC-SIGN-Fc (3 μg/ml) (32). Binding was detected using a peroxidase 
labelled goat anti-human IgG-Fc (Jackson, West Grove, PA). Separated glycolipid 
fractions (8.5 ng) and neoglycolipids were coated on polysorb plates (Nunc, 
Wiesbaden, Germany) and similarly analyzed by ELISA for reactivity with DC-SIGN-
Fc (3 μg/ml) using peroxidase-conjugated anti-human IgG (4.6 μg/ml; Sigma-
Aldrich, München, Germany). EDTA (10 mM, Roth, Karlsruhe, Germany) was added 
when indicated to investigate whether the binding was calcium dependent.  
MALDI-TOF-MS and MS/MS analysis. MALDI-TOF-MS analysis was performed on 
an Ultraflex time-of-flight mass spectrometer (Bruker-Daltonik, Bremen, Germany) 
equipped with a nitrogen laser and a LIFT-MS/MS facility as described previously 
(Geyer et al, manuscript submitted). The instrument was operated in the positive-ion 
reflector mode throughout using 6-aza-2-thiothymine (Sigma-Aldrich, München, 
Germany) as matrix. About 100 to 500 spectra were summarized in each case. 
 
Cellular adhesion assay. Ninety-six-well plates (NUNC maxisorb) were coated 
overnight at room temperature with S. mansoni cercarial and egg glycolipids, 
pseudo-Ley neoglycolipid, Lex neoglycolipid or globotriaosylceramide (Gb3) and 
blocked with 1% BSA. Cells labelled with Calceine AM (Molecular Probes), were 
added for 1.5 h at 37 ºC in the presence or absence of 20 μg/ml mAbs AZN-D1. Non-
adherent cells were removed by gently washing. Adherent cells were lysed and 
fluorescence was quantified on a Fluostar spectrofluorimeter (BMG Labtech, 
Offenburg, Germany). Results are expressed as the mean percentage of adhesion of 
triplicate wells.  
 
Isolation of Schistosoma mansoni cercarial ES products. Free cercariae were 
obtained from S. mansoni parasitized Biomphalaria glabrata snails by inducing the 
shedding process basically as described by Sluiters et al. (37). The free-swimming 
cercariae obtained were transferred to 60 ml water. After 5 hrs the cercariae/ 
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schistosomula were removed and the remaining water containing the ES products 
was concentrated.  
Molecular modeling. The coordinates of the crystal structure of human DC-SIGN 
interacting with the Lex containing pentasaccharide LNFPIII (38) (code 1SL5) were 
taken from the Protein Data Bank (39). The structure was edited using the Sybyl 
software (Tripos Inc., St Louis), in order to contain only one protein monomer 
together with calcium ions, the Lex trisaccharide, and the two water molecules that 
play an important role in bridging O4 of galactose to the protein surface. Protein 
hydrogen atoms were added, the peptide atoms partial charges were calculated using 
the Pullman procedure and the calcium ions were given a charge of 2. Atom types and 
charges for oligosaccharides were defined using the PIM parameters developed for 
carbohydrates (40). Pseudo-Ley was built by adding one fucose on position 3 of the 
terminal galactose residue. The systematic search procedure of Sybyl was used to vary 
the two torsion angles at this glycosidic linkage together with the two torsion angles 
of the Phe313 side chain. Only one conformational family was identified. Subsequent 
energy minimization was performed using the Tripos force-field (41) with geometry 
optimisation of the sugar and the side chains of amino acids in the binding sites. A 
distance dependent dielectric constant was used in the calculations. Energy 
minimizations were carried out using the Powell procedure until a gradient deviation 
of 0.05 kcal·mol-1·Å-1 was attained.
 
Results 
Recognition of Schistosoma mansoni cercarial glycolipids by DC-SIGN  
To investigate their binding to DC-SIGN, authentic glycolipids from S. mansoni 
cercariae and eggs were isolated by organic solvent extraction (5) and assayed by 
ELISA using soluble DC-SIGN-Fc. In parallel, unrelated glycolipids, such as 
globotriaosylceramide (Gb3), Forssman antigen (FA) and bovine gangliosides (BG) 
were tested together with a synthetic lacto-N-fucopentaose III (LNFPIII)-
neoglycolipid in order to evaluate the binding specificity of DC-SIGN as well as the 
potential influence of the structure of the lipid moiety in this assay. The results 
revealed that DC-SIGN-Fc strongly binds cercarial glycosphingolipids and the 
LNFPIII-neoglycolipid, whereas a weak binding was observed to egg-derived 
glycolipids. The remaining types of glycolipids were not recognized at all (Fig. 1A and 
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1B). Hence, it can be concluded that recognition by DC-SIGN is mediated by the 
carbohydrate unit and independent of the lipid part of the respective molecules.  
Figure 1. Binding of DC-SIGN to S. mansoni cercarial glycolipids and lacto-N-
fucopentaose III (LNFPIII)-neoglycolipid.  
(A) ELISA was performed to determine the binding reactivity and specificity of DC-SIGN to egg 
glycolipids (Egg GL), total cercarial glycolipids (Cerc. GL), Forssman antigen (FA), 
globotriaosylceramide (Gb3), LNFPIII-neoglycolipid (LNFPIII NGL) and bovine gangliosides (BG). 
Similar amounts of glycolipids (3 ng/well) were applied in each case. Data represent a typical result 
out of three experiments performed in duplicate. (B) A titration of egg glycolipids (Egg GL), total 
cercarial glycolipids (Cerc. GL) and LNFPIII neoglycolipid (LNFPIII NGL) was performed, starting 
with 10 ng/well, to determine the binding affinity of DC-SIGN. Results are a typical representative of 
three independent experiments performed in triplicate.
 
Characterization and fractionation of total cercarial glycolipids  
To allow the subsequent analysis of the glycolipid species that bind DC-SIGN, total 
cercarial glycolipids were analyzed by MALDI-TOF MS (Fig. 2). In agreement with 
previous studies (5), a complex pattern of different glycolipids was registered mainly 
due to the high heterogeneity of the present ceramide moieties. Prevailing species 
exhibited monosaccharide compositions of Hex2HexNAc2dHex1, Hex2HexNAc3dHex1 
and Hex2HexNAc2dHex2, thus reflecting ceramide pentahexoside and hexahexoside 
species with the Lex or pseudo-Ley determinants as described (5). In addition, a 
number of major and minor signals was registered which reflected the presence of 
additional glycolipids with diverging ceramide and carbohydrate compositions. Based 
on previous studies on the ceramide composition of cercarial glycolipids (7) the 
cluster of ions at m/z 1978.9 can be concluded to comprise species with 
monosaccharide compositions of Hex1HexNAc3dHex4 and Hex2HexNAc3dHex3 which 
is corroborated by the detection of the respective free oligosaccharides after 
endoglycoceramidase treatment (Table 1).  
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Figure 2 MALDI-TOF-MS 
analysis of isolated glycolipids 
from S. mansoni cercariae. 
Deduced monosaccharide 
compositions are assigned to major 
pseudomolecular ions ([M+Na]+) 
comprising Lex (H2N2F1 at m/z 1593.7 
or H2N3F1 at m/z 1796.8) and pseudo-
Ley epitopes (H2N2F2 at m/z 1739.8). 
The cluster of ions culminating in a 
signal at m/z 1978.9 reflects 
glycolipids with divergent ceramide 
and carbohydrate moieties including 
species with monosaccharide 
compositions of H1N3F4 and 
H2N3F3.The complex pattern of 
registered signals is due to ceramide 
heterogeneity. H, hexose; N, N-
acetylhexosamine; F, deoxyhexose 
(fucose); Cer, ceramide. 
 
 
 
 
 
To obtain individual glycolipid fractions, cercarial glycolipids were subjected to HPLC 
separation and the isolated fractions were analyzed by ELISA for their capacity to 
bind DC-SIGN (Fig. 3A). The results revealed that DC-SIGN mainly recognized 
glycolipids that occurred in HPLC fractions 40-50, whereas species with elongated 
carbohydrate units did not react. Subsequent analysis of fractions 40-50 by MALDI-
TOF-MS demonstrated that each fraction comprised a mixture of glycolipids carrying 
Lex or pseudo-Ley moieties (Fig. 3B-3E). Due to the observed ceramide heterogeneity, 
a clear separation into fractions containing solely Lex or pseudo-Ley determinants 
was not possible. To determine which of these glycan moieties are recognized by DC-
SIGN, we decided to synthesize neoglycolipids, using purified carbohydrate moieties 
that were released from the cercarial glycosphingolipids. 
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Table 1. Compilation of total glycans obtained from glycosphingolipids of S. 
mansoni cercariae and excretory/secretory (ES) products by 
endoglycoceramidase treatment. Compositions are assigned in terms of hexose (H), N-
acetylhexosamine (N) and deoxyhexose (fucose; F). Relative occurrence of individual 
compositional species is roughly estimated from the respective signal intensities registered by 
MALDI-TOF-MS. Oligosaccharides representing LeX-pentasaccharides, LeX-hexasaccharides 
or pseudo-LeY-hexasaccharides are marked in bold type. 
a
 Relative amounts were estimated as follows: +: 0-2.2 ×104; ++: 2.21-4.6×104; +++: 4.61-
6.6×104 intensity counts.
Calculated mass 
[M+Na]+ (m/z) 
Observed mass 
[M+Na]+ (m/z) 
Composition Obtained from a
   Glycolipids E/S-products 
917.32 917.3 H2N2F1 +++ +++ 
933.32 933.2 H3N2 ++ - 
958.35 958.2 H1N3F1 + + 
1063.38 1063.6 H2N2F2 ++ + 
1079.2 1079.2 H3N2F1 + - 
1104.41 1104.2 H1N3F2 + + 
1120.41 1120.3 H2N3F1 +++ ++ 
1136.39 1136.2 H3N3 + - 
1161.43 1161.3 H1N4F1 + - 
1241.43 1241.6 H4N2F1 - + 
1250.46 1250.3 H1N3F3 + - 
1266.46 1266.3 H2N3F2 ++ + 
1282.45 1282.3 H3N3F1 + - 
1307.46 1307.3 H1N4F2 ++ + 
1323.48 1323.3 H2N4F1 + - 
1396.52 1396.3 H1N3F4 ++ ++ 
1412.51 1412.3 H2N3F3 + - 
1428.51 1428.3 H3N3F2 + - 
1453.55 1453.3 H1N4F3 + + 
1469.54 1469.3 H2N4F2 ++ - 
1485.54 1485.3 H3N4F1 + - 
1510.57 1511.0 H1N5F2 - + 
1599.6 1599.4 H1N4F4 + + 
1615.59 1615.4 H2N4F3 + - 
1631.59 1631.4 H3N4F2 + - 
1656.62 1656.4 H1N5F3 + + 
1672.62 1672.4 H2N5F2 + - 
1713.65 1714.3 H1N6F2 - + 
1745.66 1745.4 H1N4F5 + - 
1802.68 1803.4 H1N5F4 - + 
1818.68 1818.4 H2N5F3 + - 
1834.67 1835.4 H3N5F2 + - 
1859.70 1860.4 H1N6F3 - ++ 
2005.76 2006.4 H1N6F4 - +++ 
2062.78 2063.4 H1N7F3 - + 
2151.82 2152.4 H1N6F5 - + 
2208.84 2210.4 H1N7F4 - ++ 
2354.89 2355.4 H1N7F5 - ++ 
2500.95 2502.3 H1N7F6 - + 
                                                                                                                     Binding of DC-SIGN to pseudo-Lewisy 
141
 
Figure 3. Binding of DC-SIGN to fractionated glycolipids of S. mansoni cercariae.  
Binding of DC-SIGN to S.mansoni cercarial glycolipids was determined by ELISA using soluble DC-
SIGN-Fc (A). Recognized species occurring in fractions 40-50 are dominated by glycolipids carrying 
Lex and pseudo-Ley epitopes as confirmed by MALDI-TOF-MS. (B-E), MALDI-TOF-MS analysis of 
HPLC-fractions 40, 42, 47 and 51 respectively. Major pseudomolecular ions ([M+Na]+) comprising 
Lex-pentasaccharide (*), pseudo-Ley-hexasaccharide (+) and pseudo-Ley-octasaccharide (++) units are 
marked. 
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Purification of the glycan moieties of cercarial glycolipids  
Glycans were released from total cercarial glycolipids by endoglycoceramidase 
treatment, separated from remaining (glyco)lipids by reversed-phase 
chromatography and analyzed by MALDI-TOF-MS (Fig. 4). In agreement with the 
spectrum obtained in the case of total cercarial glycolipids (Fig. 2), the results 
confirmed the preponderant occurrence of oligosaccharides with monosaccharide 
compositions consistent with the presence of a Lex or a pseudo-Ley determinant. In 
addition, several minor oligosaccharides with divergent compositions have been 
registered (Table 1). In order to obtain individual glycan species, the total mixture of 
oligosaccharides was subjected to HPLC separation using a TSK-amide column. 
Collected fractions were screened by MALDI-TOF-MS. Fractions containing the Lex 
pentasaccharide (m/z 917.3 [M+Na]+) plus additional pseudo-Ley (m/z 1063.6 
[M+Na]+) and/or Lex hexasaccharide species (m/z 1120.3 [M+Na]+) were re-applied 
to HPLC, in order to reduce peak heterogeneity and to obtain pure compounds as 
monitored by MALDI-TOF-MS (see insets in Fig. 5A and 5B).  
Figure 4. MALDI-TOF-MS analysis of released oligosaccharides.  
Oligosaccharides were released from cercarial glycolipids by treatment with endoglycoceramidase and 
analyzed by MALDI-TOF-MS. Monoisotopic masses of pseudomolecular ions ([M+Na]+) and deduced 
monosaccharide compositions are assigned. Signals representing free Lex pentasaccharide (m/z 917.3), 
Lex hexasaccharide (m/z 1120.3) as well as pseudo-Ley hexasaccharide (m/z 1063.6) are marked in 
bold type. H, hexose; N, N-acetylhexosamine; F, deoxyhexose (fucose). 
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Characterization of Lex and pseudo-Le y glycans by MALDI-TOF-MS/MS  
The identity of the isolated glycans was established by tandem mass spectrometry. 
MS/MS analysis verified that the parent ion with the mass of m/z 917.3 [M+Na]+ 
consisted of a pentasaccharide with a composition of Hex2HexNAc2dHex1 (Fig. 5A). 
In addition to the sequential release of the five monosaccharide units, two 
characteristic fragment ions, B2 and C2 at m/z 534.2 and m/z 552.2, could be 
observed in agreement with the presence of a Lex trisaccharide unit. The linkage of 
fucose to the subterminal HexNAc residue is confirmed by a Y3α fragment ion at m/z 
755.5. By the same line of evidence, the glycan with the mass of m/z 1063.3 [M+Na]+ 
(inset in Fig. 5B) could be shown to comprise a dHex-Hex-(dHex-)HexNAc unit due 
the observed B3 and C3 fragment ions at m/z 680.1 and m/z 698.1, respectively (Fig. 
5B). Hence, the obtained MS/MS spectra displayed all diagnostically relevant 
fragment ions to be expected for the cercarial glycolipid-derived Lex pentasaccharide 
and pseudo-Ley hexasaccharide units described previously (5). Furthermore, mass 
spectrometry revealed a high purity of the Lex and pseudo-Ley glycan fractions 
obtained. 
 
Figure 5. MALDI-TOF-MS and MS/MS analysis of purified glycans with Lex or pseudo-
Ley units. 
(A) MALDI-TOF-MS/MS spectrum of the Lex pentasaccharide (m/z 917.3 [M+Na]+). Characteristic Lex 
trisaccharide fragment ions (B2 and C2) and the diagnostically relevant Y3α fragment are marked by 
asterisks (*). (B) MALDI-TOF-MS/MS spectrum of the pseudo-Ley hexasaccharide (m/z 1063.6 
[M+Na]+). Characteristic pseudo-Ley tetrasaccharide fragment ions (B3 and C3) are again marked by 
asterisks (*). The signal at m/z 764.2 is assumed to arise from ring fragmentation accompanied by the 
loss of two water molecules (0,2A4-2H2O). Insets: corresponding MS1 spectra. Assignment of fragment 
ions is performed according to Domon and Costello (57).
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Binding of DC-SIGN to Lex and pseudo-Ley neoglycolipids  
Purified Lex and pseudo-Ley glycans were converted into neoglycolipids by coupling 
to 1,2-sn-dipalmitoylphosphatidyl-ethanolamine (DPPE) via reductive amination. 
Resulting products were analyzed by MALDI-TOF-MS (Fig. 6). Lex neoglycolipid led 
to a signal of m/z 1615.0 [M-H+2Na]+ (Fig. 6A) in agreement with the calculated 
mass of the Lex pentasaccharide (m/z 917.3) and the mass increment of DPPE (m/z 
692), taking into consideration that one oxygen is lost during reductive amination 
and the acidic proton of DPPE is replaced by a sodium ion. Likewise, pseudo-Ley 
neoglycolipid was registered with masses of m/z 1739.4 [M+Na]+ and m/z 1761.1 [M-
H+2Na]+ (Fig. 6B). Both neoglycolipid samples were quantified by compositional 
analysis with regard to their carbohydrate content in order to ensure the application 
of defined amounts of neoglycolipids in subsequent experiments.  
 
 
Figure 6. MALDI-TOF-MS analysis of neoglycolipids containing Lex or pseudo-Ley 
epitopes. 
(A and B), MALDI-TOF-MS spectra of Lex (m/z 1615.0 [M-H+2Na]+) and pseudo-Ley (m/z 1739.4 
[M+Na]+ and 1761.1 [M-H+2Na]+) neoglycolipids, respectively. 
 
 
Figure 7. DC-SIGN-Fc binds to Lex and 
pseudo-Ley neoglycolipids.  
Binding of DC-SIGN-Fc to schistosomal 
neoglycolipids was tested in ELISA. 10 ng of 
lacto-N-fucopentaose III neoglycolipid 
(LNFPIII) was coated as positive control. In 
parallel, 8 ng of Lex neoglycolipid (Lex) and 8 ng 
of pseudo-Ley neoglycolipid (pseudo Ley) were 
applied to each well. Binding of DC-SIGN-Fc to 
all neoglycolipids was completely inhibited by 
addition of EDTA (Control, only one example 
shown). Indicated standard deviations are based 
on 9 independent determinations. 
 
The binding of DC-SIGN-Fc to Lex and 
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pseudo-Ley neoglycolipids was studied by ELISA (Fig. 7). The results revealed an 
almost equivalent recognition of the two neoglycolipids by DC-SIGN-Fc when 
compared to the LNFPIII-neoglycolipid used as a positive control. This finding is 
remarkable as the pseudo-Ley epitope represents, in contrast to Lex, a parasite-
specific carbohydrate structure. To establish whether natural cell-surface expressed 
DC-SIGN binds authentic cercarial glycolipids and neoglycolipids, we performed a 
cellular adhesion assay. K562 cells stably transfected with DC-SIGN express high 
levels of DC-SIGN on their cell surface as was determined by flow cytometry (Fig. 
8A). Cercarial glycolipids as well as neoglycolipids containing pseudo-Ley or Lex 
showed binding to K-562 transfected with DC-SIGN, but not to the parental K562 cell 
line. There was no binding of cellular DC-SIGN to egg glycolipids and Gb3. The 
binding could be blocked by AZN-D1, a DC-SIGN blocking antibody, and EGTA (Fig. 
8B). Human iDCs naturally express DC-SIGN on their cell surface (Fig 8A). Cercarial 
glycolipids and the neoglycolipids containing Lex or pseudo-Ley are bound by DC-
SIGN on iDCs (Fig. 8C). Despite the fact that iDCs express multiple CLRs on their cell 
surface, adhesion is completely inhibited by the Ca2+-chelator EGTA or a DC-SIGN 
blocking antibody  (Fig. 8C), indicating that binding of the cells to the glycolipids is 
mediated via the CRD of DC-SIGN. Hence, these studies demonstrate that DC-SIGN 
mediates the binding of iDCs to authentic carbohydrate structures uniquely 
expressed by S. mansoni cercarial glycolipids.  
Docking of pseudo-Le y oligosaccharide into DC-SIGN  
The docking of pseudo-Ley in the DC-SIGN binding site was based on the crystal 
structure of the DC-SIGN complexed with Lex containing oligosaccharide (38). 
Inclusion of hydrogen atoms (not located by x-ray diffraction) and optimisation of the 
binding site of the DC-SIGN/Lex complex did not yield any significant change 
compared to the crystal structure. It allows us to propose the hydrogen bond network 
displayed in Fig. 9A, with involvement of two water molecules that bridge the 
galactose residue to Ser360 and Glu358 side chains. Pseudo-Ley was built from this 
complex by adding a fucose in position 3 of the galactose. All possible conformations 
were tested but all of them resulted in a steric conflict with the side chain of Phe313. 
After a systematic search involving both Phe313 side chain and the fucose orientation, 
one possible mode of interaction was identified. The proposed docking mode is 
represented in Fig 9B. The Phe313 side chain would adopt an orientation different 
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from the one observed in the crystal structure of DC-SIGN complexed with Lex. The 
new orientation allows for a strong “stacking” of the aromatic ring of Phe313 with the 
most hydrophobic face of fucose. Such interaction between sugar and planar side 
chains are commonly observed in protein – carbohydrate interactions.  
 
Figure 8.  DC-SIGN on human dendritic cells interacts with authentic S. mansoni 
cercarial glycolipids and Lex and pseudo-Ley neoglycolipids. 
 The expression of DC-SIGN on transfectants and immature DCs (iDCs) was determined by flow 
cytometry (A). Binding of DC-SIGN expressed on K562 transfectants (B) or iDCs (C) to glycolipids 
(GL) and neoglycolipids (NGL) was determined by plate adhesion assay in the presence or absence of 
EGTA, or a blocking mAb to DC-SIGN (AZN-D1). All results are representative of three independent 
experiments, performed in triplicate. 
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The reorientation of the Phe313 side chain does not cost significant energy. This side 
chain adopts a different orientation when compared to DC-SIGN complexed with Lex 
or with mannose oligosaccharide (59;60). Furthermore, a recent crystallographic 
work demonstrated a large conformational change in an arginine residue side chain 
for stacking to a sugar derivative in a galectin structure (61). 
S. mansoni ES products comprise glycolipids with Lex and pseudo-Ley epitopes  
It remains to be investigated whether the cercarial glycosphingolipids that have been 
shown to bind to DC-SIGN in vitro are in a position that allows an interaction with 
DCs in vivo as well. However, DCs are expected to encounter excretory/secretory 
(ES) products, a mixture of glycoproteins and glycolipids that is secreted when the 
cercariae transform to schistosomula. To determine whether the Lex and pseudo-Ley 
containing glycosphingolipids are found within ES products, glycolipids were isolated 
from ES products collected in vitro from freshly transformed cercariae. Following 
treatment with endoglycoceramidase the released oligo-saccharides were analyzed by 
MALDI-TOF-MS. The results revealed that ES product-derived glycolipids comprise 
species with Lex and pseudo-Ley determinants together with a wide panel of extended 
oligofucosylated glycan species, many of which were also recovered in the cercarial 
glycolipid fractions (Table 1). 
 
Figure 9.  Interaction of DC-SIGN with Lex and pseudo-Ley.  
Models of the interaction of DC-SIGN with Lex trisaccharide (A) and pseudo-Ley tetrasaccharide (B). 
Calcium ions are represented by grey spheres. Only the amino acids interacting directly with the 
sugars have been displayed. 
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Discussion 
In this study the interaction of DC-SIGN with S. mansoni glycolipids was 
investigated. In contrast to glycosphingolipids derived from eggs, glyco-sphingolipids 
of S. mansoni cercariae are bound by both recombinant and dendritic cell expressed 
DC-SIGN. Structural characterization of the glycolipids revealed that DC-SIGN binds 
two dominant cercarial glycosphingolipids, being Lex containing species and pseudo-
Ley species (5).  In contrast to Lex that is found in both mammals and several 
pathogens, pseudo-Ley is an oligosaccharide determinant that may be unique for 
schistosomes (5).  These are the first natural ligands identified for DC-SIGN in 
schistosomes, enabling follow-up studies to elucidate the function of the interaction 
between DC-SIGN and schistosome glycolipids in host immunity. The observation 
that egg glycolipids interacted poorly with DC-SIGN is in agreement with previous 
studies demonstrating that species with pseudo-Ley determinants are predominantly 
found in cercarial glycosphingolipids, whereas Lex containing glycosphingolipids 
represent only a very small fraction of total egg stage glycosphingolipids (5). 
 
Recently more insight was obtained into the ability of DC-SIGN to bind fucosylated 
ligands (31;38). Analysis of crystals of the CRD of DC-SIGN bound to lacto-N-
fucopentaose III (that comprises the Lex trisaccharide) showed that the 3- and 4-OH 
groups of the α1-3-linked fucose form coordination bonds with Ca2+ in the primary 
binding site. In this position the fucose is close to Val351, which forms tight van der 
Waals contacts with the 2-OH group, whereas the terminal galactose residue contacts 
the protein via Phe313 in a secondary binding site.  From the proposed models it 
appears that Val351 in DC-SIGN is close to the fucose binding site and makes a strong 
hydrophobic contact with CH at position 1 and 2 of fucose (38). By molecular 
modeling, in combination with binding studies of cell-surface expressed recombinant 
wild-type and mutant forms of DC-SIGN and its homologue L-SIGN we found very 
similar results for the binding mode of Lex in DC-SIGN (31). Both models predict that 
a substituent on the 3-OH group of galactose would give a steric conflict with the side 
chain of Phe313, which is line with the results of binding studies that showed that 3’ 
sialylation or sulfation of Lex abrogates binding (43). However, in the studies 
described here, we observed binding of soluble DC-SIGN-Fc, as well as cellular 
expressed DC-SIGN, to pseudo-Ley that does carry a fucose α1-3 linked to galactose 
(5). To fit a fucose on position 3 of galactose into the model, it appeared necessary to 
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slightly change the orientation of the side chain of Phe313, a movement that does not 
cost significant energy.  Furthermore, in this docking mode a perfect stacking with 
the hydrophobic side of the galactose-linked fucose is created. We propose that the 
secondary binding site of DC-SIGN is flexible due to the capacity of the side chain of 
Phe313 to change orientation, and that pathogens such as S. mansoni may use this 
property to target DC-SIGN. Recently, a similar change in orientation has been 
demonstrated for the side chain of Arg144 in the CRD of galectin-3 upon ligand 
binding (42). The high-resolution X-ray crystal structures of the CRD of human 
galectin-3 were solved in complex with N-acetyllactosamine (LacNAc) and a high-
affinity inhibitor. The structures showed that the side chain of Arg144 stacks against 
the aromatic moiety of the inhibitor, which was possible by a reorientation of the side 
chain relative to that seen in the complex with LacNAc. 
 
Antigen presenting cells, such as DCs and macrophages are the first immune cells 
that encounter invading pathogens and are crucially involved in the initiation and 
control of innate and adaptive immune responses (44). They often recognize 
pathogens through a wide array of molecules such as (glyco)lipids and acylated 
proteins or peptides. Interestingly, several studies indicate that glycolipids are 
capable to modulate the human immune system (45-47). The presence of lipid 
moieties within pathogen-derived products is essential for activation of specific 
pattern-recognition receptors, in particular TLR2 (48). It was recently shown that 
schistosomal egg glycolipids induce production of pro- and anti-inflammatory 
cytokines in monocytes (24). By fractionating and purification of the lipids, the 
authors showed that mono-acetylated lysophosphatidylserine (lyso-PS) promotes the 
development of T regulatory cells via interaction with TLR2 on DCs. By contrast, di-
acetylated phosphatidylserine promotes maturation of DC into a phenotype, termed 
DC2, which induces the development of TH2 responses (24). 
 
Here we report that DCs interact with authentic cercarial glycosphingolipids 
comprising Lex and pseudo-Ley via the CLR DC-SIGN. This indicates that DCs may 
likely interact with schistosomes early in infection. Schistosomes enter the human 
host in the cercarial stage, and these cercariae transform into schistosomula directly 
after penetration of the skin by shedding their glycocalyx and secretion of 
excretory/secretory (ES) products. Analysis of the glycolipids derived from ES 
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products showed that they comprise species with Lex and pseudo-Ley determinants. 
These ES products that enter the surrounding tissue are good candidate antigens to 
be encountered by surveying DCs, such as the DC-SIGN positive CD1a negative 
dermal DCs, which are found mostly in the upper dermis (35; 49; 50).  
 
A remarkable finding is that human DCs recognize Lex and LDN-F glycan antigens 
within schistosomes (28), which can be considered as “self-glycan” antigens since 
they are also found on human glycoconjugates. It has been proposed that DC-SIGN, 
which also interacts with several “self-ligands” such as ICAM-2 and ICAM-3, may 
principally function in normal homeostasis, rather than being a true pattern 
recognition receptor (26). Current views are that pathogens target DC-SIGN or other 
CLRs to promote immune escape (51). For example, Mycobacterium tuberculosis 
secretes glycoconjugates that are recognized by DC-SIGN to down regulate TLR 
induced immune activation (52).  Pathogens like HIV-1 have many strategies to evade 
immune recognition or to modulate immune responses to survive in their hosts. In 
HIV-1 infection, DC-SIGN plays a role in internalization of the virus into DCs, but 
instead of being routed to the lysosomal compartment for degradation, part of the 
infectious virus remains hidden in the DC, to subsequently infect target cells (51). 
Schistosomes survive for many years in the host despite a pronounced immune 
response, indicating that these helminths have effective strategies to escape or 
suppress the host immune system. In a mouse model system, SEA and its major 
glycan antigen Lex can induce a TH2-mediated immune response, which is associated 
with persistence of the pathogen (53). Our data here show that DC-SIGN does not 
only recognize the self-glycan ligand Lex within cercarial glycolipids, but also 
glycolipids carrying pseudo-Ley, a non-self structure that so far is only found within 
schistosome cercarial glycolipids (5) and ES products (this study). Pseudo-Ley may be 
regarded as a glycan antigen that mimics a self-glycan to fit within the CRD of DC-
SIGN. The abundant expression of such self-glycans or glycan antigens that mimic 
self-glycans, may allow schistosomes to mislead the host immune system by down 
regulating DC function in all stages of infection. However, DC-SIGN has been shown 
to internalize schistosome glycoconjugates (unpublished) and could also play a role in 
processing of these glycoconjugates and antigen presentation. Since currently more 
than 200 million people have schistosomiasis, it is challenging to understand the 
central role of DCs in both the strong immune response that is evoked upon infection, 
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as well as in the immune evasion and suppression mechanisms that are exploited by 
the schistosomes. 
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Abstract  
In Schistosomiasis, a parasitic disease caused by helminths, the parasite eggs induce 
a T helper 2 cell (TH2) response in the host. Here, the specific role of human 
monocyte-derived dendritic cells (DCs) in initiation and polarization of the egg-
specific T cell responses was examined. We demonstrate that immature DCs (iDCs) 
pulsed with schistosome soluble egg antigens (SEA) do not show an increase in 
expression of co-stimulatory molecules or cytokines, indicating that no conventional 
maturation was induced. The ability of SEA to affect the Toll-like receptor (TLR) 
induced maturation of iDCs was examined by copulsing the DCs with SEA and TLR-
ligands. SEA suppressed both the maturation of iDCs induced by poly I:C and LPS, as 
indicated by a decrease in co-stimulatory molecule expression and production of IL-
12, IL-6 and TNF-α. In addition, SEA suppressed TH1 responses induced by the poly 
I:C-pulsed DCs, and skewed the LPS-induced mixed response towards a TH2 
response. Immature DCs rapidly internalized SEA through the C-type lectins DC-
SIGN, MGL and the mannose receptor and the antigens were targeted to MHC class 
II-positive lysosomal compartments. The internalization of SEA by multiple C-type 
lectins may be important to regulate the response of the iDCs to TLR-induced signals. 
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Introduction 
The parasitic helminth Schistosoma mansoni is the causative agent of the chronic 
disease schistosomiasis, which affects ~ 300 million people worldwide, particularly in 
tropical countries (1). The disease is characterized by granulomatous reactions 
around viable eggs entrapped in host tissues (2). Schistosomes are multicellular 
organisms, which present a wide variety of antigens to the host. Increasing evidence 
indicates that glycoconjugated antigens expressed by the schistosomes play a critical 
role in the immunobiology of schistosomiasis (3). Among these are soluble egg 
antigens (SEA), a complex mixture of diverse glycoconjugates such as glycoproteins 
and glycolipids, which are secreted by Schistosoma mansoni eggs entrapped in the 
liver of the host. The early stage of infection with S. mansoni leads to a TH1 response. 
As the infection progresses and eggs are released by the adult worms, the TH1 
response declines and switches towards a TH2 response, driven by the egg antigens.  
 
Dendritic cells (DCs) are antigen-presenting cells that perform an essential role in the 
generation and regulation of adaptive immune responses. Precursor DCs migrate 
from the blood into the peripheral tissues and immature DC function as a continuous 
surveillance patrol for incoming foreign antigens. DCs capture and internalize such 
antigens/pathogens for presentation to T cells in lymph nodes. In addition, DCs 
provide signals that direct naïve TH cells to proliferate and differentiate into TH1, TH2 
or T regulatory cells (4). To become licensed to activate naïve TH cells, DCs must 
undergo a maturation process (5). Maturation can be induced by immune system 
intrinsic signals, such as IFN-α, TNF-α and CD40L (6) or by pathogen-derived 
signals (7).  
 
DCs express a wide range of receptors for the recognition of microbes or microbial 
products, including C-type lectins (CLRs) and Toll-like receptors (TLRs). CLRs 
recognize carbohydrates on self or non-self glycoproteins. SEA is highly glycosylated 
enabling its recognition by CLRs. We have previously reported that DC-SIGN (8) and 
MGL (9) strongly bind SEA, but it is unclear whether other CLRs expressed by DC are 
involved in the recognition of SEA and whether they recognition by CLRs leads to 
internalization of the antigens and induction of TH2 polarizing signals.  
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Recent reports indicate that schistosome components interact with TLRs. 
Schistosome egg-derived dsRNA has been reported as a ligand for TLR3 (10) and in 
mice TLR4 has been implicated in TH2 cell development (11). Lysophosphatidylserine 
a lipid from either S. mansoni adult worms or eggs, is able to polarize allogenic T cells 
towards a TH2 development through a TLR2 dependent mechanism (12). There is 
increasing evidence that glycans play an important role in the induction of a TH2 
response. In mice, Lacto-N-fucopentaose III, containing the trisaccharide Lewis x 
(Lex), promotes a TH2 cell response in a TLR4 dependent manner (11;13;14). Also 
glycoconjugates carrying complex-type N-glycans with amongst others core α1,3-
fucose and core β1,2-xylose determinants, have the capacity to generate a strong TH2-
biased cellular response in mice (15). Such TH2 skewing is seen in many parasitic 
helminth infections and in general is parasite permissive (16-18), but the TH2 cells 
also provide the host with protective mechanisms to survive the infection (1). The 
mechanisms by which parasite-derived carbohydrates modulate host immune 
responses remain largely unknown. Certain pathogens that target CLRs through their 
carbohydrate moieties induce inhibitory or stimulatory signals in DCs that result in 
modulation of DC function (19-22).  These examples show that CLRs can act in 
synergy with other receptors, in particular through cross talk with TLRs, which may 
also play a role in schistosome infection.  
 
To increase our understanding of the role of human DCs in the egg-induced TH2 
responses in schistosome infection, we examined in this study the ability of 
monocyte-derived iDCs, pulsed with SEA or copulsed with SEA and TLR-ligands, to 
mature and induce polarized T cell responses, and focused on the interaction of SEA 
with DC-expressed CLRs. Our results show that DC-SIGN, MGL as well as the 
mannose receptor play a role in binding and subsequent internalization of SEA. Co-
localization of SEA with MHC II in the lysosomal compartments suggests that Ag 
processing and presentation can occur. Although SEA by itself did not induce DC 
activation, copulsing iDCs with SEA and TLR ligands resulted in suppression of the 
TLR-induced maturation and modulation of the T cell polarizing capacity of DCs.  
 
 
 Chapter 7                                                                                                                                                                      _ 
158
Material and Methods 
Cells Immature DCs were obtained from buffycoats of healthy donors (Sanquin, 
Amsterdam) as previously described (23). In short, human PBMCs were isolated by a 
Ficoll gradient. Monocytes were isolated by CD14 magnetic microbeads isolation 
(MACS; Miltenyibiotec, USA) and differentiated into immature DCs in the presence 
of IL-4 and GM-CSF (500 and 800 U/ml, respectively; Biosource, Nivelles, Belgium). 
DCs expressed high levels of major histocompatibility complex class I and II, CD11b, 
CD11c, and ICAM-1 and low levels of CD80 and CD86, as was confirmed by flow 
cytometry 
 
Antibodies and reagents The following antibodies were used: AZN-D1 (anti-DC-
SIGN) (24;25), 1G6.6 (anti-MGL (26)), 3.29.B1(IgG1, anti-MR, (27)), anti-DEC-205 
(28), anti-DCIR (R&D systems), anti-LAMP-1 (H4A3, BD Pharmingen), EEA-1 
(Abcam, Cambridge, UK), Q5/13 (anti-MHC II;(29)), PE-conjugated antibodies 
against CD80, CD86 and HLA-DR (BD Pharmingen) and CD83 (Immunotech). Goat 
anti-mouse and goat anti-rabbit conjugated with Alexa Fluor 594 (Molecular Probes), 
goat anti-mouse and goat anti-human conjugated with peroxidase (Jackson 
Immunoresearch, West Grove, Pa). Carbohydrate components mannan, 
mannosylated biotinylated BSA, GalNAc and laminarin were all from Sigma Aldrich. 
Crude Schistosoma mansoni soluble egg antigens (SEA) extract was prepared as 
described previously (30) and was provided by F. Lewis (Biomedical Research 
Institute, Rockville, MD). SEA does not contain detectable levels of LPS, as was 
shown by the inability of SEA to induce IL-8 production by TLR2 and TLR4 
transfected cell-lines (kind gift of Douglas Gohlenbock) (data not shown).  
 
DC maturation Immature monocyte derived DCs (day 4) were stimulated with SEA 
(5 or 50 μg/ml) in the presence or absence of LPS (10 ng/ml; Salmonella typhosa, 
Sigma-Aldrich, St Louise, MO) or poly I:C (10 μg/ml; Sigma-Aldrich) for 24 hrs at 
37ºC. Cell-surface expression of MHC class II (HLA-DR) and co-stimulatory 
molecules CD80, CD83, and CD86 using PE-conjugated antibodies was used to 
determine maturation. 
 
Cytokines measurements For the detection of cytokines, culture supernatants were 
harvested 24 hrs after DC activation and frozen at -80°C until analysis. Cytokines 
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were measured by enzyme-linked immunosorbant assay (ELISA) with CytoSetsTM 
ELISA kits (Biosource) for human IL-6, IL-10, TNF-α and IL-12p40 according to the 
manufacturer’s instructions. Human IL-12p70 detection was determined as described 
before (31). 
 
Dendritic cell-driven TH1/TH2 differentiation Immature DCs were cultured from 
monocytes of healthy donors in Iscove’s Modified Dulbecco’s Medium (Gibco), 
supplemented with 10% FCS (BioWithaker, Verviers, Belgium), 500 U/ml IL-4 and 
800 U/ml GM-CSF (Biosource) (23). At day 6, DC-maturation was induced with SEA 
in combination with LPS or poly I:C. The following positive controls were included in 
the assay: (i) 10 ng/ml E. coli LPS, (mixed TH1/ TH2 response); (ii) 20 μg/ml poly I:C 
(TH1); and (iii) 10 μg/ml PGE2 and 10ng/ml LPS (TH2). After 2 days, DCs were 
washed and incubated with autologous CD45RA+/CD4+ T cells (5.103 DC / 20.103 T 
cells). In parallel, DCs were analyzed for maturation markers (CD83 and CD86) by 
flowcytometry. At day 5, rIL-2 (10 U/ml) was added, and the cultures were expanded 
for the next 7 days. To determine cytokine production by TH cells, at day 12-15 
quiescent T cells were re-stimulated with 10 ng/ml PMA and 1 μg/ml ionomycin 
(both Sigma-Aldrich) for 6 h. After 1 h 10 μg/ml Brefeldin A  (Sigma-Aldrich) was 
added to the T cells. Single cell production of IL-4 and IFN-γ was determined by 
intracellular flowcytometric analysis. Cells were fixed in 2% PFA, permeabilized with 
0.5% saponin (Sigma-Aldrich) and stained with anti-human IFN-γ-FITC and anti-
human IL-4-PE (BD Pharmingen). 
 
mRNA isolation and cDNA synthesis mRNA was isolated by poly (A+) RNA capture 
in streptavidin-coated tubes with an mRNA Capture kit (Roche, Switzerland) and 
cDNA was synthesized with the Reverse Transcription System kit (Promega, USA) 
following manufacturer’s guidelines. In brief, cells were washed twice with ice-cold 
PBS and harvested with 100 μl lysis-buffer. Lysates were incubated with biotin-
labeled oligo(dT)20 for 5 min at 37 °C. The mix was transferred to streptavidin-coated 
tubes and incubated for 5 min at 37°C. After washing 3 times with 200 μl washing 
buffer, 30 μl of the reverse transcription mix (5mM MgCl2, 1x reverse transcription 
buffer, 1 mM dNTP, 0.4 U recombinant RNasin ribonuclease inhibitor, 0.4 U AMV 
reverse transcriptase, 0.5 μg random hexamers in nuclease-free water) were added to 
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the tubes and incubated for 10 min at room temperature followed by 45 min at 42°C. 
To inactivate AMV reverse transcriptase and separate mRNA from the streptavidin-
biotin complex, samples were heated at 99°C for 5 min, transferred to 
microcentrifuge tubes and incubated on ice for 5 min, diluted 1:2 in nuclease-free 
water, and stored at -20°C. 
 
Quantitative Real-Time PCR Oligonucleotides were designed by using computer 
software Primer Express 2.0 (Applied Biosystems, USA) and synthesized by Isogen 
lifescience (IJsselstein, the Netherlands). Primer specificity was computer tested 
(BLAST, National center for Biotechnology Information) by homology search with the 
human genome and later confirmed by dissociation curve analysis. PCR reactions 
were performed with SYBR green method in an ABI 7900HT sequence detection 
system (Applied Biosystems). The reactions were set on a 96 well-plate by mixing 4 μl 
of the 2 times concentrated SYBR Green Master Mix (Applied Biosystems) with 2 μl 
of the primer solution containing 5 nmol/μl of both primers and 2 μl of a cDNA 
solution. The thermal profile for all the reactions was 2 min at 50°C, followed by 10 
min at 95°C and then 40 cycles of 15 sec at 95°C and 1 min 60°C. The fluorescence 
monitoring occurred at the end of each cycle. The Ct value is defined as the number of 
PCR cycles where the fluorescence signal exceeds the threshold value, which is fixed 
above 10 times the standard deviation of the fluorescence during the first 15 cycles 
and typically corresponds to 0.2 relative fluorescence units. This threshold is set 
constant throughout the study and corresponds to the log linear range of the 
amplification curve. The normalized amount of target, or relative abundance, reflects 
the relative amount of target transcripts with respect to the expression of the 
endogenous reference gene. GAPDH served as an endogenous reference gene (32).  
 
Fluorescent bead adhesion assay SEA binding to whole cells was measured by bead 
adhesion assay as described previously (33). In short, streptavidin was covalently 
coupled onto carboxylate-modified TransFluorSpheres (488/654 nm, 1.0 μm, 
Molecular Probes Inc, Eugene, OR). SEA was biotinylated with EZ-linkTM NHS-LC-
LC-Biotin, according to the manufacturer’s protocol (Pierce, Rockford, IL). 
Biotinylated SEA was coupled to streptavidin coated fluorescent beads (34). Cells 
were resuspended in TSM (20 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1mM CaCl2, 2 
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mM MgCl2) and 0.5% BSA. After pre-incubation with blocking antibodies against C-
type lectins (20 μg/ml), mannan (50 μg/ml), GalNAc (50 mM), mannosylated 
biotinylated BSA (50 μg/ml), laminarin (100 μg/ml) or EGTA (10 mM) for 10 min at 
room temperature in TSM-0.5% BSA, cells were incubated with ligand-coated 
fluorescent beads (20 beads/cell) for 45 min at 37ºC. Bead adhesion to the cells was 
determined using flow cytometry (FACScan, Becton Dickinson, Oxnard, CA).  
Internalization assay Immature DCs were incubated with biotinylated SEA (10 
μg/ml) in TSA for 1 h on ice and were subsequently washed. Where indicated cells 
were pre-incubated with Abs directed against C-type lectins for 30 min at 37ºC. Cells 
were incubated at 37°C for various times, placed on ice and incubated with 
streptavidin Alexa Fluor 488. To control for off-rate of SEA at 37°C, cells were fixed 
(2% PFA) before SEA binding to prevent membrane transport. Cells were analyzed 
using flow cytometry, and the relative difference in mean fluorescence intensity 
compared with fixed cells was calculated. 
 
Confocal laser scanning microscopy SEA was labeled with Alexa Fluor 488 according 
to the manufacturer’s protocol (Molecular Probes, Eugene, OR). Dendritic cells were 
incubated for 2 hrs at 37ºC with Alexa Fluor 488-conjugated SEA (10 μg/ml). 
Labeled cells were fixed and permeabilized for 20 min at 4ºC (BD cytofix/cytoperm 
TM, BD). Cells were stained in phosphate-buffered saline containing 0.5 % bovine 
serum albumin and 0.1% saponin, with antibodies against LAMP-1, EEA-1, DC-SIGN, 
MGL or MR and subsequently with Alexa Fluor 594-conjugated secondary 
antibodies. Cells were allowed to adhere to poly-L-lysine-coated glass slides, mounted 
with anti-bleach reagent and analyzed by confocal microscopy. Leica AOBS SP2 
confocal laser scanning microscope (CLSM) system was used, containing a DM-IRE2 
microscope with glycerol objective lens (PL APO 63x/NA1.30) and images were 
acquired using Leica confocal software (version 2.61).   
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Results 
SEA inhibits DC activation induced by TLR3 and TLR2/4 ligands 
To examine the capacity of SEA to induce maturation of human DCs, we pulsed 
monocyte-derived immature DCs (iDCs)  with SEA in different concentrations. SEA 
alone did not induce DC maturation, as none of the activation markers CD80, CD83, 
CD86 or HLA-DR were up regulated, not even at high concentrations of SEA (up to 
100 μg/ml, Fig. 1A and data not shown). Furthermore iDCs incubated for 24h with 
SEA do not secrete any IL-10, IL-6, IL-12p40, IL-12p70 or TNF-α, as is shown for 5 
and 50 μg/ml SEA in Fig. 1B. Next, we investigated whether SEA could inhibit the 
maturation of DCs induced by the TLR3 and TLR2/4 ligands, poly I:C and LPS 
respectively, to mimic the situation in schistosome infection where TLR2, TLR3 and 
TLR4 have been implicated to play a role (10-12). The results show that both the LPS 
and the poly I:C induced maturation was inhibited in the presence of SEA in a dose 
dependent manner as 50 μg/ml SEA induces more inhibition than 5 μg/ml SEA. 
CD80, CD83 and CD86 up-regulation is inhibited (30 to 45%) compared to LPS- or 
poly I:C-activated DCs (Fig. 1C). Furthermore in the presence of SEA, DCs produced 
reduced levels of all cytokines tested, TNF-α, IL-6, IL-10, IL-12p40 and IL-12p70, in 
a dose dependent manner (Fig 1D). For IL-10 we observed that although most donors 
tested (19 out of 30) displayed a reduction in IL-10 production in the presence of 
SEA, some donors did not produce IL-10 at all (n=3), or produce equal amounts of 
IL-10 in the presence or absence of SEA (n=8). In conclusion, SEA does not induce 
maturation of human iDCs, but inhibits both the TLR3 and TLR2/4 ligand induced 
activation of DCs. Such inhibition is not a generally observed; as for example E/S 
products secreted from schistosomula do not have this effect on DC activation (van 
Liempt et al., unpublished). 
 
                                                                                                         SEA is internalized by multiple C-type lectins 
163
 
Figure 1. SEA inhibits the poly I:C or LPS induced DC activation and cytokine 
production.  
A. SEA does not induce maturation of immature DCs. Immature DCs were incubated with LPS or 
different concentrations of SEA for 18h, and activation was determined by measuring the expression of 
CD80, CD83 and CD86. Dotted line represents isotype controls; dark line represents immature DCs 
treated with either LPS (10 ng/ml) or SEA (5 or 50 μg/ml). One representative experiment out of three 
is shown. Numbers reflect mean fluorescence intensity values. B.SEA does not induce production of 
IL-10, IL-6, IL-12p40, IL-12p70 and TNF-α. Supernatants were harvested after 18h and cytokine 
production was determined  by ELISA. C. SEA inhibits the LPS or poly I:C induced maturation. 
Immature DCs were treated with LPS (10 ng/ml) or poly I:C (10 μg/ml) in the presence or absence of 
SEA (5 or 50 μg/ml). Activation was determined as in A. D. SEA inhibits the LPS or poly I:C induced 
cytokine production for IL-10, IL-6, IL-12p40, IL-12p70 and TNF-α, in a dose dependent manner. 
Supernatants were harvested after 18h and cytokine production was measured by ELISA.  
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Modulation of polarized T cell responses by SEA 
In schistosomiasis, the early phase of infection is characterized by TH1 immune 
responses that are modulated to TH2 upon egg laying, driven by the egg antigens (1). 
To asses the DC-driven T cell responses, DCs were pulsed with SEA in combination 
with LPS or poly I:C and cocultured with naïve T cells . As described previously (35), 
DCs incubated with LPS induce naïve T cell differentiation into a mixed TH1/TH2 
response, whereas poly I:C induces a dominant TH1 response and PGE2 a TH2 
response (Fig. 2). Our data show that SEA alone could not support T cell 
differentiation (Fig. 1 and data not shown). Interestingly, coculture of iDCs with a 
mixture of SEA and TLR ligands resulted in a down modulation of the TH1 responses 
induced by poly I:C and skewing of the mixed TH1/TH2 response induced by LPS 
towards a TH2 response.  SEA could not skew the T H1 response of poly I:C towards a 
T H2, possibly because the T H1 response induced by poly I:C is too strong. 
 
Figure 2. Poly I:C and SEA co-
stimulation results in down 
modulated TH1 response.  
DCs were incubated with SEA, LPS, poly I:C 
or PGE2 for 48 h, washed and co-cultured 
with highly purified CD45RA+CD4+ T cells. 
Naïve T cells were restimulated with PMA 
and ionomycin, and intracellular IL-4 (TH2) 
and IFN-γ (TH1) was analyzed on a single 
cell basis by flow cytometry. Two out of five 
donors are shown. 
 
 
 
 
 
 
SEA binds to both immature and mature dendritic cells. 
To assess the capacity of different immune cells to bind SEA, a bead adhesion assay 
was performed. SEA was biotinylated, coupled to streptavidin coated fluorescent 
beads [34] and incubated with different immune cells. As shown in Figure 3, SEA 
does not bind to monocytes, PBMCs or PBLs isolated from blood of healthy donors. 
In contrast, SEA bind strongly to iDCs, and displays a reduced binding to DCs 
matured with LPS or poly I:C (Fig. 3). The binding of iDCs to SEA could be 
completely blocked by preincubation with EGTA, indicating that the binding is Ca2+- 
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dependent. Both findings suggest that DC-expressed CLRs are involved in the 
recognition of SEA.  
 
Figure 3. SEA-beads bind to immature and 
mature DCs. 
SEA was biotinylated and coupled to streptavidin-
coated fluorescent beads (SEA-beads). Binding of 
the beads to the cells was measured by FACScan 
analysis using Cellquest (Becton Dickinson, 
Oxnard, CA). SEA-beads show binding to 
immature and mature DCs. The binding was 
completely blocked by the calcium chelator EGTA. 
 
 
 
Expression of pathogen receptors on DCs 
We have previously reported that SEA is recognized by iDCs through the CLRs DC-
SIGN (8) and MGL (9). Because SEA contains many different glycan antigens it is 
likely that also other CLRs than DC-SIGN and MGL are involved in the binding of 
SEA. To identify possible candidate lectins, we determined the expression levels of 
CLRs by RT-PCR for both immature and mature DCs. DCs express high levels of DC-
SIGN, MR and MGL as is indicated by a relative abundance of 1 or higher, moderate 
levels of Dectin and DCIR (relative abundance of 0.84 and 0.41, respectively) and low 
levels of DEC-205 (Table 1A). Upon maturation with either LPS or poly I:C, down- or 
up regulation is indicated as a percentage of the expression on iDCs, which was set a 
100%. Our data show that DC-SIGN is down regulated on mDCs to 2% (LPS) and 15% 
(poly I:C) of the expression level of iDCs, and also MGL, MR, DCIR and Dectin are 
down regulated on mDCs (Table 1A). In contrast, DEC-205 is up regulated on mDCs 
(1175% and 784%). We also analyzed the expression levels of TLRs, as these are 
known to play a role in S. mansoni induced immune responses. Monocyte-derived 
DCs express all TLRs tested except TLR9. Upon maturation by LPS and poly I:C 
TLR1, TLR2, TLR4, TLR6, CD14 and MD2 are down regulated, whereas TLR3, TLR7 
and TLR10 are up regulated. In DCs incubated with poly I:C, the TLR-8 expression 
levels are up regulated.TLR5 expression levels remain unchanged upon maturation, 
as well asTLR8 in DCs stimulated with LPS (Table 1B). In table 1C we show that 
interaction of SEA with iDCs does not influence the expression of DC-SIGN, MGL 
and MR in the absence, nor in the presence, of the TLR ligands LPS or poly I:C on 
either immature or mature DCs. Thus, DCs express a variety of receptors that could 
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be involved in SEA recognition and in particular TLR-induced maturation regulates 
the expression level of these receptors. 
 
Table 1. Expression levels of TLRs and CLRs on immature DCs or DCs stimulated with 
LPS or poly I:C. 
A and B). The relative abundance is shown for iDCs which reflects the relative amount of target 
transcript with respect to the expression of the endogenous reference gene GAPDH (including 
standard error). For LPS or poly IC stimulated DCs, the percentage of up- or down regulation is given, 
with standard error. The primers used were tested on positive controls prior to use. The values for 
TLR9 are indicated with bd, which means that the values were below detection limits. 
C). The expression levels of DC-SIGN, MGL and MR are shown on iDCs and DCs stimulated with LPS 
and poly I:C in the presence of SEA. The relative abundance is shown for iDCs. For the other 
conditions the percentage of up- or down regulation is given, with standard error, similar as described 
in A and B. Data represent mean values out of 6 donors. 
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C-type lectins interact with SEA 
Next, the role of DC-expressed C-type lectins in the binding of SEA was analyzed. As 
is shown in Figure 4a, DCs express DCIR, DEC-205 and MR on the cell surface, in 
addition to DC-SIGN and MGL (filled histograms). On mature DCs, the expression of 
DC-SIGN, MGL, MR and DCIR is reduced compared to iDCs, whereas higher 
amounts of DEC-205 protein was observed (Fig. 4A, thick grey lines), as is in 
agreement with mRNA levels (Table 1A). Specific antibodies to DC-SIGN and MGL 
could reduce binding of iDCs to SEA with 40%, indicating that DC-associated DC-
SIGN and MGL bind to SEA (Fig. 4B). In addition, blocking antibodies to the 
Mannose receptor (MR) could partially block binding, indicating that the MR is 
involved in the binding of iDCs to SEA. Addition of sugar inhibitors that are known to 
block interactions with these three CLRs (GalNAc (MGL), BSA-mannose (MR) and 
mannan (DC-SIGN/MR)), resulted in a comparable reduction in binding as found by 
using the anti-CLR antibodies as inhibitors. Remarkably, the binding of iDCs to SEA 
could be completely inhibited by a combination of antibodies against DC-SIGN, MGL 
and MR (Fig. 4B). By contrast, we could not observe inhibition of DC-binding to SEA 
using blocking antibodies against DEC-205 (28) or DCIR (Fig. 4B), suggesting that 
these CLRs are not involved in binding. The lack of inhibition by laminarin, which 
inhibits binding to Dectin-1, suggests that Dectin-1 is not involved in binding of iDCs 
to SEA (Fig. 4B). Together these data indicate that iDCs recognize SEA through the 
CLRs DC-SIGN, MGL and the MR. The reduction of SEA binding to mature DCs (Fig. 
3) corresponds to the observed lower expression of DC-SIGN, MGL and MR on 
mature DCs compared to immature DCs (Fig. 4A/Table 1A).  
 
SEA is internalized by DCs and targeted to the MHC class II+ LAMP+ 
compartments 
C-type lectins function as endocytic receptors on DCs and are either constitutively 
internalized from the cell surface, like the MR or internalized upon ligand binding, as 
we have previously shown for DC-SIGN (27). We investigated whether SEA, upon 
binding by C-type lectins, is internalized from the cell surface. Indeed, we found that 
50% of the SEA is internalized from the cell surface, within 15-30 min (Fig. 5A). Next, 
we investigated which CLRs on iDCs facilitate this rapid internalization of SEA. Our 
results show that pre-incubation of DCs with blocking antibodies against DC-SIGN, 
MR or MGL, could partially block the internalization of SEA up to 25%, 30% and 35%  
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Figure 4. C-type lectins DC-SIGN, MGL and MR bind SEA on iDCs. 
A. C-type lectin expression on immature and mature DCs. Open histograms represent the isotype 
control and filled histograms represent the anti-C-type lectin mAb staining on iDCs. The thick grey line 
shows C-type lectin expression on LPS matured DCs. The CLR expression on poly I:C matured DCs are 
comparable to those on LPS matured DCs (not shown). B. Immature DCs strongly bind SEA through 
DC-SIGN, MGL and MR. A bead adhesion assay was performed in the presence or absence of blocking 
mAbs directed against C-type lectins or the polysaccharide mannan (DC-SIGN and MR), BSA-
mannose (MR), Laminarin (Dectin), GalNAc (MGL) or EGTA (blocking all CLRs). Experiments were 
performed in duplicates and one representative experiment out of three is shown. 
 
respectively (Fig. 5B). However, the combination of antibodies against all three CLRs 
could block internalization of SEA completely, confirming that DC-SIGN, MGL as 
well as the MR are all involved in capture and subsequent internalization of SEA into 
DCs. In addition, co-localization of SEA with all three CLRs could be observed, using 
confocal laser scanning microscopy (CLSM) (Fig. 5C). The subcellular localization of 
SEA upon internalization was examined by staining with the lysosomal marker 
LAMP-1 or early endosomal marker EEA-1 (Fig. 5D). After 30 min, SEA was localized 
in EEA-1 positive compartments, whereas after 2h all SEA was localized within 
LAMP-1 positive compartments, indicating that SEA captured by DC-SIGN, MGL and 
MR traveled within 2h through endosomal compartments into lysosomes. At these 
later time points, SEA co-localized with MHC class II molecules (Fig. 5E). Thus, we 
conclude that upon capture, SEA is rapidly internalized by DCs through the CLRs DC-
SIGN, MGL and MR and targeted to the MHC class II+ lysosomes, suggesting that 
SEA might be processed and presented. 
 

 Chapter 7                                                                                                                                                                      _ 
170
Discussion 
In schistosomiasis, eggs released by the adult worms are entrapped in host tissues 
and secrete soluble egg antigens (SEA), which results in the induction of a TH2 
response (36-40). The mechanism by which DCs induce SEA-specific TH2 responses 
during infection is not clearly understood. We show here that human monocyte-
derived iDCs pulsed with SEA, do not undergo a conventional maturation process in 
vitro. However, SEA is rapidly internalized through multiple C-type lectins (CLRs) 
and targeted into the MHC II+ lysosomal compartments. Furthermore, SEA can 
inhibit the LPS- or poly I:C induced DC activation and subsequent production of IL-
12, TNFα, IL-6 and IL-10, resulting in modulation of the T cell polarizing capacity of 
the DC. From these data we hypothesize that internalization of SEA through CLRs on 
DCs leads to processing and presentation of SEA to T cells and may contribute to the 
outcome of the TH1/TH2 balance by providing a TH2 polarizing signal to the DCs. In 
addition, we propose that these CLRs may play a role in the SEA-induced down 
modulation of LPS- or poly I:C induced maturation and subsequent cytokine 
production.  
 
Our data show that the C-type lectins DC-SIGN, MGL and the MR contribute to the 
internalization and targeting of SEA to MHC II+ lysosomal compartments, where the 
SEA can be processed and subsequently presented to T cells leading to a specific 
immune response. Lectin-mediated uptake pathways have been shown to be highly 
efficient to elicit immune responses (27,41). 
 
Previously, we showed that DC-SIGN binds to SEA through the glycan antigens 
Galβ1,4(Fucα1,3)GlcNAc (Lex) and GalNAcβ1,4(Fucα1,3)GlcNAc (LDNF) (8), whereas 
MGL recognizes both LDNF and GalNAcβ1,4GlcNAc (LDN) moieties within SEA (9). 
The actual glycan ligands for the MR within SEA have not been identified yet. The 
MR preferentially targets mannose containing structures and differs from DC-SIGN 
as it does not interact with Lex, despite having affinity for fucose (42). At this point it 
remains unclear whether all schistosome antigens that are captured and internalized 
by DCs will be presented to T cells, or that there is a more selective form of 
presentation in which CLRs determine which antigens are presented and which are 
not.  
 
                                                                                                         SEA is internalized by multiple C-type lectins 
171
The immuno-regulatory role of DCs is believed to be determined by ligation of 
pathogen-recognition receptors such as TLRs and CLRs, and signaling pathways 
induced by these receptors, which can interconnect through a so-called cross talk. 
Interestingly, a recent study shows that targeting the MR could prime a regulatory 
program in DC, leading to the production of anti-inflammatory cytokines and 
induction of TH2 cells with regulatory capacity (43). In addition, the production of 
inflammatory cytokines by the TLR4-ligand LPS was prevented implying cross talk 
between the MR and TLR4. Several examples illustrate that pathogen-induced 
signaling through DC-SIGN results in a shift in TH1/TH2 balance. Signaling through 
DC-SIGN by Lewis positive Helicobacter pylori results in a shift in the TH1/TH2 
balance towards TH2, whereas Lewis negative H. pylori do not bind DC-SIGN and 
trigger TH1 responses (19). Lactobacillus species L. reuteri and L. casei instruct DCs 
to induce IL-10 producing regulatory T cells that suppress T cell responses through 
engagement of DC-SIGN (35). Mycobacterium tuberculosis interacts with DCs 
through its cell wall component ManLAM with DC-SIGN, which inhibits the TLR-
induced maturation and induces the immunosuppressive cytokine IL-10 (21). 
Neisseria meningitidis expressing IgtB LPS targets DC-SIGN and skewed T cell 
responses driven by DC towards TH1 activity (22). These reports suggest that CLRs 
could play an important role in determining the outcome of the TH1/TH2 balance. 
More insight in the signaling capacities of DC-SIGN was recently provided by studies 
of Caparros et al. (44), which showed that ligation of DC-SIGN results in the 
phosphorylation of ERK1/2 and Akt. Interestingly, DC-SIGN ligation synergizes with 
TNF-α receptor-initiated signals for enhanced IL-10 release (45). Our observation 
that copulsing of DC with SEA and LPS inhibits the capacity of LPS to activate DCs to 
produce IL-10, despite the binding of SEA to DC-SIGN, indicates that SEA in addition 
triggers other receptors that participate in the integration of the intracellular signals 
to generate the SEA specific immune responses. Such receptors may include the MR 
and/or MGL, but other unidentified TLRs or CLRs cannot be excluded. Our data 
show that DC, pulsed with SEA, do not mature and cannot induce a T cell response in 
vitro. In addition, coculture of SEA with cell-lines transfected with TLR2 or TLR4, 
respectively, did not lead to induction of IL-8 (results not shown). Although these 
data do not exclude the presence of TLR ligands in the SEA preparation, their 
concentrations apparently are too low to induce maturation signals that support the 
differentiation of naïve T cells in vitro. However, TLR agonists may in vivo be 
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provided via other components of the eggs or worms. Aksoy and coworkers showed 
that S. mansoni living eggs activate murine bone marrow-derived DCs through TLR2 
and TLR3 engagement (10). Egg-derived RNA possessed RN-ase A-resistant and RN-
ase III-sensitive structures, suggesting the presence of double-stranded (ds) 
structures, which are capable of triggering TLR3 activation. In addition, the 
schistosome-specific lysophosphatidyl-serine was shown to activate human monocyte 
derived DCs through TLR2, which results in the ability of DCs to induce the 
development of IL-10 producing regulatory T cells as well as the induction of a TH2 
response (12). Thus, since TLR2, TLR3 and TLR4 ligands have been implicated in 
schistosomiasis (10-12), our data showing that SEA inhibits the poly I:C (TLR3) and 
LPS(TLR2/TLR4)-induced maturation may have in vivo functional relevance.  
Experimental infection of mice with S. mansoni has provided an extensively used 
model for examining the development and role of TH2 responses driven by egg 
antigens. Whereas SEA in the human system similarly as in mice has a TH2 polarizing 
capacity, some differences in the mechanism are observed between the murine and 
human system (36-40). Kane and coworkers reported that in BM-DCs of C57BL/6 
mice SEA is able to down modulate LPS induced maturation, IL-12 production and to 
up regulate IL-10 production (39). By contrast, we observed down regulation of both 
IL-12 and IL-10 using human monocyte-derived DC upon copulsing with SEA and 
LPS, or poly I:C, respectively. In addition, whereas we observed a rapid 
internalization and targeting of SEA to MHC II positive lysosomal compartments by 
human DC. Cervi et al., reported that murine bone-marrow-derived DCs internalized 
SEA, but the SEA stayed in LAMP-2 negative compartments unless a maturation 
stimulus was supplied (37). The observed differences between the mouse and human 
system may reflect differences in DC receptors that are triggered by SEA. In 
particular the expression in the type and specificity of C-type lectins may be different 
between the mouse and human system.  
 
Thomas et al. showed that HSA-conjugated Lacto-N-fucopentaose III, which contains 
Lex, can activate murine bone marrow-derived DCs into a TH2 inducing phenotype 
through a TLR4 dependent mechanism (11). LNFP III – TLR4 interaction in mice 
induces signaling through the ERK pathway, and differs from the LPS-induced TLR4 
activation that leads to intracellular signaling through three MAP-kinase signaling 
pathways: ERK, p38 and JNK (11). Remarkably, signaling through DC-SIGN also 
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leads to ERK signaling without p38 stimulation, and thus resembles the LNFP III-
TLR4 signaling in that respect. Although many receptors will participate in the 
integration of the intracellular signals to generate SEA specific responses in 
schistosomiasis, it is tempting to speculate that the Lex - DC-SIGN interaction in 
humans has a similar function as the Lex –TLR4 interaction in the murine system, 
leading to ERK-signaling and contributing to a TH2-inducing DC maturation. It 
would be interesting to investigate whether bone-marrow derived murine DCs show 
next to TLR4-Lex interaction, also a (C-type) lectin-mediated binding of Lex or other 
carbohydrate determinants. Clearly, the dissection of the receptors that interact with 
Schistosome egg antigens, as well as the intracellular signals triggered upon binding, 
need to be further investigated both in the human and murine system to clarify the 
role of the different pathogen-recognition receptors in the generation of the egg-
specific TH2 responses.
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Human dendritic cell expressed CLRs play an important role in the recognition of 
pathogens, but they also play an important role in the recognition of self-
glycoproteins as the interaction of DCs with the endothelium is mediated by DC-
SIGN and ICAM-2 and appeared to be dependent on the carbohydrate Lewis y 
(chapter 5). In this discussion we will focus on the interactions of CLRs with 
Schistosoma mansoni derived antigens. 
 
Schistosomes appear to have evolved several strategies to down-regulate the host 
immune response in order to promote their own survival. It is widely accepted that 
schistosomes modulate the immune response during the chronic phase of infection 
after the deposition of eggs, which is characterized by a TH2 response. Dendritic cells 
are important key players in the immune response against schistosomes since they 
are able to stimulate naïve T cells. In this thesis we show that DCs and especially 
CLRs play an important role in the recognition of Schistosoma mansoni or its 
secretion products. How this interaction relates to the induction of the schistosome 
specific TH2 response remains to be elucidated. 
 
TH1-TH2 response during Schistosoma mansoni infection 
Schistosoma mansoni infection expresses both faces of the TH-balance. During the 
first 3-5 weeks after infection the host is exposed to migrating immature parasites. 
During this so-called acute schistosomiasis, the immune response is primarily TH1 in 
nature. Although a lot of detailed understanding of this phase of the immune 
response is missing, as the response is mainly directed against worm antigens (1;2). 
After parasite maturation, sexual reproduction can occur and egg production is 
initiated. The production of eggs results in inflammation of the liver and intestine as 
the host responds to parasite eggs in these tissues. A marked TH2 response develops 
against these novel egg antigens. During this chronic phase of infection, the egg stage 
of the schistosome is responsible for inducing the TH2 response. By contrast the 
worms themselves were shown to be poor inducers of a TH2 response (3).  
 
The underlying mechanism by which egg production and egg secretion products 
induce a TH2 response is not clear. A role for DCs has been suggested; since SEA 
pulsed DCs are able to elicit a TH2 response (4). How DCs recognize SEA is unclear, 
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nor has it been established whether DCs are able to initiate an egg-specific response 
during infection.  
 
Dendritic cells and schistosome infections 
Parasites and their products are clearly able to activate DCs and this interaction is 
believed to play a crucial role in initial T cell priming (5). The response of murine DCs 
to Schistosoma mansoni provided surprising results. DCs that were exposed to SEA 
failed to upregulate costimulatory molecules and MHC II. SEA-pulsed DCs did not 
produce cytokines. We reported that human monocyte-derived DCs exposed to SEA 
failed to respond in a conventional way (6; chapter 7 of this thesis), while others 
indicate that these DCs display a level of phenotypic activation (7-9). Although these 
DCs pulsed with SEA failed to mature, they are able to induce a TH2 response. These 
findings suggest that besides DC activation other DC-linked mechanisms might play a 
role in the initiation of a T cell response. Since DCs express a wide array of pattern 
recognition receptors, which can interact with diverse pathogens or their products, 
they are the potential candidates that may play a role in TH2 priming. 
 
Is there a role for TLRs in the SEA-induced TH2 response? 
Among the PRRs expressed on DCs are the Toll-like receptors. Recent reports 
indicate that Schistosoma mansoni derived (glycan-) products interact with this 
family of receptors. Living eggs of Schistosoma mansoni activate murine bone 
marrow-derived DCs through TLR engagement. Living eggs selectively activate TLR2 
and TLR3. Further investigation revealed that dsRNA structures that are present in 
the egg are able to activate TLR3 (10). Lacto-N-fucopentaose III (LNFP III) contains 
a Lewis x trisaccharide and can directly activate murine bone marrow derived-DCs 
through a TLR4 dependent mechanism. These DCs are able to drive naïve T cells 
towards a TH2 response (11). Also schistosome glycolipids are able to interact with 
TLRs. The lyso-phosphatidyl-serine was shown to activate human monocyte-derived 
DCs through TLR2, which results in the development of IL-10 producing regulatory T 
cells and the induction of a TH2 response (9). Further investigation of the interactions 
of Schistosoma mansoni and its products with TLRs is necessary.  
 
The past years a lot of work has been done on TLR signaling. Intracellular signaling 
from the distinct TLRs exhibit the common property of NF-κB activation, but their 
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differential coupling to adaptor molecules, their differential activation of MAPKs and 
modulation of their signals by other PAMP receptors contribute to the generation of 
pathogen-specific dendritic cell maturation and pathogen-tailored immune responses 
(12). The signaling pathways induced by the TLRs might influence the DC in its naïve 
T cell polarizing capacities.  
 
Initial studies established the importance of TLRs in inducing TH1 responses, since 
TLR4 ligands induce the production of IL-12p70 and IFN-α and stimulate TH1 
responses (13). However certain TLR ligands may also mediate a TH2 response. The 
TLR4 ligand, LPS from E. coli induces a TH1 response, while LPS from P. gingivalis, a 
TLR2 ligand, induces a TH2 response (14). Several studies suggest that TLR2 
signaling results in TH2 or T regulatory responses. Comparison of the intracellular 
signals from TLR2 and TLR4 has recently suggested that TLR agonists differentially 
instruct DCs to initiate TH responses via modulation of intracellular signaling 
pathways (7). TLR4 ligation favors pro-TH1 dendritic cell maturation through 
p38MAPK-dependent synthesis of IL-12p70, whereas TLR2 ligands stimulate TH2 
responses via preferential activation of ERK1/2 and c-fos resulting in increased IL-10 
release and reduced IL-12p70 synthesis (15). Signaling through TLR3, 7 and 9 
induces cross presentation and the expression of type 1 IFNs, generating cytotoxic T-
lymphocytes (CTLs). These studies show that T cell response can be influenced by 
TLR signaling. Therefore interactions of Schistosoma mansoni eggs and SEA with 
TLRs could play an important role in skewing the T cell response towards a TH2.  
 
Is there a role for CLRs in the SEA-induced TH2 response? 
Within the last few years several C-type lectins have been identified on both DCs and 
macrophages. These CLRs recognize specific carbohydrate structures in a Ca2+-
dependent manner (16). The carbohydrate specificity of these C-type lectins have 
been poorly characterized, but due to advances in microarray technology more tools 
become available to characterize or identify, the carbohydrate specificity of these 
receptors. The carbohydrate specificity of DC-SIGN and MGL has been described in 
this thesis (17;18). Knowledge on the exact carbohydrate recognition is essential to 
understand their importance in immune-related functions and to predict the 
pathogens that they might recognize and interact with.  
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CLRs are able to recognize incoming foreign antigens, which they can process and 
present to naïve T cells. Due to the ability to activate naïve T cells, CLRs could play an 
important role in T cell priming. It remains unclear whether all antigens that are 
captured and internalized by DCs can be presented to T cells, or that there is a more 
selective form of presentation in which CLRs determine which antigens are presented 
and which are not. The carbohydrate recognition capacity of CLRs might play a key 
role in this process.  
 
Schistosoma mansoni derived glycans can be recognized by multiple CLRs. We have 
shown that in the human body four CLRs are involved in the recognition of SEA (19), 
and three of these CLRs are present on DCs. We have shown that LDN and LDNF 
glycan moieties are recognized by MGL  (17). DC-SIGN interacts with Lewis x and 
LDNF glycans present in SEA (18;20;20). For the mannose receptor the specific 
glycan ligands in SEA have not been characterized, but these might be mannose 
containing glycan structures (21). The other CRL that interacts with SEA is the 
human homologue of DC-SIGN, L-SIGN that is found on LSECs the APCs of the liver. 
The exact ligands within SEA for L-SIGN have not been characterized yet, but Lewis x 
can be excluded (19). Since eggs entrapped in the liver secrete SEA, L-SIGN is an 
important candidate receptor to investigate schistosomiasis, especially granuloma 
formation and T cell responses, in more detail. In chapter 7 we showed that there is 
co-localization of SEA with MHC II suggesting that SEA might be presented on MHC 
II. Furthermore we showed that CLRs on DCs are able to capture and internalize SEA 
to the lysosomal, MHC II positive compartments. Here SEA might be processed and 
loaded on to MHC II, which can present these antigens to T cells. We therefore 
speculate that CLRs play an important role in generating a T cell response during 
schistosomiasis. The CLRs and/or the antigens that are presented by MHC II, could 
play a critical role in the SEA-specific TH2 response. Furthermore, Faveeuw et al., 
reported that SEA would be presented on CD1d, which is a molecule implicated in 
glycolipid presentation (22). Ag presentation of parasitic glycoconjugates to CD1d-
restricted T cells may be important in the early events leading to the induction of TH2 
responses and to egg- induced pathology during murine schistosomiasis. It would be 
interesting to investigate whether the glycolipids of cercariae that are recognized by 
DC-SIGN containing Lewis x and pseudo Lewis y, are presented by CD1 molecules. 
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Since pseudo Lewis y is a glycolipid specific for cercariae it could play a role in the 
induction of the early TH1 response.  
 
Besides playing a role in the presentation of SEA antigens on MHC II to naïve T cells, 
CLRs are also able to induce intracellular signaling pathways. CLRs contain signaling 
motives in their cytoplasmic tail, which might be able to induce intracellular signaling 
upon ligand recognition (16). The signal transduction pathways induced by each CLR 
remain to be elucidated, but for some individual signaling motifs their function has 
been identified. DC-SIGN, MGL and MR, all contain a tyrosine-based motif. It has 
been reported that this motif is involved in rapid internalization from the cell surface. 
Some tyrosine-based motifs can additionally mediate lysosomal targeting, 
localization to specialized endosomal-lysosomal organelles such as antigen-
processing compartments (23). DC-SIGN, L-SIGN and MGL also have a di-leucine 
motif in their cytoplasmic tail. This di-leucine motif is involved in targeting to the 
lysosomal/endosomal compartment and can promote receptor-mediated endocytosis 
(24). DC-SIGN and L-SIGN also contain a tri-acidic cluster in their cytoplasmic tail. 
This cluster plays a role in recycling beyond early endosomes, through deeper MHC II 
positive, late endosomes and lysosomes (25). The presence of these signaling motifs 
in the cytoplasmic tail, could explain the targeting of SEA to MHC II positive, 
lysosomal compartment. Taken together these findings indicate that SEA captured by 
CLRs might be processed and presented on MHC II, leading to the induction of the 
SEA specific TH2 response.   
 
Signal transduction pathways induced by CLRs could also have other roles than 
targeting to specific compartments within the cell. Upon ligand binding signaling 
cascades can be induced like phosphorylation and activation of signaling molecules. 
At present there is hardly any information on the induced signaling cascades by CLR-
ligand recognition. A recent report of Caparros and coworkers, revealed the first clues 
on signaling transduction pathways upon DC-SIGN-ligation (26). They showed that 
DC-SIGN induces the phosphorylation of ERK and Akt, without the concomitant 
p38MAPK activation. DC-SIGN ligation also triggers the PLCγ phosphorylation and 
calcium fluxes. The activation of ERK has been proposed to favor TH2 responses (15). 
The ERK signaling events result in an increased IL-10 release and reduced IL-12p70 
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synthesis. These cytokines could play a role in T cell polarization by functioning as 
the so-called third signal.  
 
Agrawal and colleagues (7), investigated the role of MAP kinase signaling pathways in 
the TH2 response induction by SEA. They showed that SEA is a weak inducer of p38, 
but results in an enhanced duration or magnitude of ERK1/2 phosphorylation, which 
suppresses IL-12p70 production. Blocking ERK1/2 does not result in a consistent 
increase in IL-12p70, suggesting that additional mechanism regulate the suppression 
of IL-12p70 by SEA. Since SEA by itself does not result in the production of IL-12p70, 
the suppression of IL-12p70 could play an important role in the generation of a TH2 
response (7). The additional mechanism described by Agrawal and coworkers (7), 
could be induced by signaling through DC-SIGN, as intracellular signaling reduces 
IL-12p70 synthesis through ERK activation (26). However this hypothesis needs to be 
further investigated. 
 
The findings described above, are in agreement with the observation, that most DC-
SIGN interacting microbes elicit TH2 –type responses which result in impaired 
pathogen clearance and the establishment of chronic infections. This has led to the 
proposal that pathogens subvert DC-SIGN function as a mean to avoid immuno-
surveillance and the generation of effective immune responses (27). Besides 
Schistosoma mansoni also other pathogens express Lewis x like Helicobacter pylori. 
Signaling through DC-SIGN by Lewis antigen expressing Helicobacter pylori results 
in immune regulation, but is not accompanied by inhibition of DC maturation or the 
induction of regulatory T cells. Lewis negative Helicobacter pylori do not bind DC-
SIGN and trigger TH1 responses, whereas the Lewis positive Helicobacter pylori 
induce a shift in the TH1/TH2 balance towards TH2 (28). Lactobacillus species L. 
reuteri and L. casei instruct DCs to induce IL-10 producing regulatory T cells that 
suppress T cell responses through engagement of DC-SIGN (29). Mycobacterium 
tuberculosis interacts with DCs through its cell wall component ManLAM with DC-
SIGN. ManLAM inhibits the TLR-induced maturation and induces the 
immunosuppressive cytokine IL-10 (30). Taken together these data indicate that the 
interaction of different pathogens with DC-SIGN influences the fate of naïve T cells, 
which might be a more common mechanism among CLRs.  
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Model of DCs interacting with Schistosoma mansoni SEA 
SEA are captured and internalized by APCs. On dendritic cells DC-SIGN, MGL and 
MR interact with SEA and in the liver on LSECs L-SIGN is able to interact with SEA. 
The SEA is internalized towards the MHC II positive, lysosomal compartments. Here 
the SEA are processed and loaded onto MHC II and subsequently presented to naïve 
T cells (signal 1). In combination with the co-stimulatory signal and the polarizing 
signal a T cell response is elicited (Figure 1a). When stimulated simultaneously with 
SEA and TLR-ligands LPS or poly I:C, DC maturation and cytokine production are 
suppressed (Figure 1b). The exact signaling pathway resulting in this inhibition needs 
to be further analyzed in more detail.  
 
Figure 1 Models of DC interactions with SEA. 
A) SEA is captured and internalized by three C-type lectin receptors on iDCs; DC-SIGN, MGL and MR 
respectively. SEA is internalized to the MHC II positive lysosomal compartments. After processing the 
antigen can be loaded on MHC II and be presented to naïve T cells. B) Toll like receptor - ligand 
interactions result in the up regulation of both maturation markers and cytokine production. When a 
DC simultaneously encounters SEA and a TLR-ligand (LPS or poly I:C), SEA inhibits the maturation 
and cytokine production induced by the TLR-ligand. The T cell response is skewed towards a TH2 
response. 
 
Concluding remarks 
The T cell polarizing capacities of DCs during schistosomiasis has been focusing on 
the interactions of the T cell receptor with MHC II associated peptides and on the co-
stimulatory signal. The possible role of TLRs and CLRs has not been taken into 
account in these studies. TLRs and CLRs are both pattern recognition receptors that 
are able to elicit a proper immune response against the pathogenic parasitic intruder. 
Reports on the signaling of CLRs and mainly TLRs, make it plausible to ascribe a role 
for CLRs and TLRs in determining the outcome of the immune response balance, 
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suggesting that signaling via distinct PRRs triggers qualitatively different responses 
from the innate immune system. Modulating TLR or CLR signaling, could lead to a 
better understanding in TH1/TH2 balance in general and could result in novel 
therapeutic opportunities to manipulate adaptive immunity in the immune therapy of 
allergy, chronic infections, autoimmunity, transplantation and cancer.  
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Summary 
 
Schistosomiasis is the major parasitic worm infection in the world. Schistosomes 
have a complex life-cycle, in which every stage interacts with the host either directly 
or indirectly through the secretion of highly glycosylated proteins and lipids. 
Increasing evidence indicates that glycoconjugates play an important role in the 
manipulation of the immune system for the parasites benefit and  to escape the 
immune response of the host. The first cells to come in contact with invading 
pathogens are dendritic cells (DCs). DCs recognize pathogens and through cell-cell 
interactions with T cells, an immune response is elicited. DCs express receptors that 
recognize glycans expressed by pathogens, these receptors are called C-type lectin 
receptors. Schistosomiasis is characterized by a strong TH2 response, induced by 
soluble egg antigens (SEA) secreted by eggs of the parasite. The mechanism of how 
SEA induces a TH2 response is unknown. To be able to understand the induction of 
this TH2 response, it is important to investigate which receptors on DCs are able to 
interact with SEA. To gain more insight in the recognition of Schistosoma mansoni 
glycans by C-type lectins and the consequences for dendritic cell mediated immune 
responses, the studies described in this thesis were performed. As a first approach to 
understand the molecular interactions of schistosome glycans and dendritic cells that 
lead to TH2 cell polarization, the recognition of schistosome glycan antigens by DCs 
were investigated. 
 
In the general introduction (Chapter 1) the parasite Schistosoma mansoni is 
introduced. A general overview of glycoconjugates, their biosynthesis and examples 
in Schistosoma mansoni are discussed. The immune system with a focus on dendritic 
cells and the pattern recognition receptors they express, proceed the immune 
response to Schistosoma mansoni. The parasite Schistosoma mansoni is the major 
parasitic worm infection in the world. The larvae of the parasite live in fresh water 
and when humans come in contact with this water they become infected with 
Schistosoma mansoni. During infection the host is sequentially exposed to different 
sets of specific antigens present on different life-cylce stages and in secreted/excreted 
products. Increasing evidence indicates that the highly glycosylated antigens play an 
important role in the immunobiology of schistosomiasis. The parasite can survive 
many years in the hostile environment of the host. Thus, the parasite must have 
evolved mechanisms to escape the immune response of the host. The first immune 
cells that come in contact with invading pathogens are dendritic cells, the sentinels of 
the immune system. Dendritic cells express receptors which are able to recognize 
glycoconjugates through their carbohydrate recognition domain. These receptors are 
the C-type lectin family receptors. These receptors are able to capture and present 
antigens to T cells and an immune response is elicited. In this thesis we made a first 
approach to investigate how the molecular interactions of schistosome glycans and 
dendritic cells, lead to TH2 cell polarization, characteristic for Schistosoma mansoni 
infections. 
 
In chapter 2 we started to investigate the carbohydrate specificity of DC-SIGN to be 
able to predict which carbohydrates of Schistosoma mansoni could be recognized by 
DC-SIGN. We found that DC-SIGN recognizes at least two classes of glycans, 
mannose rich and fucosylated glycans. DC-SIGN binds to N-linked oligomannose 
with the highest apparent affinity for the structure Man9GlcNAc2, and decreasing 
binding affinity as the number of mannoses decreases. DC-SIGN binds Lewisx and 
LDNF, however diantennary N-glycans containing these epitopes show a 4-fold 
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increase in binding of DC-SIGN-Fc over the terminal trisaccharides alone. 
Multivalenly expressed Lewisx show an even more increased binding of DC-SIGN-Fc, 
indicating that DC-SIGN prefers multivalently expressed glycans, which is in 
agreement with the capacity of DC-SIGN to bind many pathogens through there 
multivalently expressed glycans. 
 
Another C-type lectin expressed on dendritic cells is Macrophage galactose-type 
lectin, MGL. In chapter 3 we used carbohydrate profiling to gain more insight in the 
function and carbohydrate specificity of MGL. We identified oligosaccharides 
containing terminal α- and β-linked GalNAc residues as high affinity ligands for 
MGL. Identification of the carbohydrate specificity of MGL, led to discovery that 
MGL is able to bind to glycan antigens within egg glycoproteins of the pathogenic 
helminth Schistosoma mansoni. In addition MGL strongly interacted with tumor 
cells in a GalNAc specific manner. These data strongly implicate a role for MGL in 
recognition of self-gangliosides, tumor antigens and pathogenic helminthes by DCs. 
 
In chapter 4 we investigated whether L-SIGN, a human homologue of DC-SIGN, 
like DC-SIGN is able to bind fucosylated oligosaccharides, since increasing evidence 
indicates that the major ligands for DC-SIGN are α3/α4 fucosylated glycans. Here we 
demonstrate that like DC-SIGN, L-SIGN is able to bind to Lewis a, Lewis b and Lewis 
y. In contrast to DC-SIGN, L-SIGN does not bind Lewis x containing 
oligosaccharides. L-SIGN is able to bind SEA of the parasite Schistosoma mansoni, 
however this binding is not through the Lewis x epitope. A specific mutation in the 
carbohydrate recognition domain of DC-SIGN (V351G) abrogates binding to all Lewis 
antigens. In L-SIGN Ser363 is present at the corresponding position of Val351 in DC-
SIGN. Replacement of this Serine into valine resulted in a “gain of function” L-SIGN 
mutant that binds Lewis x and shows increased binding to other Lewis antigens. 
Molecular docking and modeling demonstrates that the valine amino acid in DC-
SIGN creates a hydrophobic pocket that strongly interacts with the Fucα1,3/4-
GlcNAc moiety of the Lewis antigens. The Serine in L-SIGN creates a hydrophilic 
pocket, which prevents interaction with the Fucα1,3-GlcNAc of Lewis x. These data 
demonstrate for the first time that DC-SIGN and L-SIGN differ in their carbohydrate 
binding profiles, and will contribute to our understanding of the functional roles of 
these C-type lectins, both in recognition of pathogen and self-glycan antigens. 
 
One of the first roles described for DC-SIGN, is that DC-SIGN is able to mediate 
rolling and adhesion of precursor DCs over the endothelium, which suggested to be 
mediated through interactions with ICAM-2. In chapter 5, we investigated the DC-
SIGN ligands present on endothelial cells that are crucial for the adhesion and rolling 
of DCs. In this study we showed that ICAM-2 expressed on endothelial cells 
constitutes the major scaffold protein ligand for DC-SIGN. We identified Lewis y as 
the major carbohydrate ligand for DC-SIGN on endothelial cell-expressed ICAM-2. 
Furthermore we demonstrate that fucosylation is essential for the rolling and 
adhesion of monocyte-derived DCs. Silencing of Fucosyltransferase 1 (FUT-1), 
resulted in a reduction of rolling and adhesion. The discovery of FUT-1 as a key 
enzyme in the synthesis of the endothelial DC-SIGN-ligands opens new possibilities 
in the manipulation of DC migration. 
 
During the human parasitic disease schistosomiasis, the immune system is 
continuously challenged with an array of molecules associated with parasite 
metabolism and reproduction. These glycoconjugates, consisting of both 
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glycoproteins and glycolipids are shown to play important roles in host-parasite 
interactions. In chapter 6 we investigated whether DC-SIGN recognizes glycolipids 
of the parasite Schistosoma mansoni. DC-SIGN is able to bind to cercarial 
glycolipids, but not egg glycolipids. Structural characterization of the glycan moieties 
of the glycosphingolipid species revealed that a pentasaccharide containing Lewis x is 
one of the main ligands recognized by DC-SIGN. Furthermore we found that DC-
SIGN binds to pseudo-Lewis y, a hexasaccharide found so far only on glycolipids of 
cercaraie of schistosomes. Pseudo Lewis y is the first parasite specific ligand 
identified for DC-SIGN. Molecular modeling showed that binding of pseudo-Lewis y 
could fit in the model, if the orientation of the side chain of Phe313 in the secondary 
binding site of DC-SIGN was slightly changed. This flexibility in the secondary 
binding site of DC-SIGN might be used by pathogens to target DCs, which may 
contribute to immune escape. 
 
To understand the mechanism of how SEA induces a TH2 response, it is important to 
investigate which receptors on DCs are able to recognize SEA. As SEA is highly 
glycosylated, we focused in chapter 7 on the interaction of SEA with DC-expressed 
C-type lectins (CLRs). We showed that DC-SIGN, MGL as well as the mannose 
receptor play a role in binding and subsequent internalization of SEA. Co-localization 
of SEA with MHC II in the lysosomal compartments suggests that Ag processing and 
presentation can occur. Although SEA by itself did not induce DC activation, addition 
of SEA suppressed the TLR-induced activation and cytokine production of DCs. 
Moreover, SEA induced a down modulation of TH1 responses and even skewing 
towards TH2 responses induced by poly I:C and LPS respectively. These data show 
that multiple C-type lectin receptors on DCs can capture and internalize the complex 
mixture of antigens secreted by Schistosoma mansoni eggs, and subsequently 
regulates the ability of iDCs to respond to TLR ligands. 
 
In this thesis we showed that C-type lectins on DCs play an important role in the 
recognition of Schistosoma mansoni and its secretion products. How these 
interactions relate to the induction of the schistosome specific TH2 response remains 
to be elucidated. In chapter 8, we discuss the role of DCs in the schistosome specific 
TH2 response and which DC-expressed receptors could play an important role in this 
immune response. Moreover, cross talk between receptors and signal transduction 
pathways make things even more complicated. Modulating TLR and CLR signaling, 
could lead to a better understanding of the TH1/TH2 balance in general and could 
result in novel therapeutic opportunities to manipulate adaptive immunity in the 
immune therapy of allergy, chronic infections, autoimmunity, transplantation and 
cancer. 
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Schistosoma mansoni is een parasiet die mensen infecteert met name in de derde 
wereld landen. Mensen kunnen de infectie oplopen als ze in aanraking komen met 
zoetwater waarin de larven van de Schistosome-parasiet leven. Schistosome-
parasieten zijn zuigwormen en hebben een ingewikkelde levenscyclus. Ze gebruiken 
bepaalde zoetwaterslakken als tussengastheer. Uit deze slakken komen grote 
aantallen minuscule larven vrij, die vervolgens in het water rondzwemmen en binnen 
een paar seconden de huid van mensen kunnen binnen dringen. Een kortstondige 
aanraking met besmet water is dus al voldoende om de infectie op te lopen. In de 
aderen ontwikkelen de larven zich binnen vijf weken tot volwassen wormen. De 
vrouwtjes leggen gemiddeld vijf jaar lang 200 –2000 eitjes per dag. Het zijn de eitjes 
en niet de volwassen wormen die de organen zoals de lever, darmen en blaas 
aantasten.  
 
Strandwachters staan voortdurend op de uitkijk om strandgasten te beschermen 
tegen de gevaren van de zee en de gevaren veroorzaakt door mensen zelf. Wanneer er 
zich op het strand een gevaarlijke situatie voordoet, verzamelen de strandwachters 
zich om tot een gezamenlijke reddingsactie over te gaan. De strandwachters van ons 
lichaam zijn gespecialiseerde cellen, die vanwege hun uitlopers dendritische cellen 
worden genoemd. Deze dendritische cellen beschermen ons lichaam tegen indringers 
als bacteriën, virussen en parasieten. De dendritische cellen bevinden zich in onrijpe 
vorm in alle weefsels, waar zij op de uitkijk staan voor indringers. Wanneer er gevaar, 
bijvoorbeeld in de vorm van een infectie in het menselijk lichaam optreedt, 
verzamelen de dendritische cellen informatie in de vorm van kleine eiwitdeeltjes die 
uniek zijn voor de bacterie, virus of parasiet, om uiteindelijk een reactie van je 
afweersysteem (immuun systeem) opgang te brengen. De kleine eiwitdeeltjes, ook wel 
antigenen genoemd kunnen door de dendritische cellen worden opgenomen, waarna 
de dendritische cel met deze informatie van de infectieplaats via de lymfevaten naar 
de lymfeklieren gaat.  Hier worden de antigenen gepresenteerd aan T cellen, die een 
rol spelen bij de vernietiging van de indringers. De T cellen die het antigeen 
herkennen vermenigvuldigen zich en gaan naar de infectieplaats om de geïnfecteerde 
cellen te doden. 
 
Dendritische cellen hebben eiwitten (receptoren) op hun oppervlak, die specifieke 
eiwitten van indringers herkennen. Tot deze receptoren behoren de zogenaamde C-
type lectins, die een speciaal domein hebben waarmee ze specifieke suikers kunnen 
herkennen. Eén van deze receptoren is DC-SIGN, die alleen op DCs voorkomt. DC-
SIGN herkent bacteriën, virussen, parasieten en hun uitscheidingsproducten aan de 
aanwezige suikerketens. Daarnaast kan DC-SIGN interacties aangaan met andere 
moleculen op endotheel cellen of T cellen. Het doel van dit proefschrift is de 
suikerherkenning van DC-SIGN meer gedetailleerd te bestuderen, om vervolgens de 
interactie met Schistosoma mansoni met DC-SIGN op dendritische cellen beter te 
kunnen bestuderen. Daarnaast werd ook de herkenning van Schistosoma mansoni 
door andere C-type lectins onderzocht. Tenslotte werd de rol van DCs (en C-type 
lectins) in de aanzet van een immune reactie tegen Schistosoma mansoni onderzocht. 
 
Om in staat te zijn te voorspellen welke suikers van Schistosoma mansoni herkend 
kunnen worden door DC-SIGN, werd de suikerspecificiteit van DC-SIGN nauwkeurig 
onderzocht (hoofdstuk 2). We hebben gevonden dat DC-SIGN twee klassen suikers 
herkend, namelijk hoog-mannose suikers en bepaalde fucose-houdende suikers. 
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Zowel DC-SIGN in oplossing als DC-SIGN op het oppervlak van cellen, kunnen beide 
klassen van suikers binden. De mate van binding neemt toe met het aantal 
beschikbare suikers. 
 
Een ander C-type lectine is MGL. MGL komt voor op dendritische cellen en 
macrofagen. In hoofdstuk 3 is de suikerspecificiteit van MGL bepaald door de 
binding aan diverse suikerstructuren te testen. MGL herkent andere suikers dan DC-
SIGN, namelijk de galactosebevattende suikers. Deze suikers komen voor op onder 
andere stadia van de parasiet Schistosoma mansoni en zijn uitscheidingsproducten, 
maar ook op tumoren. Deze bevinden geven aan dat MGL een functie kan spelen in 
de herkenning van pathogenen en de interactie met tumoren.  
 
In het menselijk lichaam komt een op DC-SIGN gelijkende receptor voor namelijk L-
SIGN. L-SIGN komt voor op bepaalde cellen van de lever en de lymfeklier. DC-SIGN 
en L-SIGN delen bepaalde eigenschappen zoals de interactie met endotheel cellen en 
T cellen. L-SIGN herkent ook hoog mannose suikers, maar het is echter niet bekend 
of L-SIGN ook fucose-houdende suikers herkend, dit is onderzocht in hoofdstuk 4. 
L-SIGN kan net als DC-SIGN bepaalde fucose houdende suikers binden, die behoren 
tot de Lewis-familie. L-SIGN verschilt echter van DC-SIGN omdat L-SIGN geen 
Lewis x herkent, terwijl DC-SIGN dat wel doet. De moleculaire achtergrond van dit 
verschil werd onderzocht door veranderingen in L-SIGN of DC-SIGN aan te brengen 
en met behulp van de analyse van de binding met de computer. 
 
DC-SIGN op dendritische cellen kan een interactie aangaan met ICAM-2 op 
endotheel cellen. Echter hoe deze interactie tot stand komt is niet bekend. In 
hoofdstuk 5 wordt deze interactie nader bestudeerd. We laten zien dat deze 
interacties afhankelijk zijn van de aanwezigheid van de suikerstructuur Lewis y op 
ICAM-2. 
 
De verschillende levensstadia van de parasiet Schistosoma mansoni hebben diverse 
suikers op hun oppervlak of uitscheidingsproducten. Een deel van deze suikers zit op 
vetten (lipiden). In hoofdstuk 6 is onderzocht of DC-SIGN suikers op de lipiden van 
Schistosoma mansoni kan herkennen. We hebben aangetoond dat DC-SIGN wel 
suiker-lipiden van cercariae herkent, maar niet de suiker-lipiden van de eieren. 
Nadere analyse van deze suiker-lipiden laat zien, dat Lewis x en pseudo-Lewis y de 
suikerstructuren zijn op suiker-lipiden van cercariae die door DC-SIGN herkent 
worden. 
 
Dendritische cellen staan continue op de uitkijk naar indringers. De parasiet 
Schistosoma mansoni is zo’n indringer. De eieren van Schistosoma mansoni 
scheiden een sterk besuikerd product uit, dat SEA wordt genoemd. Hoewel er een 
afweer reactie tot stand komt die specifiek is voor SEA, is de rol die dendritische 
cellen daarin spelen nog niet duidelijk. In hoofdstuk 7 wordt beschreven dat drie C-
type lectins, DC-SIGN, MGL en de mannose receptor, SEA kunnen binden en 
betrokken zijn bij de opname ervan. Daarnaast heeft SEA een onderdrukkend effect 
op de maturatie en cytokine productie van dendritische cellen. Hier laten we zien dat 
dendritische cellen een rol spelen bij het opstarten van een reactie van het immuun 
systeem op Schistosoma mansoni infecties. De bevindingen in dit hoofdstuk geven 
bovendien aanwijzingen voor de antigeen presentatie van SEA door DCs, wat een rol 
speelt in de T cel gereguleerde afweerreactie. 
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Tenslotte wordt er in hoofdstuk 8 beschreven wat de resultaten betekenen voor de 
inzichten van de immuun reactie tegen SEA van de parasiet Schistosoma mansoni. 
De SEA specifieke reactie kan mogelijk door meerdere factoren beïnvloed worden dan 
tot nu toe werd gedacht. 
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